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The emergence of chloroquine (CO) resistance in Plasmodium falciparum throughout the 
malaria-endemic tropical world has necessitated alternative treatments for malaria. One 
approach is to restore CO's efficacy by using it in combination with resistance reversers or 
chemosensitizers like verapamil and chloropheniramine. However, most of these 
. chemosensitizers are effective only at concentrations toxic to humans. A series of novel 
compounds were designed, synthesized and tested with the aim of assessing their effect on CO 
effectiveness in Plasmodium falciparum resistant strains. 
In the initial exploratory drug discovery phase, a series of compounds were rationally designed 
based on known structure-activity relationship studies on multi-drug resistant chemosensitizers 
and synthesized via polymer-assisted synthesis in solution. N'-[4-(Biphenyl-2-ylmethoxy)-
benzy~-N,N-dimethyl-propane-1 ,3-diamine displayed the greatest potential as a dual-acting 
antiplasmodial agent (ICso< 0.6 ~) and chemosensitizer (RMIK1=0.67; RMIRSA11=0.82), and low 
in vitro cytotoxicity against a mammalian cell line (CHO). The biphenyl moiety in the identified hit 
molecule was tentatively proposed as the potential pharmacophore. Subsequently a library of 
biphenyl compounds, which varied in the structural features of the aromatic ring system and the 
amine moiety, were synthesized in solution. The novel compounds were characterized by 
infrared spectroscopy, 1H, 13C NMR, mass spectroscopy and microanalysis and tested in vitro for 
anti plasmodial and chemoreversal activity as well as cytotoxicity and their effect on tritiated CO 
uptake. Comparisons of the 17 bi- and tri-arylamines revealed several generalizations on 
structure-activity relationships for antiplasmodial and chemoreversal activity. A number of 
derivatives increased CO accumulation and potentiating effects against resistant strains of P. 
falciparum (K1 and RSA11) with 1-biphenyl-2-ylmethyl-4-methyl-piperazine also displaying 
strong intrinsic antimalarial activity. In addition, one compound (1-[A;.(3';A/::(jimethoxy-biphenyl-4-
ylmethoxy)-benzyn-4-methoxy-piperazine) exhibited a strong resistance reversal effect 
(RMIRSA11=O.31) without promoting the uptake of CO within the resistant parasites. Three of the 
synthesized compounds showed considerable potential and warrant further investigation as 
leads. In terms of substrate specificity, it is the first time studies on the effect of antimalarial 
resistance reversers on drug transporters in yeast have been attempted. Although the drug 
transporter study did not shed light on the CO resistance mechanism, it has provided a new 
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Chapter 1 Introduction: Malaria 
1.1 Historical outlines of malaria 
recorded the affliction. 
Malaria caused by protozoan parasites of the genus Plasmodium 
was traced back more than 4000 years ago as its characteristic 
symptom of enlarged spleens were found in Egyptian mummies. 
Elsewhere in the world, writers, poets and religious figures have 
When unable to defend herself by the sword 
Rome could defend herself by means of the fever. 
- The poet Godfrey of Viterbo, 1167 
In ancient Rome, outsiders were most vulnerable to the disease; the conditions were 
described as 'Roman fever' which later gave rise to the Italian word, ma/'aria (bad air) to 
describe the cause of the disease (Sherman, 1998). It was only in the early 1880s that 
malarial gametocytes found in human blood were viewed under the microscope. 
Pioneering work by Dr. Giovanni Battista Grassi and Sir Ronald Ross established the 
parasite's life cycle, for which the latter was awarded the Nobel Prize for medicine and 
physiology in 1902. As the history unraveled, collective wisdom of discovery, 
development of antimalarial drugs and knowledge of mosquito vectors have helped to 
better understand malaria. 
1.2 Malaria epidemics 
The global picture of malaria is such that 300 million to 500 million people are infected 
and at least one million die each year, mostly children under the age of 5 (WHO, 2004). 
As the life-threatening infectious disease persists, it has occurred in tropical and 
subtropical developing countries on all continents (Fig. 1.2.A). Today, 90% of malaria 
cases and deaths are recorded in sub-Saharan Africa. 
There are two main factors responsible for the high mortality in Africa, namely natural 










Chapter 1 Introduction: Malaria 
conflict of war, mining and failure of control measures make the physical environment 
more suitable for the growth of the transmission vector - the female Anopheles mosquito. 
Other factors such as massive refugee movements, the emergence of multi-drug 
resistant parasites, mosquito resistance to antimosquito compounds and weak health 
care infrastructures have also contributed to the problem of eradicating the scourge of 
malaria. However, the World Health Organisation and other campaigns have committed 
to halve the deaths from malaria by 2010 whereas the current strategies focus upon 
prompt access to treatment, provision of clean water and use of insecticide treated bed 
nets. 
Worldwide malaria distribution in 2002 
_ ArIJCl!i where malajio Iral"lliflhsDn OCOJNi 
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Fig. 1.2.A. Global distribution of Malaria. (Reproduced from http://www.gmap.net/oxford/image/ 
malaria 2002.jpg) 
The distribution of endemic malaria in South Africa is confined to the provinces of 
KwaZulu-Natal, Mpumalanga and Limpopo (Fig. 1.2.8) (Department of Health, 2003; 
http://www.malaria.org.za/MalariaRisk/Update/update.html). In South Africa today, the 
highest risk areas are the international Mozambican border areas. The dangerous 
endemic disease is brought across mostly by infected travelers, who further transmit 
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Chapter 1 Introducbon: Malaria 
1.3 The socioeconomic burden of malaria 
Malaria is recognized not only as a health problem but also as a social and economic 
problem since it is closely associated with poverty. When highly exposed populations are 
attacked in malaria endemic areas, where the agriculture need is great, the number of 
working days will be reduced, and the monetary loss as a result of fewer working days 
will limit the human resources to contribute to social and economic development. It will 
also endanger children's education owing to low school attendance. Malaria is believed 
to be responsible for hindering economic growth up to 1.3% annually in some African 
countries (http://www.rbm.who.inUcmc upioad/O/OOO/015/370/RBMInfosheet 3.htm). It 
therefore affects the survival of the inhabitants and continues the marginalization. 
In South Africa today, malaria is understood to be a disease of poverty and a cause of 
poverty as well. Despite the extensive effort by the Department of Health to prevent and 
control malaria by lowering the cost of insecticide-treated bed nets, chemoprophylaxis 
and vector control by intra-domiciliary spraying, the emergence of drug resistance 
remains one of the greatest challenges to eradicate malaria as it does worldwide 
(Department of Health, 2003). The prevalence of malaria will hamper international trade, 
foreign investments and tourism that is particularly essential for economic growth in our 
rainbow nation. 
1.4 Parasite-host interactions 
In 1880, scientists discovered a one-cell parasite, Plasmodium, as the real cause of 
malaria. Human malaria is caused by four species of the Plasmodium parasites including 
P falciparum, P vivax, P ovale and P malariae of which falciparum malaria is the most 
common infection and causes the greatest risk of complications and deaths (Sherman e/ 
al., 1998). The life cycle of malaria parasites involves four stages and two hosts, human 
host and female Anopheles mosquito. Plasmodium parasites undergo asexual 
reproduction both in the tissue and in red blood cells of the vertebrate hosts and one 
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Fig. 1.4. The life cycle of malaria parasites. 
(Reproduced from http://images.encarta.msn.com/xrefinedia/aencmed/targets/illus/iltfT073615A.gif) 
The infective forms of human malaria parasites, sporozoites, enter blood circulation by 
means of an infected Anopheles mosquito during a blood meal and travel rapidly to the 
liver cells where they grow and multiply to produce merozoites asexually (Bitonti et aI., 
1988; Dieckmann-Schuppert et al., 1993). Upon maturation, merozoites are released 
into the bloodstream to invade other erythrocytes or parenchymatous cells of the liver. 
During the intra-erythrocytic stage, merozoites undergo a process of asexual 
reproduction in human hosts by feeding on the erythrocytes, growing and multiplying 
cyclically from trophozoites to mature blood schizonts with a number of nuclei. Malaria 
symptoms such as chills, fevers and nausea only begin when the parasites start to divide 
asexually in the red blood cells. One schizont can divide to produce numerous 
merozoites which ingest the erythrocytes and are released back to the bloodstream to 
invade new red blood cells. This is referred to as the erythrocytic stage of the life cycle, 
and is repeated every 48 hours (Bitonti et aI., 1988). These multiplied parasites are now 
capable of developing into male and female gametocytes which will unite to form zygotes 
in the gut of the mosquito when taken up by a blood feed. In the sporogonic cycle in the 
mosquito body, a zygote then forms an oocyst which multiplies and divides asexually into 
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and make their way to the mosquito's salivary glands, which allow the transmission when 
saliva and anti-coagulants are injected into a non-immune human host to perpetuate the 
malaria cycle. Thus, it completes the life cycle of malaria - man to mosquito to man 
(Dieckmann-Schuppert et al., 1993). At each transmission cycle, sexual exchange 
occurs and is believed to be one of the reasons for rapid spread of traits through parasite 
populations (Bitonti et al., 1988). 
1.5 Prevention and control 
Prevention is better than cure! The current measures to prevent malaria are 
controversial as there are numerous developments taking place. Growing political 
commitment has taken action on the battle by making public awareness and constructing 
appropriate health infrastructures and resources. The key to preventing malaria is to 
correctly identify populations at risk and then give them prompt access to early diagnosis 
and effective treatment. Moreover, innovative controls need not only be efficient 
therapies but also cost-effective regimens, especially in the malaria prevalent African 
continent. 
Measures to control the progression of malaria should be aimed at reducing contacts 
with the transmission vector, mosquitoes, by means of effective insecticides and 
larvicidies spraying at risk environments. For example, dicophane (DDT) is remarkably 
safe when used in small quantities (Smith et al., 2000). One of the main reasons for the 
resurgence of malaria in South Africa is the discontinued use of DDT in 1996 resulting in 
malaria cases soaring in KwaZulu Natal (Vamey et al., 2004). Personal preventive 
measures include the use of window screens, protective clothing, insect repellents, 
mosquito-proof bed nets and appropriate chemoprophylactic agents to avoid the 
development of the disease. 
Although Plasmodium possesses a multi-stage life cycle and diverse genetics has 
complicated vaccine developments for years, the treatment and control of malaria is still 
profoundly reliant on chemoprophylaxis and chemotherapy nowadays. Until a powerful 
wonder drug is developed in future, the current choice of therapies depends on scientific 
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control and efficient, safe, cost-effective and up-to-date antimalarial agents. 
Nevertheless, the greatest current problem with drug prophylaxis is not only drug 
resistance but also compliance to drug regimens. 
1.6 Antimalarial chemotherapy 
The malaria burden is compounded by the relationship between human hosts and the 
complicated parasitic life cycle. Because of the 48 hour parasitic cycle, the reduction of 
parasitaemia in vivo can be used as a pharmacodynamic measure of antimalarial drug 
effect. Parasites persisting beyond 48 hours after starting antimalarial treatment (Le. 
parasite clearance time) are a sensitive indication of drug resistance. Moreover, 
depending on the doses and patient factors, side effects are a common problem with any 
drug. A number of currently used antimalarial medications cause side effects, which are 
recorded (Table 1.6). Antimalarial agents, despite their difficulties, remain an essential 
means to prevent the infectious disease. 
Table 1.S. Example of current antimalarials and their associated problems. 
Quinine Sulfate Tinnitus Sherman ef al., 1998 
Mefloquine Nausea, headache and diarrhea Department of Health, 2003 
Chloroquine Oral aphthous, ulceration Department of Health, 2003 
Proguanil Mouth ulcers Sherman et a/ .. 1998 
Hyde et al., 2002 
Fansidar Severe allergiC reactions Sherman et al., 1998 
Ridley, 2002 
Arternisinin Recrudescence and neurotoxicity Pasvol st al., 1995 
Sherman st al., 1998 
Antimalarials are categorized by their mode of action at different parasitic stages that 
they affect (Schmatz and Schaeffer, 1991). The vast majority of the currently used 
antimalarial drugs are aimed at the intra-erythrocytic stage of the parasitic life cycle thus 
preventing disease development and further transmission. The first category comprises 
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derivatives chloroquine (CO), amodiaquine, mefloquine and halofantrine. Antifolate 
(sulfa) drugs as the second main group includes pyrimethamine, proguanil, sulfonamide 
and sulfadoxine which are representatives of dihydrofolate reductase (DHFR) and 
dihydropteroate synthetase (DHPS) inhibitors. Artemisinin and its analogues artesunate 
and arteether complete the third main class of antimalarials in the pipeline. 
Although remarkable progress has been made towards vaccine development, an 
effective and affordable vaccine is not yet available. The genetically diverse Plasmodium 
and evolutionary parasite resistance to the therapeutic agents have complicated vaccine 
development. However, comprehension of the mode of action of the drug and resistance 
mechanism will provide invaluable insight into rational vaccine design and drug 
discovery to thwart and at last eradicate the scourge of malaria. 
1.6.1 Quinine and its derivatives 
The antimalarial properties of quinine (ON) (Fig. 1.6.1) were first discovered from the 
bark of the Cinchona tree in the early 1 th century. In modern African history, ON also 
had a profound influence when Europeans attempted to explore Africa. Expeditions by 
non-immune travelers often ended up in disasters. As a result West Africa was once 
called the "white man's grave". At present, ON still plays an important role in the 
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Chapter 1 Introduction: Malaria 
ON was synthesized for the first time in 1944, but because of its complex structure, there 
is not an economically viable synthesis available and ON is still obtained 'from natural 
sources. The miraculous 'fever tree' plantations were in Java, which came under 
Japanese control in the Second World War, and ON was no longer available to the allied 
forces. In addition to this, setbacks such as parasite resistance to ON and it 
side effects - including sharp ringing in the ears - have driven research into alternative 
treatments. Ultimately it led to the development of chloroquine (CO) - the most important 
antimalarial for almost half a century (Krogstad, 1996). 
1.6.1.1 Chloroquine 
CO, 7-chloro-4-(4-diethylamino-1-methylbutylamino)quinoline, was synthesized as a 
less-toxic ON derivative by Bayer AG in 1934 (Krogstad et al., 1987; Ward et al., 1997;). 
It is relatively easy to make and hence very cheap. Conversely, novel drugs are very 
expensive - as much as 8 dollars a pill - compared to pennies for CO. In addition, CO 
was the only antimalarial known for its safety in therapy during pregnancy and in young 
children (Wolfe and Corders, 1985; Francis et aI., 1997; Bray and Ward, 1998). 
Thousands of compounds have been screened for malaria treatment, however, none 
was found to be as powerful and as safe as CO. Consequently, safety, affordability, rapid 
onset of action and minimal side effects attributed to the success of the most widely used 
therapeutic agent in the world. 
The popularity of orally administered CO, which became a prophylactic for travelers as 
well as a chemotherapeutic, inevitably led to widespread drug resistance; particularly in 
regions where table salts were chloroquinized in this endeavor to eliminate the risks in 
entire populations. This directed research to the development of its synthetic analogues 
mefloquine and amodiaquine. Many more 4-aminoquinoline and 8-aminoquinoline 
derivatives await approval for clinical use (WHO, 1981; Hawley et al., 1998). Despite the 
prominent use of this class o'f antimalarials, its mechanisms of resistance and mode o'f 
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The advantages of CO include well-established safety, cost-effectiveness and biological 
activity in vivo, which could provide insightful information on its mechanism of action. Its 
ease of synthesis has highlighted the importance of studying CO since similar synthesis 
strategies may be used in drug development (De at al., 1997). It is therefore hoped that 
CO resistance will be reversed by better understanding of the drug and the molecular 
basis of drug-parasite interaction so that it can be reintroduced to treat complicated 
falciparum malaria. 
1.6.1.2 CQ's mode of action 
Evidence has shown that CO is able to bind to DNA and inhibit DNA replication by 
intercalation (O'Brien and Hahn, 1965; Ciak and Hahn, 1966). It was therefore believed 
that this was the mode of action in P. falciparum. However, the specificity and 
concentration dependence of CO with respect to non-specific DNA binding have 
questioned this hypothesis (Krogstad at al., 1992). Currently there are various 
hypotheses to explain the mode of action of CO (Ward at al., 1997). Several common 
features were ascertained including that: (i) CO is highly effective against the asexual 
blood stage of the parasite life cycle by interfering with the haemoglobin degradation 
process in the parasitic Iysosomes, (ii) there is a high concentration of the weak base CO 
in the acidic vacuole. 
During the intra-erythrocytic stage of parasite development, P. falciparum ingests up to 
80% of host-derived haemoglobin (Hb) as nutrient source (Yayon at al., 1984; Zarchin at 
al., 1986; Goldberg at al., 1990; Slater and Cerami, 1992; Sullivan at al., 1996). Hb is 
ingested via the cytosome, which is a mouth-like structure that engulfs the erythrocytes 
into the parasites in a process resembling endocytosis. Vesicles are then pinched off and 
Hb is carried to CO's believed site of action, the acidic food vacuole, where proteolysis 
occurs (Goldberg at al., 1990; Goldberg and Slater, 1992). Hb is broken down by 
aspartic (plasmepsins I and II) and cysteine (falcipain) proteases of which the primary 
degradation is considered to be the interaction of plasmepsin I with the native Hb. This 
Hb digestion process produces a byproduct of haem moiety. ferriprotoporphrin IX (FPIX) 
(Goldberg and Slater, 1992; Rosenthal at al., 1996; Foley and Tilley, 1997). The potential 
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soluble (Slater and Cerami, 1992). Although lacking haem oxygenase, the parasite 
perfected the detoxification mechanism by dimerizing haem into non-toxic insoluble 
crystals, haemozoin (malaria pigment). which remain until infected erythrocytes burst. In 
light of the above, it is proposed that CO's principle mode of action is to interfere with 
haem dimerization resulting in a build up of toxic free haem (haematin) and/or 
drug-haem complexes, leading to parasite death (Chou et al., 1980; Dorn et al., 1994; 
Orjih et al., 1994). Egan and coworkers further support this hypothesis by providing 
compelling evidence that haemozoin is structurally identical to p-haematin, which can be 
made spontaneously under non-physiological conditions (Egan et al., 1994). Under the 
physico-chemical process in vitro, CO was found to perturb the dimerization equilibrium 
between monomeric (a-haematin) and dimeric (p-haematin) form of haematin by 
preferentially binding to haem dimers to form CO-haematin complex (FPIX-CO-FPIX) 
(Sullivan et al., 1996b; Dorn et al., 1998; Egan, 2001). Consequently, CO reduces the 
availability of free haem to be integrated into haemazoin, leading to parasite lysis as a 
result of toxic free haem accumulating within the acidic food vacuole. 
Although there is substantial evidence suggesting CO acts through interaction with 
haem-derived compounds, the precise mechanism of action remains to be established. 
In addition, it has been proposed that CO accumulation in the Plasmodium food vacuole 
is directed by its dibasic property and the pH gradient across the vacuolar membrane 
(Ferrari, et al., 1991). The uncharged CO is protonated once it diffuses passively into the 
acidic environment (pH 4.5 - 5.0). The diprotonated CO cannot move across the 
hydrophobic vacuolar membrane, and is effectively trapped within the acidic food 
vacuole. The stage-specific CO is thus proposed to inhibit haemoglobin proteolysis 
and/or alternatively inhibit the dimerization process. In contrast, CO competitively inhibits 
haem degradation by glutathione thus increasing haem efflux out of the food vacuole 
(Ginsburg et al., 1998; Deharo et al., 2003), leading to haem accumulation within the 
parasite membrane. The damaging of the biological membrane leads to homeostasis 
disruption, causing parasites to burst. All these hypotheses are consistent with CO's 
safety since the parasitic food vacuole does not exist in mammalian cells and is therefore 
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1.6.1.3 CQ resistance 
It is well accepted that CQ's antimalarial activity stems from the drug's uptake and 
accumulation into the parasites. However, evolved CQ resistant (CQR) strains 
accumulate less CQ than their susceptible ones, thereby reducing CQ uptake to prevent 
the incorporation of potentially toxic haematin into inert haemozoin within the food 
vacuole of the parasites (Fitch et a/., 1982). The molecular explanations remain subject 
to much debate. Several leading biochemical models proposed include (i) alteration of 
the digestive vacuole (DV) pH, (ii) changes in CQ flux across the cytoplasmic membrane 
of parasites or parasitic DV membrane (iii) reduced binding to an intracellular receptor, 
haematin and (iv) increased glutath:one-mediated detoxification. 
1.6.1.3.1 Alteration of digestive vacuolar pH 
As a lipophilic basic drug, non-protonated CQ (pKa1 = 8.1, pKa2 = 10.2) enters the 
parasitic lysosome (DV) by passive diffusion, where it becomes protonated and remains 
'trapped' (Foley and Tilley, 1997). The membrane-impermeable CQ accumulates at mM 
concentration levels, preventing parasite detoxification of its own waste. It is thought that 
the smaller the pH gradient, the smaller the CQ accumulation. According to this model, 
COR P fa/ciparum achieves an increased lysosomal pH to limit pH gradient differences, 
thereby reducing the expected CQ accumulation by a weakened ATPase proton pump in 
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1.6.1.3.2 Decreased CQ uptake and increased CQ efflux 
Since haemaglobin is host-derived, it is thought that CO resistance cannot arise 'from the 
structural change of the haematin target; in turn, a reduced uptake of CO to lower the 
levels of CO in resistant isolates has been proposed. Interesting results have shown that 
some inhibitors of the Na+/H+ exchanger competitively inhibit the transport of CO, further 
supporting this notion (Sanchez et aI., 1997; Wunsch et al., 1998). 
Alternatively, CO resistant falciparum malaria has been proposed to possess an efflux 
process analogous to multi-drug resistant (MDR) cancer cells. One such distinguishing 
feature of MDR cancer cells is the overexpression of an ATP-dependent drug exporter, 
P-glycoprotein (Pgp) which is thought to be the characteristic transporter of a wide range 
of unrelated compounds out of the cells (Riordan et al., 1985). Genetic evidence 
revealed a homologue of Pgp in P. falciparum, termed PfPgh-1, localizing to the DV 
membrane (Foote et al., 1990; Ridley, 2002). Krogstad and his colleagues further 
support this proposal by the observation that the efflux rate of pre-accumulated CO in 
COR parasites is faster than in COs parasites (Krogstad et al., 1987; Martiney et al' J 
1995). More recent investigations put forward suggest that the transfection of the Pgh-1 
encoding gene, Pfmdr1 on the chromosome 5, from COR to COS results in decreased 
CO concentration in resistant parasites, also supports the involvement of Pgh-1 (Reed et 
al' J 2000). Furthermore, reversal of CO resistance with verapamil and other resistance 
modulators provides additional evidence for the analogy to MDR cells as MDR 
phenotypes can be reversed by compounds inhibiting Pgp transport to increase their 
sensitivity to the drug (Martin et al., 1987; Ford, 1996). 
1.6.1.3.3 A molecular marker for CQ resistance - PfCRT 
CO resistance was very slow to develop, suggesting multiple mutations were required to 
produce the resistance phenotype. Laborious gene mapping efforts have been carried 
out by investigators worldwide and a CO resistance candidate gene was eventually 
identified on chromosome 7 and thought to be responsible for the difference in CO 
accumulation between CO-sensitive and -resistant isolates (Wellems et al., 1991; Su et 
al' J 1997; Wootton et al., 2002). A milestone in CO resistance was established by the 
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(Plasmodium falcparum CO resistance transporter) in genetic cross analysis in vitro 
. (Fidock et al., 2000). 
Compelling evidence showed that sensitive parasites conferred a resistance phenotype 
with a mutant pfcrt gene transfection. In addition, transfected mutants were found to 
have a lower vacuolar pH, contradicting the hypothesis that resistant parasites possess 
elevated vacuolar pH. In a complementary study, Dzekunov and co-workers further 
demonstrated a lower pH in COR parasites rather than in COs clones (Dzekunov et al., 
2000). These observations put forward the hypothesis that a lower vacuolar pH favours 
the haemozoin formation (Fidock et al., 2000; Hyde' 2002). Moreover, it has been 
reported that verapamil reversibility was associated with a mutated chloride channel 
(Martiney et al., 1995); recent empirical data showed that PfCRT expressed in yeasts 
exhibited some chloride channel features (Zhang et al., 2002). This chloride channel 
could direct an increase in DV pH by varying the entrance and exit of chloride ions, 
thereby preventing access of basic drugs interacting with haematin (Zhang et al., 2002). 
Despite the fact that verapamil has little ~ntimalarial effect, it is shown to restore CO 
sensitivity in COR P. falciparum (Martin et al., 1987; Adovelande et al., 1998). A recent 
study on the correlation of drug activity with residue hydrophobicity, side-chain volume 
and charge in mutant PfCRT CO-sensitive and -resistant parasites showed verapamil 
chemosensitized the pfcrt-modified isolates to CO (Sidhu et al., 2002). The results 
provide additional evidence that PfCRT may function as a channel which, when mutated, 
permits efflux of CO from DV, thereby decreasing the CO concentration within the 
Iysosomes of CO resistant parasites. Evidence brought forward suggests that verapamil, 
as a known COR reversal agent, interacts hydrophobically with the lysosomal intergral 
proteins and replaces the lost positive charge of PfCRT causing the protonated CO to be 
trapped inside the parasitic DV, leading to parasite death (Sidhu et al., 2002; Warhurst, 
2003). it is thought that the more hydrophobic resistance reversers are more likely to 
bind to PfCRT proteins and block the efflux of protonated CO, restoring CO sensitivity. 
Although a number of hypotheses have been proposed to be possible mechanisms of 
CO resistance, it is inevitable to conclude that the transmembrane protein may be 
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1.6.2 The antifolates 
The antifolate antimalarials were generated through the knowledge of cell biology and 
synthetic medicinal chemistry (Ridley, 2002). This class of compounds is still commonly 
used as the first-line alternative to CQ in Africa since they are cheap and particularly 
effective against a mass scale of CQ-resistant African lines (Landgraf et al., 1994). 
However, the long established parasite resistance to antifolates in parts outside Africa 
has threatened the use of this formulation (Sherman et al., 1998). The principal 
antifolates are dihydrofolate reductase (DHFR) inhibitors, pyrimethamine and proguanil, 









Fig. 1.6.2. Chemical structures of antifolate drugs. 
1.6.2.1 Antifolate's mode of action 
Most host tissues either synthesize purine and pyrimidine rings de novo from their 
precursors (C02 , folic acid) or use exogenous uptake to produce nucleotides (Sherman 
et al., 1998). Malaria parasites exhibit de novo folate biochemical pathways during 











Chapter 1 Introduction: Malaria 
acids. Instead, humans obtain the vital nutrients through dietary intake. The principal 
action of antifolates is the inhibition of plasmodial folate biosynthetic pathways 
consequently inhibiting DNA synthesis. 
Fully reduced folate cofactors are essential for nucleotide and amino acid metabolism 
and are therefore essential for Plasmodium growth (Ridley, 2002). However, the 
multi-step folate synthesis involves various enzymes of which DHFR and DHPS are 
targeted by current antifolates. Cycloguanil, the active metabolite of both pyrimethamine 
and proguanil, inhibits DHFR activity which reduces dihydrofolate into the reduced 
functional form by competing with its natural substrates (Pasvol et al., 1995). Similarly, 
sulfadoxine competitively inhibits the dihydrofolate precursor formation by mimicking the 
natural substrate of DHPS, p-aminobenzoic acid (Pasvol et al., 1995; Hyde, 2002). 
Pyrimethamine and sulfadoxine combination, known as Fansidar, is the most significant 
formulation as both compounds act synergistically with each other and target the same 
biosynthetic pathway. Furthermore, long half-lives of the components highlights the 
practical use of treating sensitive falciparum particularly to out-patients as a single dose 
regimen (Pasvol et al., 1995). 
1.6.2.2 Antifolate resistance 
Extensive use of Fansidar inevitably led to antifolate resistance which is now widespread. 
Resistance to antifolates is by far the best understood mechanism in all drug-resistance 
processes to date. The major resistance mechanism is mutations at the target enzymes 
(Wang et al., 1997; Ridley, 2002). High-level pyrimethamine resistance results from the 
accumulation of mutations in the dhfrdomain whereas the relationship of dhps mutations 
correlates with sulfadoxine resistance (Hyde, 2002). The acquired mutations alter the 
binding affinity of the inhibitors to the target enzymes, thereby enabling the parasites to 
tolerate elevated concentrations of antifolate antimalarials (Sherman et al., 1998). 
Despite the combination of mutations in the target enzymes of Plasmodium, exogenous 
uptake of folate by human hosts also contributes to the clinical failure of this class of 
antimalarials by means of parasite's salvage of pre-formed folate, thus by-passing the 











Chapter 1 Introduction: Malaria 
In response to the emergence of antifolate resistance, another synergistic combination is 
proguanil with atovaquone, Malarone, was licensed for clinical use in 2002. It is currently 
used primarily as a prophylactic agent. This fixed-dose formulation of Malarone shows 
similarity to that of Fansidar though targeting mitochondrial electron transport (Ridley, 
2002). However, drawbacks associated with high cost due to complex synthetic routes to 
atovaquone and the rapid development of atovaquone resistance prevent Malarone's 
widespread use, especially in malaria endemic areas of the African continent. 
1.6.3 Artemisinin and its derivatives 
The active antimalarial ingredient artemisinin originated from the Chinese herbal plant 
qing hao (Artemisia annua) in the early 1970s (Hyde, 2002). The isolated natural product 
artemisinin was used as a parent compound to generate several semi-synthetic 
analogues, sodium artesunate, arteether, artemether and dihydroartemisinin, in order to 
increase its solubility and antimalarial activity (Fig. 1.6.3). This class of drugs has a 
unique structural feature that lacks a nitrogen-containing heterocyclic ring, which is 
found in most antimalarials. 








Fig. 1.6.3. Chemical structures of artemisinin and its derivatives. 
These antimalarials are fast acting against gametocytes, the sexual stage of parasites 
that infect Anopheles vectors, thereby limiting the transmission to new hosts and 











Chapter 1 Introduction: Malaria 
analogues play an invaluable role in the treatment of acute and uncomplicated malaria in 
South-East Asia (Pasvol et al., 1995). In other parts of the world, artemether, arteether 
and artesunate are being used increasingly or being evaluated for use. 
1.6.3.1 Artemisinin's mode of action 
The precise mode of action of artemisinin is still to be settled, however, there is a 
consensus that the mechanism involves the unique structural feature of the 
endoperoxide bridge of artemisinin and its derived free radicals. 
Peroxides are known to transform into free radicals, accordingly it has been suggested 
that free radicals cause oxidative stress in Plasmodium, resulting in parasite death. This 
model involves activation and alkylation (Meshnick et al., 1996). The activation is thought 
to be initiated by an Fe(II)-mediated cleavage of the endoperoxide bridge (Fig. 1.6.3.1). 
Consequently, this process generates one or more types of highly reactive free radicals 
which are capable of alkylating or otherwise covalently modifying parasitic proteins 
(Meshnick et al., 1996; Olliaro et al., 2001; Hyde, 2002; Ridley, 2003). This theory thus 
suggests the oxido-reductive interaction with Fe(U)-haem in the parasitic digestive 













Fig. 1.6.3.1. Proposed interaction of artemisinin with iron (Reproduced from Dr. Robert G. Ridley, 
UNDPlWorldBanklWHO SpeCial Programme for Research and Training in Tropical Disease, World Health 











Chapter 1 Introduction: Malaria 
In contrast, Krishna and co-workers showed compelling evidence that artemisinins are 
found to spread throughout the cytoplasm, but specifically in the food vacuole of the 
parasites (Eckstein-Ludwig et al., 2003). Moreover, the study demonstrated that the 
iron-dependent mechanism generates artemisinin-derived free radicals that are able to 
inhibit a malarial calcium-dependent ATPase, eventually resulting in parasite death 
(Eckstein-Ludwig et al., 2003; Ridley, 2003). Meshnick and colleagues have shown 
artemisinin can bind to several different proteins; thus it is thought that the drug has 
other molecular targets, in addition to the Ca2+ - ATPase (Meshnick et al., 1996). 
Furthermore, the effect of artemisinin on nitric oxide (NO) synthase and transcriptional 
factor NF-kB activation in a human astrocytoma cell line was investigated (Aldieri et al., 
2003). Cerebral malaria is caused by parasite accumulation in the capillaries of the brain 
and/or excess tumor necrosis factor-alpha (TN F-a,) , which is regulated by the most 
upstream nuclear factor, NF-kB. TNF-a, further correlates with the severity of P. 
falciparum since it can induce NO overproduction related to neuronal dysfunction in 
cerebral malaria. This study suggested another mechanism of action that arteminisin 
was able to modulate NO synthesis by suppressing the transcriptional factor, NF-kB, as 
well as its antiparasitic properties. 
1.6.3.2 Artemisinin resistance 
There have been no significant clinical reports of resistance to artemisinin and its 
derivatives even though these drugs are being used increasingly. However, in vitro 
investigations revealed artemisinin resistance has been achieved in P. falciparum by 
drug pressure, demonstrating the possibility of resistance (Inselburg, 1985). In a 
complementary study, some parasites were shown to respond to drug pressure by 
entering a dormant stage that is resistant to further inhibition (Hoshen et al., 2000). 
Short half-lives of these antimalarials necessitate a longer term regimen as monotherapy 
often leads to high recrudescence rates (Pasvol et al., 1995). It is therefore 
recommended to be co-administered with drugs from different families with longer 
half-lives to decrease the possibility of inevitable drug resistance (Ridley, 2002). 
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than the conventional antimalarials has hampered the practical use on a large scale, 
particularly in Africa where help is needed the most. 
1.6.4 Urgent medical aid for malarial chemotherapy 
The competence of parasites to evolve resistance has outpaced the strenuous efforts of 
investigators and heath officials worldwide to eradicate this global burden of malaria 
through vector control programs, preventive and curative measures. However, despite 
the weight of previous failures to combat malaria, and the variety of threats we endure, 
the fact that mosquito and parasitic genomes have been sequenced recently has raised 
hopes to control and treat this disease in the coming 7 - 15 years (Holt et a/., 2002; 
Gardener et a/., 2002). At present, since malaria control relies profoundly on 
chemotherapeutic agents, it is imperative to rapidly put in place strategic plans for the 
discovery and development of novel antimalarials and/or other alternatives if we are to 
avoid the ever-increasing drug resistance phenomenon. An alternative strategy to 
overcome this obstacle is drug combination. One approach to drug discovery and 
development is the investigation of new resistance modulators by combining the power 
of biology and medicinal chemistry. 
1.7 The need for drug combinations 
There is a growing consensus that fixed-dosed combinations are crucial to malaria 
control as drug combinations potentially offer several important advantages over 
monotherapy. Most importantly, drug combination would reduce the possibility of 
antimalarial drug resistance to evolve since at least one agent would have been clinically 
active. Second, they should provide improved efficacy because the appropriate 
combinations would have afforded additive potency, providing synergistic effects. Third, 
poor compliance with complex drug regimens could be Significantly improved particularly 
in areas with poor health infrastructure and follow up supervision. Another probable 
additional advantage would be cost-effectiveness if the combinations would increase the 
potency of one drug to another, thereby reducing dosages of individual agents (Fidock, 
et a/., 2004). In Thailand, the combination of artesunate and mefloquine is a 
recommended policy and has already shown excellent efficacy and reduced the 











Chapter 1 introduction: Malaria 
Ideally, combination regimens should incorporate two novel agents to limit the exposure 
of single agents to resistance. However, these are the major challenges in new 
antimalarial drug discovery and development. An alternative approach is to realize 
resistance modulators which potentiate the action of current existing antimalarials. 
1.7.1 Chemosensitizersl resistance modulators 
Multi-drug resistance (MDR) in cancer is defined as the capability of tumor cells to 
survive continuous exposure to chemotherapeutic drugs. In MDR, inhibitors applied to 
drugs or compounds that are able to overcome MDR are called "overcoming agents", 
"reversers", "modulators", "modifiers" and "chemosensitizers". Work with MDR cells has 
shown the possibility to reverse anticancer agent resistance by using a combination of 
chemosensitizers or resistance modulators, which are agents able to antagonize 
multi-drug resistance, at safe therapeutic doses (Hwang et al., 1996). In P. falciparum, it 
has been suggested that a phenomenon similar to the MDR phenotype in cancer cells 
may be a possible mechanism to explain the CO resistance since the combination of the 
calcium channel blocker, verapamil, with CO was able to sensitize malaria parasites to 
CO in vitro (Martin et al., 1987). Such a combination strategy has been adapted to 
overcome and/or delay multidrug resistance in malaria. It is based on the principle that 
drug resistance to antimalarial drugs occurs by an independent mechanism and that 
multidrug resistance will only occur when a single organism or cell develops mutations 
which leads to resistance to each independent drug (Bitonti et al., 1988). This multidrug 
therapy has been investigated widely and comprehended. One major advantage of this 
tactic is the possibility of prolonging the life of CO which provides invaluable advantages 
such as safety, efficiency, cost-effectiveness, and wide versatility for both prophylactic 
and curative purposes. 
1.7.1.1 Synthetic chemosensitizers in malaria 
Chemosensitizers in malaria are ideally drugs which do not exhibit intrinsic antimalarial 
activity when used alone but enhance the effect of antimalarial drugs. Furthermore, 
reversal of resistance is associated with an increase in drug accumulation in the drug 
resistant lines. A number of commonly used synthetic drugs such as calcium channel 











Chapter 1 I ntroduction: Malaria 
the antipsychotic trifluoperazine; antihistamines, chlorophenaramine and promethazine 
have been demonstrated to restore drug sensitivity in resistant cells by reducing the 
inhibitory concentration to that of the susceptible cells within tumor cells (Fig. 1.7.1.1-A). 
In parallel, initiated by the pioneering studies in cancer therapy, these cancer MDR 
chemosensitizers have been shown to restore CO sensitivity in COR isolates in vitro and 
in animal models (Martin et al., 1987; Sherman et al., 1998; Adovelande et al., 1998). 
Unfortunately, unacceptably high concentrations of these resistance reversers are 
required for their effects in many cases. On the other hand, the inexpensive 
antihistamine chloropheniramine has been shown to restore CO sensitivity at safe 
dosing levels. However, the adverse effect of drowsiness has limited the acceptance of 
this therapy (Sowunmi et al., 1997). In a more recent study, the combination of a cocktail 
of structurally and functionally diverse MDR chemosensitizers in cancer cells at 
pharmacological concentrations has shown clinically relevant resistance reversal against 
CO resistance strains (van Schalkwyk et al., 2001). In view of the striking similarity with 
those observed in MDR anticancer agents, it has been postulated that a similar 
resistance reversal mechanism exists in malaria (Martin et al., 1987; Rasoanaivo et al., 
1996). In cancer therapy, lines of evidence suggested that a decrease in drug 
accumulation within tumor cells is a mechanism of anticancer drug resistance. In the 
mechanism of CO resistance, it has been reported that resistant malaria parasites 
accumulate less CO than their sensitive counterparts so that CO does not reach the 
required dose level to kill the resistant malaria parasites (Fitch, 1970; Krogstad et al., 
1987). More recently, there has been evidence supporting the mechanism that the active 
verapamil-sensitive efflux carrier (via either P-glycoprotein efflux pump and/or the 
transporter protein, PfCRT, and/or through vacuole proton leak) expels the incoming CO 
from the parasites in resistant cells (Sanchez et al., 2003). It showed that the efflux pump 
has a low affinity for ATP. In resistant celis, an ATP-dependent CO efflux carrier moves 
CO out of its intracellular compartment with the result that a small rise in the intracellular 
ATP level was not sufficient to activate the pump fully; compared to an increased extent 
in CO accumulation with the addition of glucose in sensitive strains. Although the precise 
mechanism of CO resistance and its reversal remain a subject of debate, it has 
prompted research into the mechanism of CO resistance and its reversal and stimulated 
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Figure 1.7.1.1-A. Chemical structures of commonly used drugs as modulating agents in cancer 
cells and in caR p. fa/ciparum isolates. 
It has been proposed that studies on diversity-oriented chemical synthesis involving the 
generation of random mutations of resistance proteinsl proteins involved in resistance, 
and directing chemical libraries against these mutants can be used as the first step in a 
process to explore cellular and organismal pathways (Spring et al., 2001; Chibale, 2002). 
The success of this approach would provide simultaneous identification of the protein 
target (therapeutic target validation) and chemosensitizers that modulate the functions of 
these proteins (chemical target validation). With respect to this, structure-activity 
relationships and molecular modeling studies should provide a pharmacophoric moiety 
for reversal agents and propose a model of drug interactions (Alibert et al., 2002). 
Several synthetic potential CQ resistance reversers have shown some interesting results 
for Plasmodia (Fig. 1.7.1.1-8) (Rasoanaivo et al., 1996; 1999; 8atra et al., 2000; Guan et 
al., 2002; Osa et al., 2003). 
The calcium channel modulator, chloropromazine was found to act synergistically with 
CQ in vitro against the resistant strain from Indochina at concentrations much lower than 
therapeutically required doses (Kyle et al., 1990; Rasoanaivo et al., 1996). Compounds 
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Chapter 5, section 5.3.2) of 0.21 and 0.23 compared to that of verapamil (0.51) in vitro 
(Guan et a/., 2002). In the complementary studies, synthetic compounds CDRI-87/209 
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Figure 1.7 .1.1-B. Chemical structures of some synthetic malaria chemosensitizers under 
investigations. 
1.7.1.2 Naturally occurring chemosensitizers 
In natural products, structurally related flavonoids castitin and artemitin were found to be 
capable of enhancing the growth inhibition of artemisinin selectively of P. fa/ciparum (Fig. 
1.7.1.2) (Rasoanaivo eta/., 1996). In addition, the structurally related isoquinoline dimers 
of herveline A, Band C, isolated from the stem barks of Hemandiaceae species from 
Madagascar and the indole alkaloids of strychnobrasiline were found to restore CQ 
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Figure 1.7.1.2. Structures of several naturally occurring products as chemosensitizers in malaria. 
The circumvention of drug resistance in malaria by the use of resistance reversal agents 
in combination with standard antimalarial drugs may serve as a viable treatment to 
restore the efficacy of the latter in patients with malaria. However, even though these 
preliminary results of combination therapy in malaria have shown some potential in the 
treatment of complicated malaria, further details of pharmacological safety and efficacy 
studies are necessary to reveal clinical importance. In this regard, new resistance 
modulators with more selectivity in the mechanism of reversal are needed. Although CQ 
appears to have failed as a first-line antimalarial in most parts of the world, this 
well-tolerated antimalarial agent may be resurrected by combination therapy with 
effective resistance reversal agents (Rosenthal, 2003). 
1.8 Impact of ABC drug transporter stUdies on drug discovery and development 
Drug transporters also playa significant role in drug delivery, drug design, discovery and 
development processes. The important information on their functional characteristics 
such as substrate specificity and their localization provides imperative information about 
the mechanisms of drug disposition. In addition, knowledge about the resistance 
mechanism involved will allow the development of new drugs to minimize and 
circumvent drug resistance. Transporters of the ATP-Binding Cassette (ABC) family are 
known to provide the basis for drug resistance mechanisms from pathogenic yeasts, 
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1.8.1 AlP-Binding Cassette (ABC) transporters 
Transporters are categorized into primary, secondary or tertiary active transporters. 
Primary active transporters like ABC transporters are driven by ATP hydrolysis. The 
driving force for secondary or tertiary active transporters, such as organic anion 
transporters (OAT), organic anion transporting polypeptides (OATP), sodium 
taurocholate cotransporting peptide (NTCP), organic cation transporters (OCT), novel 
organic cation transporters (OCTN), and oligopeptide transporters (PEPT) is an 
exchange of intracellular and/or extracellular ions (Mizuno et al., 2003; Burckhardt and 
Wolff, 2000; Lee et al., 2001). 
The ABC transporter proteins can be classified into two major subfamilies which are 
extensively involved in the tolerance to' a wide diversity of cytotoxic agents (Cui et al., 
1996). One subgroup consists of human mediating multidrug resistance (MDR) of which 
MDR1 was the first discovered ABC transporter protein (Katzmann et al., 1999). The 
other comprises of human multidrug resistance-associated proteins (MRP) that have 
more recently been found. Members of the ABC superfamily share similar molecular 
architecture with a repeating structure of a set of transmembrane domains followed by 
nucleotide-binding domains (NBD) (Cui et al., 1996; Katzmann et al., 1999). 
Nonetheless, MRP possesses several distinct features different from MDR1. First, MRP 
has an additional set of transmembranes at its N-terminus. Second, MRP proteins 
modify substrates such as glutathione (GSH) and glucuronide conjugates (Fig. 1.8.1) 
(Mizuno et aI., 2003; Katzmann et a/., 1999; Li et al., 1997). Lastly, NBD10f MRP has a 
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Several well known ABC transporter proteins are medically associated with clinical drug 
resistance in humans, for instance, the mdr1 gene product of Pgp, MRP1-8 proteins and 
more recently breast cancer resistance protein (BCRP) (Klokouzas et al., 2003). These 
transporter proteins have been targeted for inhibition by resistance modulators to 
enhance the chemosensitivity of resistant tumors. Similarly, the Pfmdr1 encoded PfPgh1 
in P. falciparum adapted the human multidrug resistance phenomena and there is 
consistent evidence of its involvement in the resistance process (Martin et al., 1987; 
Adovelande et al., 1998; van Schalkwyk et al., 2001). Such a drug targeting approach is 
one effective tactic to optimize pharmacological profiles of drug candidates. 
1.8.2 ABC transporters in Saccharomyces cerevisiae 
It is well accepted that PfPgh1 and PfCRT are involved in the drug resistance process in 
falciparum malaria. Even though PfCRT shares no homology to the ABC superfamily, its 
critical role in transport function has yet to be shown. In contrast, the knowledge and 
technology required for transport studies are well established in yeasts, it is thought that 
the study of drug transport in malaria will be greatly assisted by the infonnation from 
yeast transport systems. 
The baker's yeast, Saccharomyces cerevisiae, was the first eukaryotic organism found 
to possess a number of ABC transporter proteins (Bauer et al., 1999). It is believed that 
mammalian MDR and P. falciparum multidrug resistance phenomenon are analogous to 
pleiotropic drug resistance (PDR) in yeasts. In addition, the fact that yeast has several 
orthologues of mammalian disease genes makes yeast an invaluable model system to 
unravel molecular mechanisms of transport function (Bauer et al., 1999). In an attempt to 
better understand the function of PfCRT, a successful expression of a full-length malaria 
parasite integral membrane protein in yeast Pichia pastoris was achieved despite the 
very high AT content in malarial genes (Zhang et al., 2002). The study concluded that 
mutant Pfcrt function in conferring caR may include the effect on the H+ pump system. 
The heterologous Pfcrt expression in yeast has undoubtedly assisted further 











Chapter 1 Introduction: Malaria 
Inspired by this successful manipulation in yeast transport systems, another attempt at 
transport protein study in yeast is of interest. A homologue of mammalian multidrug 
resistance protein, yeast cadmium factor protein (YCF1 p), localized to the vacuolar 
membrane in yeast S. cerevisiae is investigated (Fig.1.8.2). 
GSH ~:1,ep 




Weak orgainc anions 
GSH-congugates, metals (Cd, pt, As) 
Yef3p 
Pdr5p. Pdr10P. Pdr11p 
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non-charge drugs 
Weak organic anions (anthracyclines) 
Figure 1.8.2. Schematic diagram of ABC transporters of yeast S. Cerevisiae. YCF1 p is localized 
to the vacuolar membrane. ER, endoplasmic reticulum; G, Goigi apparatus; M, mitochondrion; N, 
nucleus; P, peroxisomes; and V, vacuole. (Adapted from Bauer et al., 1999, Biochimica et Biophysica Acta) 
1.8.3 The yeast cadmium factor protein (YCF1 p) 
The mammalian MRP homologue YCF1 p coded by 1515 amino acids was the first ABC 
transporter protein identified in response to its ability to elevate Cd2+ tolerance. YCF1 p 
shows a domain organization similarity to MRP (42.6% identity; 63.4% similar) and also 
to human MDR (Li et al., 1996; Cui et aI., 1996; Kolaczkowski et al., 1998). In addition, 
evidence revealed that YCF1 p not only shares structural resemblance but also a 
functional homology to MRP (Li et al., 1996). It plays an important role in vacuolar 
detoxification of heavy metals like arsenite, arsenate and antimony in addition to Cd 2+. 
YCF1 P localizes to the membrane of the digestive vacuole which is the primary turnover 
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localize to the DV membrane. Thus, potentially important information derived from the 
drug interaction against YCF1p in S. Cerevisiae is likely to provide information into the 
function of the related eukaryotic proteins. 
1.8.4 ABC transporters and their role in Chloroquine resistance in P. falciparum 
ABC transporters have become the targets for inhibition by resistance modulators to 
enhance chemosensitivity in tumor cells, for example, the recently discovered breast 
cancer protein (Klokouzas et al., 2003). Multiple cellular mechanisms in MDR involve 
cellular reaction and intracellular distribution, which involves the efflux transport and 
intracellular entrapment of the chemosensitizers (Wiese and Pajeva, 2001). The outword 
transport is associated with the transport protein, Pgp and to a lesser extent MRP. The 
idea that ABC transporters may be involved in CO resistance in P. falciparum came from 
the initial finding that CO resistance appears to be modulated by the human Pgp 
modulators verapamil and desipramine in vitro. 
Some research has shown the involvement of P. falciparum MDR (PfMDR1) gene in 
antimalarial resistance by transfections of the polymorphic mutations of the PfMDR1 
gene into CO-sensitive clones containing the wild-type PfMDR1 gene (Foote et al., 1990; 
Reed.et al., 2000). The studies showed that although not the determinant of CO 
resistance, the Pgp homologue in P. faiciparum (Pgh-1) modulates resistance to quinine, 
to CO (in a strain-specific manner) but not to mefloquine, halofantrine and the 
structurally unrelated artemisinin (Reed et al., 2000; Duraisingh et al., 2000). It can be 
tentatively concluded that the Pgh-1 substrates are chemically and structurally different 
compounds considering the fact that some reversers (verapamil, cyclosporine A, 
diltiazem) were found to be able to bind to Pgp and are transported by it, others 
(progesterone) block the efflux of the cytotoxic agents even though binding to it (Wiese 
and Pajeva, 2001). 
More recent work has brought evidence for a drug efflux carrier as the mechanism of CO 
resistance in falciparum (Sanchez et al., 2003). The data suggests that CO binds to 
intracellular binding sites; however, in CO resistant cells the energy-dependent 
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compartment so that there was not sufficient CO accumulation to cause parasite death. 
Such efflux process can be inhibited by CO resistance reversers like verapamil. 
Collectively, the very substantial studies on the accumulations of CO in malaria-infected 
red blood cells have shown that ABC transporters are relevant to CO resistance in P. 























Chapter 2 Drug research and development 
2.1 Drug discovery and development 
To tackle the global burden of malaria, new treatments such as vaccines, antimalarial 
drugs and/or resistance modulators are desperately needed to meet the challenge of 
resistance as it arises. The current drug discovery and development process attempts to 
identify molecules not only easy to manufacture (affordability is crucial), stable, readily 
formulated but also in consideration of bioavailability ADMET (adsorption, distribution, 
metabolism, excretion and toxicity) properties. Worldwide, investigators have focused 
upon drug research and development (R&D) with enormous effort put into traditional 
medicinal plant discovery and more recently in medicinal chemistry approaches. 
However, only a limited number of potential molecules meet the criteria as drug 
candidates and even fewer are registered as medicines (Table 2.1). Drug design and 
discovery is envisioned as an extraordinary complex process. In the early discovery 
process, a hit molecule which gives a positive outcome in a bioassay in the exploratory 
screens has to be realized before being modified as a lead. A lead is the molecule 
optimized through pharmacokinetic, pharmacodynamic as well as efficacy stUdies into 
promising lead compounds that can be selected as pre-clinical candidates. In passing 
the need for a lead series of compounds, it is essential to show evidence of in vivo 
activity, structure·activity relationship (SAR) trends, known mechanism of action, 
selectivity, physical properties and chemical tractability. Physical properties are as 
referred by the Lipinski's rule of 5 (see section 2.1.1 for details) while chemical tractability 
deals with the presence of multiple functional groups at which the molecule can be 
modified to improve desirable properties. Followed by successful animal studies, the 
ultimate drug candidate(s) enter the human three-phase clinical development before 
registration. Major hurdles encountered are i) the potential molecules are toxic to 
humans even though they are highly active in vitro and ii) although meeting the 
requirements in vitro, fail to reveal activity in vivo. Drug efficacy, pharmacology and 
toxicity are all important parameters in the selection of compounds for development. 
In this study, it is the intention to exploit the use of technologies of medicinal chemistry 
with the knowledge of basic biology and biochemistry of parasites to synthesize and 
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Table 2.1 Criteria for hit, lead and pre-clinical candidate compounds 
in vitro activity 
in vivo activity 
Structure-activity-relationship trends 
Known mechanism of action 
Pharmacokinetic profile 
Acceptable estimated daily dose 
Selectivity: related systems 
Selectivity: wide range system 
Acceptable cytochrome P450 profile 




Clean in early toxicology (e.g. 7 day rat) 
Hit 
" 
2.1.1 Lead identification and optimization 














This transition phase before entering pre-clinical development undergoes extensive 
analyses with respect to improved pharmacological activities and minimized undesired 
properties of the hit molecules identified. This process is likely the most labor intensive 
and difficult to achieve as identified hits are to be developed into lead molecules which 
are often further modified into promising pre-clinical candidates. 
Lead optimization includes identification of a pharmacophore. The pharmacophore of a 
compound is the minimum structural requirement for binding to a receptor. It is 
responsible for the observed pharmacological activities. It is normally identified prior to 
any modifications to the hits. This requires repetitive cycles of chemistry and biology in 
order to generate structure-activity relationships using medicinal chemistry, which can 
generate a vast chemical diversity of compounds simultaneously in a resource-effective 
manner (Terret et aI., 1995). Much effort has gone into rational drug design of new 
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Much progress has been made to define adequate parameters to guide chemical 
synthesis producing molecules that possess the desired pharmacological properties and 
bioavailability. This is perhaps best embodied in 'Lipinski's' rule of 5' (Lipinski et al., 1997; 
Lipinski et al., 1997; Ridley, 2002; Fidock et al., 2004). These defined frontiers 
encompass low molecular weight «500 Da), Log P «5; where P is a lipophilicity 
measurement), the number of hydrogen-bond donors «5) and the number of 
hydrogen-bond acceptors «10) (Lipinski et al., 1997). Therefore, the pharmacological 
properties (ADMET) of a compound can be estimated as a function of its physiochemical 
profiles. Implementation of these parameters is ultimately important to obtain leads that 
are likely to demonstrate activity in an in vivo model. In the drug development process,a 
lead compound is modified until its property profiles fulfill the required criteria (see Table 
2.1) for pre-clinical candidates. 
2.2 Rational drug design 
There are different approaches in drug discovery to discover hit compounds: empirical 
screening, rational drug design, drug metabolism studies and clinical observations, of 
which, the rational approach is one of the major source of hits. Rational drug design is 
based on desjgning a compound to interact with an identified biological target. This 
approach is summarized in Table 2.2. 
Table 2.2 Rational drug design 
1. Identify gene or protein target ~ determine whether the target is amenable to the treatment 
2. Obtain structural information on target protein ~ pharmacophore 
3. Virtually screen chemical libraries using pharmacophore ~ SAR studies 
4. Synthesize suitable compounds using chemical approach ~ Chemical synthesis 
5. Perform in vitro biological evaluation ~ hits? leads? 
6. Determine the effects of potential candidates on target protein function ~ antagonists? 
To generate drugs targeting an identified protein, structural and functional information on 
the pharmacophore of the target is useful when available. Prior to synthesis of a 
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substrates to the pharmacophore are studied in order to identify new compounds. 
Subsequently, libraries of compounds with known structures are evaluated in vitro to find 
pharmacophore matches in order to discover hit and/or lead molecules. Those candidate 
compounds then undergo further investigations to reveal their clinical properties as 
agonists or antagonists. 
2.2.1 Fragment - based drug discovery approach 
In efforts to improve hit rates, investigators have analyzed the relationship between the 
structural configurations of leads and their corresponding pharmacological activities 
(Teague et al., 1999; Hann et al., 2001). This led to the conclusion that ''the smaller the 
better". Fragment-based approaches are the strategies that low molecular weight 
chemical fragments are initially selected on the basis of their ability to bind to or inhibit 
the target of interest in a functional assay (Erlanson et al., 2004). In other words, these 
small molecules are considered as building blocks of more complex molecules which are 
optimized further to meet the criteria as hits or leads. Fragment optimization, which is the 
process of converting fragments into hits and/or leads, generally involves combining a 
fragment with elements from a known substrates or inhibitor to create a hybrid molecule 
with improved pharmacological properties (ADMET). For example, the Alzheimer's 
disease target acetylcholinesterase (AChE) is the protein used to assemble its own 
inhibitor (Fig. 2.2.1). The dimeric molecule (4) enhanced the affinities compared to their 
monomeric components (5). In addition, AChE was chemically modified by linking with 6 
using cycloaddition chemistry to produce the AChE inhibitor 7 with potent affinity for 
enzyme binding (Kd :::: 410 femtomolar) (Erlanson et al., 2004). 
"Fragment-based" approaches have been developed to generate a series of 
non-complex molecules which are built by combination or optimization of small 
fragments. The rationale behind fragment-based strategies is to produce simple 
lead..:like molecules that can be further modified into better selective leads retaining 
drug-like propelties. Lead-likeness and drug-likeness are best interpreted by Rishton; 
"drug-likeness serving to identify compounds suitable for drug development and product 
candidacy, and lead-likeness serving to identify compounds that are tractable for 














Kd :: 0.Q18 IlM (mouse) 
IGso :: 0.590 IlM (rat brain) 
4 
+ 
IGso == 4 x 10-4 11M (rat brain) 
Drug research and development 
6 
Kd == 1.1 11M (mouse) 
cCoHN~6NH l..-'i /: ~ N N VS. 
5 
IGso :: 0.390 JJM (rat brain) 
Figure 2.2.1. Fragment optimization of acetylcholinesterase. (Adapted from Erlanson et al., 2004, 
J. Med. Chern.) 
2.2.2 The privileged structure approach 
Initially, the term "privileged structure" was first defined as "a single molecular framework 
able to provide ligands for diverse receptors" by Evans et al. in 1988. In the development 
of the benzodiazepine-based cholecystokinin-A antagonists, certain so called "privileged 
structures" or substructural motifs were shown to be capable of providing useful ligands 
for more than one receptor in the study and thereby concluded that "these structures 
appear to contain common features which facilitate. binding to various proteinaceous 
receptor surfaces, perhaps through binding elements different from those employed for 
binding of the natural ligands". Since the privileged structure term was introduced, the 
selection and derivatization of these substructural motifs has become a working strategy. 
For example several pre-clinical or clinical candidates evolved from their corresponding 
leads were under investigations in Merck (Fatteri, 2004) (Fig. 2.2.2). For example, the 
privileged spiropiperidine fragment (shown in red) was incorporated into the synthesis of 
pre-clinical or clinical candidates from the corresponding leads (left). The preferred 
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optimization process In the development of growth hormone secretagogues, 
Somatostatin-2 receptor and Melanocortin-4 receptor agonists. Nevertheless, the 
strengths of the privileged structure approach are the potential to use less complex 
molecules and therefore more 'drug-like' and the possibility to easily enter the areas of 
biology and chemistry not previously explored. 
Growth hormone secretagogues 
IGso = 300 nM 
Somatostatin-2 receptor agonists 
Ki = 122 nM 
Melanocortin-4 receptor agonists 





IGso = 102 nM 
~: ~I(~~ I H 0 lj) NON Ho9 
IGso = 50 nM 
Ki = 1.0 nM 
IGso = 500 nM 
IGso = 1.3 nM 
Ki = 0.01 nM 







Figure 2.2.2. Several pre-clinical or clinical candidates obtained in Merck through derivatization 
of one among the privileged fragments, the spiropiperidine unit (red). Evolution from lead (left) to 
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2.2.2.1 Structure-activity relationships in chemosensitizers 
Careful inspection of the structures of selected MDR chemosensitizers in malaria (Fig. 
1.7.1.1-A) showed that two essential features of the molecules for resistance reversal 
activity are observed: a hydrophobic aromatic ring and an alkyl side chain with two amino 
groups separated by two or three carbons (Rasoanaivo et al., 1996; Guan et al., 2002). 
In a complementary study in cancer, it has been reported that a derivative of 
4-quinolino-2-hydroxypiperazine(5-[3-{4-(1 0, 11-dihydro-SH-dibenzo[a,d]cycloheptane-5-
yl)piperazin-1-yl}-2-hydroxypropoxy]quinoline) (DSP) had high MDR reversal activities 
against resistant cancer cells without significant toxicity (Suzuki et al., 1997). There were 
then attempts to synthesize and investigate a number of its derivatives for their reversal 
of MDR P. falciparum (Os a et al., 2003). Similarly, a phenothiazine derivative 8, which 
consists of a phenothiazine ring system and a pyrrolidinyl group joined by a 4-C alkyl 
linkage, displayed superior in vitro resistance reversal effect to verapamil in malaria (Fig. 
2.2.2.1-A) (Guan et al., 2002). These studies indicate the general structural features of 
the aromatic ring systems and a tertiary amine that are frequently observed in MDR 
modulators (Ferte et al., 1999; Guan et al., 2002). In line with the hydrophobicity 
requirement on the aromatic ring for good reversal effect, the introduction of a 
hydrophobic group in chalcones resulted in much more active compounds than the 
parent chalcones in cancer (Bois et al., 1999; Rasoanaivo et ai, submitted). In contrast, 
the uncharged polyethoxylated nonylphenol compound, NP30, was able to reverse 
mefloquine, ON, and quinidine resistance (> 80%) and, to a lesser extent, CO resistance 
(Fig. 2.2.2.1-A) (Ciach et al., 2003). The fact that the structure of NP30 does not contain 
nitrogen atoms leads to the suggestion that the proton able nitrogen in the chemical 
structures of resistance reversers is more important for CO resistance reversal. Using 
the MDR Pgp inhibitor vinblastine as a probe, it was reported on the other hand that the 
two planar aromatic domains and the basic nitrogen were important features for cancer 
MDR reversal activities (Pearce et al., 1990; Wiese and Pajeva, 2001). 
In addition, the sUbstitution patterns of the aromatic rings also play an important role in 
effecting CO resistance reversal. Since veraparnil, fangchinoline (9c) and fantofarone 
were found to be very potent resistance modulators both in cancer and malaria, it was 
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groups in the structures of verapamil, fangchinoline and fantofarone points to the 
importance of this substituent in the aromatic ring system for resistance reversal. It is 
noteworthy that the promising CO resistance modulator 1-(3'-diethylaminopropyl)-3-
«4-methoxyphenyl) methylene)pyrrolidine (10 in Fig. 2.2.2.1-A) also possesses a 
methoxy group in addition to the lipophilic aromatic ring and two protonatable nitrogens 
in its structure. 
NP30 
I 
HO~OH ~ I ;rx ~I 
OH 0 
9a: R=Me; 
















Parent Chalcone: X :: halogen 
Chalcone derivative: X = O-alkyl 
(0-n-CZH5; O-n-C.H,; O-n-CSH13; 
O-n-cyclohexyl; O-n-CsHu; 
0-n-C1oHz1 and 0-n-C14H20). 
1S, 1'S: Tetrandrine 
1R, 1'R: Phaeanthine 
1S, 1'S: Fangchinoline 
1R. 1'R: limacine 
Vinblastine 
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8esides the aromatic hydrophobic group, protonatable nitrogen and side chain 
substitutions, structural configurations are also an important factor. When compared 
within the bisbenzylisoquinoline (88IQ) analogues, tetrandrine (9a) was found to act 
synergistically compared to its enantiomer phaeanthine (9b), which showed additive 
effects against CQ resistant parasites (Fig. 2.2.2.1-A). This suggests that the 
configurations at C-1 and C-1' have an effect on the reversal activity within the 881Q 
family. Moreover, the other two alkaloids 9c and 9d differ only by their configurations at 
C-1 and C-1', Fangchinoline (9c) having the configuration of 1S, 1'S was a more 
effective CQ resistance reverser than its enantiomer limacine (9d) (Rasoanaivo et al., 
1996). 
2.2.2.2 A basic chemosensitizing pharmacophore hypothesis 
In connection with the MDR modulators, it was recently proposed that basic 
chemosensitizing pharmacophores may be present in most malaria reversers. Such 
basic pharmacophores were identified as -S-(CH2)n-S' (Fig. 2.2.2.2-A), in which Sand S' 
could be nitrogen or phenyl groups and n :::: 3, 4, 5, 6, by careful inspections of some 
synthetic and naturally occurring chemosensitizers isolated from medicinal plants of 
Strychnos myrloides and Erythroxylum pervillei (Rasoanaivo eta/., submitted). In the 
study, a common unit of N-phenyl-1,3-diamino-propane was identified from 
malagashanine, chloropromazine and desipramine (Fig. 2.2.2.2-8). In addition, a 
1-phenyl-4-amino unit was also identified in the synthetic chemosensitizers 
cyproheptadine, amitriptyline and penfluridol. In another complementary study, the 
reduction of the benzene ring of the indoline group in malagashanine showed similar 
activity to that of the parent compound (Trigalo et al., 2004), which suggests that this 
functional group (benzene ring) was not directly involved in the chemosensitization of the 
concerned indole Strychnos alkaloids (Rasoanaivo et al., submitted). This led to the 
proposal that the 1,4-diamino fragment (red) is another bioactive unit which is also found 
embedded in a number of synthetic chemosensitizers, Strychnos alkaloids and 
chlorpheniramine (Fig. 2.2.2.2-8). Of those compounds studied, all showed resistance 
reversal activities in vitro and thus it was concluded that 1 ,n-diphenyl structure (n :::: 3, 4, 
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/s-(c)n--S' 
R 
S = C, N; R = Phenyl 
S = N; R = Alkyl 
S· = N, Phenyl 
Figure 2.2.2.2-A. Proposed unifying chemosensitizing pharmacophore in malaria. (Reproduced from 
Rasoanaivo et 81., submitted). 
I 
~N" 
(XNl('YCI I~ ~ s 
Malagashanine Chloropromazine Desipramine 
F 
\ N ___ dOH'Q ~ ,J CI N CF 
3 
F 
Cyproheptadine Amitriptyline Penfluridol 
CI 
Nb-C(3)-seco type" Nb-C(21 )-seco type" Chlorpheniramine 
Figure 2.2.2.2-8. Chemical structures of diverse chemosensitizers. A common basic 
chemosensitizing fragment (shown in red) was proposed as the chemosensitizing pharmacophore. 
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2.2.2.3 Potential of biphenyl-based chemosensitizers 
Statistical NMR-derived (nuclear magnetic resonance) binding data on 11 protein targets 
was analyzed in an effort to identify favoured protein binding molecular motifs (Hajduck 
et a/' J 2000). It was found that the biphenyl substructure preferentially binds to nearly 
50% of the proteins tested. This study confirmed that the biphenyl motif is a simple 
substructure, which can fit into a wide range of pockets that exist on protein surfaces 
(Table. 2.2.2.3). It has also been found to appear in 4.3% of all known drugs (Horton et 
a/' J 2003). 
Table 2.2.2.3. identified privileged structures using NMR-Derived Binding data (Adapted from 
Hajduk et a/'J 2000, J. Med. Chern.) 
COOH C02H 6 (55%) 19.4 
Biphenyl 0-0 - ~ /; 5 (45%) 4.3 
Diphenylmethane ()() A- A- 3 (27%) 8.6 
Naphthyl (X) A- A- 1 (9%) 3.3 
Phenyl 0 1 (8%) 73.3 
Cyclohexyl 0 1 (9%) 12.2 
Bibenzyl o--rO ~ A 1 (9%) 5.9 
H 
Benzimidazole erN I A- :> 1 (9%) 0.8 
Quinoline CO I A- N~ 1 (9%) 4.2 
N~N 
1 (9%) 0.2 Triazine ~) 
N 
Benzofuran <X) ~ ~ I 1 (9%) 0.8 
Phenyl phosphate o-POH 3 2 1 (9%) 0.03 
number of projects (11) for which the substructure was represented. 
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The privileged biphenyl framework offers a great degree of flexibility about the aromatic 
linkage as well as molecular rigidity and bioavailability; studies have revealed aromatics 
form favourable interactions with polar substituents and even positively charged groups 
(Hajduck et al., 2000; Horton et al., 2003; Fattori, 2004). With this degree of versatility, 
the biphenyl substructure (Fig. 2.2.2.3) is very popular in pharmaceutical industries and 
has produced a number of promising leads (Patchett, 2002; Fattori, 2004). For example, 
biphenyls are shown as potential anti-tumor, anti-hypertensive and anti-atherosclerotic 
agents (Horton et al., 2003). 
Figure 2.2.2.3. Chemical structure of biphenyl motif. 
From a synthetic chemistry point of view, the biphenyl motif is an attractive template for 
chemical library generation. Several known reactions are utilized for biphenyl privileged 
fragments, including Ullmann synthesis, Stille, Kharasch, Negishi and Suzuki reactions 
(Horton et al., 2003). Suzuki chemistry particularly lends itself to chemical diversity 
generation due to the commercial availability of boronic acid monomers, which can also 
be synthesized. 
In this study, the rationale behind the drug design is to generate potential CQ resistance 
modulators consisting of a hydrophobic biphenyl moiety as a template or scaffold and 
incorporating amino groups based on previous SAR studies. It is hypothesized that the 
lipophilic character of the biphenyl moiety could result in attachment to the PfCRT 
channel and a positive charge possibly provided by the amino group could replace the 
lost positive charge on the mutated channel protein, PfCRT, subsequently restoring CQ 
sensitivity as suggested by Sidhu, Warhurst and co-workers (Sidhu et al., 2002; 
Warhurst et al., 2002). It is therefore of interest to investigate and examine the resistance 
reversal activity and toxicity of the novel compounds at an optimal concentration that 











Chapter 2 Drug research and development 
2.2.3 Efficacy screening models 
Drug discovery involves several different stages in which selection of potential molecular 
targets is the primary process in the early investigation (Fig. 2.2.3). Initially, an improved 
understanding of the molecular basis of the pathogens, the drug's mode of action and 
resistance mechanism can provide potential targets. These targets can be selected from 
enzymes or pathways that are present in the pathogen, but absent from humans or those 
shared between two hosts with structural differences provided. Employing mutated 
organisms is an alternative means to measure the effect of an inhibitor. It will 
demonstrate the mutated form, which an enzyme or receptor loses its efficacy, is infact 
the target (Fidock et a/., 2004). In addition, new genomic and proteomic technologies 
have greatly improved our capabilities to characterize potential molecular targets. 
In addition, it is equally important to develop an appropriate in vitro bioassay in initial 
screening to provide essential information on the activities of potential hit molecules. 
Generally, in vitro screens for compounds are often more rapid and less expensive than 
in vivo animal models since lower organisms or sub-cellular cultures are commonly used. 
Once appropriate laboratory tools are established, different compounds generated can 
be readily screened. Consequently, hits are identified when positive results are produced 
from the assay. 
Iterative medicinal 
Target selection o chemistry ~ 
-8- Drug candidate 
Product 
Development 
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In summary, once a target is selected, potential hit molecules which are rationally 
designed and synthesized are screened in the preliminary in vitro assay until a positive 
result is produced. This identified hit molecule can thus be further modified into potential 
leads. This process requires repetitive chemical modifications and biological evaluations 
until a potential lead molecule gives the confidence that a pre-clinical candidate can be 
found (see Table 2.1). At this stage the drug candidate will enter pre-clinical and clinical 
studies (Fig. 2.2.3). 
2.2.4 Drug development 
Broadly speaking, there are three main stages in the drug development process, 1) 
pre-clinical evaluation, 2) clinical validation and 3) registration (Fig. 2.2.4). When the lead 
molecule is identified during the drug discovery process, it will enter pre-clinical safety 
and efficacy studies. During pre-clinical development, extensive detailed 
pharmacological properties such as acute toxicity and pharmacokinetics (ADMET) are 
assessed from relevant animal models to generate a wide range of safety measures 
before entering human clinical trials. The first phase of clinical verification is aimed at 
safety, pharmacokinetics and tolerability in healthy volunteers whereas finding the 
dose-range, side-effect and clinical proof profiles occur during phase II (Fidock et aI., 
2004). In the last phase of clinical trials, a large sample of subjects is examined to 
confirm a wide margin of safety profile and efficacy of the drug before submission for 
registration (Ridley, 2002). Together with the registration process, it is estimated that 
10-15 years is required to complete the analyses of a drug. 
Risks 
Financial resources 
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The risks of taking the newly developed drug are reduced as the drug development 
progresses. However, this drug development process requires not only devoted 
manpower but also huge financial resources which currently rely upon pharmaceutical 
industries and donations from the private and public sectors. 
2.3 Scope of the study 
This study combines the knowledge of biology and medicinal chemistry to identify 
potential selective and non-toxic chloroquine-resistance reversal agents based upon the 
privileged biphenyl sub-structural motif as well as investigations into transport of 
cytotoxic compounds in a yeast membrane protein. 
Objectives of this study are to: 
1. Rationally design and synthesize novel potential CO resistance reversal agents 
or chemosensitizers in malaria, based upon known structure-activity relationship 
studies 
2. Generate preliminary structure-activity relationships within a series of 
biphenyl-based chemosensitizers 
3. Investigate the in vitro antiplasmodial activity and resistance reversal effect of 
the potential hits in P falciparum 
4. Perform in vitro investigations into the function of specific transport of cytotoxic 






















Chapter 3 Materials and methods 
3.1 Chemistry 
3.1.1 General 
1-Phenylpiperazine and N-methylpiperazine were obtained from Lancaster, Scientific, 
and Sigma-Aldrich South Africa, respectively while 1-benzylpiperazine was synthesized 
chemically. The remaining reagents and solvents were obtained from Sigma-Aldrich 
South Africa. Reactions were monitored by thin layer chromatography (TLC) on 
aluminium-backed silica gel 60 F254 coated sheets (Merck) and visualized with a 
combination of ultraviolet light (254 nm) and anisaldehyde spray (freshly prepared from a 
2.5% solution of p-methoxybenzaldehyde (20 cm3) and IBM sulfuric acid (1 cm3», 
followed by heating at 200°C. Column chromatography was carried out using Merck 
Kieselgel 60: 70-230 mesh. Melting points were measured on a Reichert-Jung hot stage 
microscope and are uncorrected. Infrared (IR) spectra were recorded (NaCI) on a 
Thermo Mattson Satellite FTIR spectrometer connected to a desktop PC running EZ 
OMNIC software (version 6.0A). 1H NMR and 13C NMR spectra were recorded on either 
a Varian VXR-200 at 200 MHz, Varian Mercury 300 MHz or a Varian Unity spectrometer 
at 400 MHz instrument (Department of Chemistry, University of Cape Town) and are 
recorded in parts per million (ppm). All NMR spectra were measured in CDCh and 
tetramethylsilane (TMS) was used as an internal reference. Mass spectra were recorded 
on LC-MS (Department of Pharmacology, University of Cape Town). (See Chapter 4 for 
further details). 
3.2 Cultivation of P. falciparum in vitro 
Different strains of P. falciparum were selected for this study: D10 (ICso ce ::: 23 nM), a 
CO-sensitive strain (provided by the Walter and Eliza Hall Institute of Medical Research 
in Melbourne, Australia), RSA11 (ICso
ce ::: 186 nM) and K1 (lC50
ce ::: 190 nM), 
CO-resistant strains (provided by Dr. Janet Freese, Malaria Research Programme, 
Medical Research Council of South Africa, Durban, South Africa; and isolated at 
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Materials and methods 
The parasites were maintained at 5% haematocrit in continuous culture 
by a method modified from that of Trager and Jensen (Trager and 
Jensen, 1978). P fa/ciparum parasites were infected with type O-positive 
human erythrocytes (Western Province Blood Transfusion Service, 
Groote Schuur Hospital, Cape Town, South Africa) with 10% type 
A-positive human serum. The culture was suspended in RPMI 1640 
(Biowhittaeker) culture medium supplemented with 25 mM HEPES buffer 
(Sigma), 1 % sodium bicarbonate and gentamicin (40 mg/ml) and 
hypoxanthine (44mg/L). Medium was renewed daily and parasitaemia 
was determined using Giemsa stained blood smears of the cultures. The 
A nucleic acid cultures were kept continuously at 37°C under an atmosphere of 3% O2, 
stain used to 
visually .-~ 4% CO2 and 93% N2 . Cultures were synchronized by treatment with 5% 
distinguish 
~~~~;~~~i~~~e:~~ D-sorbitol (Sigma) in the ring stage of development (Lambros and 
Vanderberg, 1979). 
3.2.1 Dose response curve experiments 
3.2.1.1 Drug preparations and dilutions 
CO (Sigma) was used as a positive control to determine in vitro susceptibility and the 
interactions of two drugs in both combination studies against the different clones of P 
fa/ciparum. CO and verapamil stock solutions of 1 mg/ml were made up in Millipore water 
and serially diluted with complete medium to the desired concentrations for use. The 
novel compounds generated were first dissolved in minimal DMSO and then Millipore 
water to achieve a 2mg/ml stock solution before sonication. The amount of DMSO added 
varied between 0% - 8.4% depending on the solubility of the compounds. The highest 
DMSO concentration reached in the wells of the microtitre plate is 1.7% which exerts 
non-detectable measurement on parasite survival on the system. The stock solutions of 
CO and newly synthesized compounds (less than 2-weeks old) were aliquoted in 
multiple eppendorffs and stored at -4°C till use. However, the otherwise unstable 
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3.2.1.2 Plate design 
The blank wells were prepared with 2% haematocrit of 0+ red blood cells (RBC) in 
complete medium whereas parasitized red blood cells (pRBC) of 2% haematocrit and 
2% parasitaemia served as a control. Synchronized parasitic erythrocytes were 
harvested in the trophozoite stage of the growth development (2% haematocrit, 2% 
parasitaemia) and incubated in 96-well microtitration plates (Greiner) arranged in a 
matrix of eight rows (A to H) and 12 columns (1 to 12) (Fig. 3.2.1.2). The plates were 
incubated in an airtight gas chamber with a gas environment of 3% O2 , 4% CO2 and 93% 









Figure 3.2.1.2. Visual presentation of a microtitration plate. 
To start the dose response experiment, 200 fll of drug solution (typically 100 flg/ml) was 
added into each well in column 3 using a dispenser. To the rest of the wells, 100 fll of 
complete medium was added throughout the test plate by the dispenser. Two-fold serial 
dilutions were made from column 3 across the plate by removing 100 fll of the drug 
solution from column 3 and then added into column 4 and so on using a multi-channel 
dispenser. To the designed blank wells of column 1, 100 fll of prepared RBC was added. 
To the control wells of column 2 together with the rest of the test wells were topped up 
with 100 fll of previously prepared pRBC. Therefore, the final concentration for each well 
consisted of 1 % haematocrit and 1 % parasitaemia with respect to 1 % haematocrit of the 
blanks. A large concentration range of 100 flg/ml to 0.20 flg/ml of the sample tested was 
achieved. The prepared test plates is therefore made up of a blank in column 1, control 
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The designed microtitre plates were covered with lids and incubated in an airtight gas 
chamber at 37 DC for 48 hours until further bioassay development after flushing with a 
gas mixture of 3% O2, 4% CO2 and 93% N2. 
3.2.2 Lactate dehydrogenase assay 
Intrinsic antiplasmodial activities and the abilities of the synthesized compounds to 
reverse CO resistance were evaluated in CO-sensitive (D10) and CO-resistant strains 
(K1 and RSA 11) using the parasite lactate dehydrogenase (pLDH) assay described by 
Makler et aI, 1993. This is a non-radioisotopic method used in vitro to study malaria drug 
susceptibility by an index of parasite growth. 
The assay is based on the conversion that host lactate dehydrogenase (LDH) activity 
uses 3-acetyl pyridine adenine dinucleotide analogue (APAD) and nicotinamide adenine 
dinucleotide, NAD, as a coenzyme during the conversion of lactate to pyruvate (Fig. 
3.2.2) (Makler et aI, 1993). In other words, the parasitic LDH (pLDH) uses APAD as a 
coenzyme and reduces it to APADH during the conversion of pyruvate to lactate. 
The formation of APADH can be colorimetrically measured using the yellow 
light-sensitive nitroblue tetrazolium (NBT)/ phenazine ethosulphate (PES) regent which 
is subsequently reduced into a blue formazan product. In addition, the amount of the 
blue formazan product formed is proportional to the pLDH activity. 
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The plDH activity can therefore be monitored using the Malstat reagent containing triton 
(1 mill), APAD (0.33g/l) and TRIS buffer (3.3g/l) and 1.96 mM NBT with 0.24 mM PES 
(Sigma) solution in millipore water. At the completion of the 48 hour incubation period of 
the test plates, 100 III of Malstat reagent and 25 III of NBT/PES solution were added into 
each well of new microtitre plates. The test plates were removed from the incubation gas 
chamber and the parasites were re-suspended within the original test plates before 
transferring 15 III of the parasites with a multi-channel dispenser into the corresponding 
well of the plates containing prepared Malstat reagents and NBT/PES solution. The 
absorbance of the formed formazan salts was then measured at a wavelength (t..,) of 620 
nm on a 7520 Microplate reader from Cambridge Technology Inc. Since the plDH is 
proportional to the blue formazan products formed, the percentage parasite viability is 
determined on the basis of the formula below: 
~ 
% Parasite viability::: A,,620 test well (pRBC + drug) - A]"620 Blank well (PBC) x 1 00 
A]"620 Control well (pRBC) - A]"620 Blank well (PBC) 
The resulting absorbance data were transformed into percentage viability and analyzed 
with calculated values of means and standard errors of the mean by Sigmaplot. Using a 
non-linear regression analysis in GraphPad Prism, fractional inhibitory concentrations 
(lC50::: 50% inhibitory concentration) of the synthesized compounds were determined 
graphically from semi-logarithmic plots. 
3.2.3 In vitro drug interactions 
3.2.3.1 Resistance reversal effect 
The susceptibility of the Plasmodium falciparum to ca, verapamil and synthesized 
compounds alone and in combination with sub-inhibitory concentrations were compared. 
Serial dilutions of ca were prepared as above (Chapter 3.2.1.2) in a designed microtitre 
plate. This is followed by the addition of 10 III of each individual sample at a selected 
SUb-lethal dose, which was pre-determined from intrinsic antiplasmodial activity from 
dose response curves, into the test wells of column 3 to 12 across the plate. Similarly, 
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3.2.3.2 Fixed - ratio method 
A fixed-ratio technique was adapted 'from Chawira and Warhurst, 1987 to investigate the 
drug interactions of CQ and the hit compound, P1, which showed the best positive 
results from the primary in vitro screens (Chapter 5), against both CQs andCQR isolates 
of P. falciparum in vitro. This graphical representation is called isobologram analysis 
which gives an indication of whether the interaction is additive, synergistic or 
antagonistic. This is to assist the clinical potential for the combination. 
Prior to commencing this drug-interaction study, the acquired fractional inhibitory 
concentration values (ICso, IC2s, IC10 and IC1) of CQ and P1 in D10 and RSA11 were 
predetermined from the aforementioned dose response curve experiments. Several 
inhibitory concentrations were chosen because variation between interaction studies is 
expected to produce different results (Gupta et al., 2002). 
RBC of 2% haematocrit and pRBC of 2% haematocrit and 2% parasitaemia were 
prepared as described previously. Dose response bioassays of CQ and compound P1 
were included as controls for this study in rows A-B and C-D, respectively, of a 96-well 
microtitre plate while column 1 served as a blank. For the ICso drug-interaction, 100lli of 
2 x ICso concentration of CQ and P1 prepared were added into wells E to H of column 2 
and 12, respectively to achieve a final concentration of 50% inhibitory concentration in 
the corresponding wells (Fig. 3.2.3.2). Similarly, in the each well of E to H of column 3 to 
11 across the plate received a total1001l1 of 2 x ICso concentration aliquots of CQ and P1 
in the ratio of 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In 
column 1, 100ili of RBC was added to complete the blanks whereas 100ili of pRBC was 
added into the rest of the wells on the plates to top up to a final volume of 200lli in each 
well. The designed test plate was covered with a lid and incubated in a gas chamber with 
a gas environment of 3% O2, 4% CO2 and 93% N2 at 37°C. Likewise, this protocol was 
repeated with other drug-interaction studies of different fractional inhibitory 
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Figure 3.2.3.2. Graphical presentation of plate design for drug-interaction studies. 
After 48 hr, the plate was developed using the pLDH assay and the resulting data were 
calculated and transformed into isobolograms by Sigmaplot and GraphPad Prism. 
3.2.4 Radio-labeled CQ accumulation assay 
Synchronous parasitized red blood cells were harvested In the trophozoite growth 
development (1 % haematocrit, 5% parasitaemia) in microcentrifuge tubes. Together with 
solvent controls, the tubes were pre-incubated in a water bath at 37 DC for 15 min in the 
presence of a fixed concentration of the potential resistance reversers before being 
exposed to 20111 of pre-aliquoted 100nM 3H-CQ (18.8 Ci/mmol; Amersham) to achieve a 
final concentration of 1 nM 3H-CQ in each tube. After 1 h incubation, 100 ,ul of dibutyl 
phthalate DBP (Sigma) was added into each tube and centrifuged. The supernatant was 
then aspirated off leaving the parasitized/uninfected erythrocytes behind. The tip of each 
eppendorff was cut into labeled scintillation vials to which 2 ml of scintillation liquid was 
added in advance. It was followed by the addition of 25 fll EDTA into each vial to form a 
stable chelator complex before being lysed down with 100 III of Solvable. Lastly, 100 III 
of H20 2 (30%) was used to quench the colour effect of the red blood cells. The 
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scintillation spectrophotometer. The resulting experimental data obtained were 
calculated and transformed into comparable bar charts using GraphPad Prism software 
and Microsoft Excel. 
3.3 Mammalian Cell Culture 
The cytotoxicity tests of the novel compounds were evaluated against the mammalian 
Chinese Hamster Ovarian (CHO) cell line, which was maintained continuously. The CHO 
cells obtained were donated by S. Schwager, Department of Medical Biochemistry. 
University of Cape Town. 
The cells were cultured as adherent monolayers in Oulbecos Modified Eagles Medium 
(OM EM) supplemented with 10% heat-inactivated fetal calf serum (FCS) and 
gentamycin (0.04 IJg/ml). The cells were maintained in 5% C02 - 95% air humidified 
atmosphere at 37°C. The medium was changed at frequent intervals to stabilize the pH 
as well as remove waste products and cell debris. 
Medium renewal was done by washing twice with sterile, warm PBS (Phosphate 
Buffered Saline) buffer followed by 5 ml trypsin-EDTA (1 %), which "lifted" the cells from 
adherent flasks for less than 2 min at 37°C. Trypsin was inactivated by adding an equal 
amount of growth medium. The cell suspension was centrifuged at 750 rpm for 5 min 
with the supernatant discarded. The cell button was resuspended with a volume of 
medium relative to the size of the cell pellet, and aliquots of the cell suspension were 
transferred into new culture flasks (75 ml) with fresh medium. Culture flasks were then 
incubated in an incubator of 5% - 95% air humidified environment at 37°C. The trypan 
blue colourimetric method was used to investigate the viability since viable cells have 
intact cell membranes, which prevent the blue dye entering the cells. Therefore, viable 
cells appeared bright in the field of view. Thus the percentage of viable cells can be 
determined. In addition, those cells that underwent less than 10 subcultures were used 
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3.3.1 Cell plating 
Cells in the exponential phase of the growth development are required to perform 
cytotoxicity screening. Cell plating was performed when cells reached confluency. CHO 
cells were plated in 96-well flat-bottomed microtitre plates (Costar) at a cell density of 
1x104 cells per well, in which cells were ensured to be in the exponential growth. 
A positive control of daunomycin (Sigma) was used in this cytotoxicity study. Dilution of 
daunomycin and synthesized compounds were made on the day experiments were 
commenced with cell culture medium. The stock solution of daunomycin was made up 
for 2mg/ml while the stock solutions were made as prepared in dose response assays. 
Similarly, the highest DMSO concentration reached in the well was 1.7%, which was 
insufficient to cause an effect in the system. This was followed by six stock dilutions 
raging from 1 OO~g/ml to 1 ng/ml. 
Cells were harvested as previously described and cell density was estimated using the 
Trypan blue method on a haemocytometer. Cell dilutions were made accordingly before 
being plated in the microtitre plates, which were incubated at 5% - 95% C02 - air 
humidified atmosphere at 37°C for 24h. After the incubation, the medium was carefully 
aspirated off from each well and appropriate drug concentrations accordingly added into 
the wells. Cell cultures were plated and allowed to incubate for a further 48h for cell 
attachment and flattening (Mosmann, 1983). A colorimetric (MTT) assay was then 
performed to determine the percentage of viable cells. 
3.3.2 MTT assay 
Selected synthesized compounds were assessed for cytotoxicity, in terms of 
mitochondrial impairment, using the Tetrazolium Salt assay (Mosmann, 1983). This 
method is based on the breakdown of the ring structure of the tetrazolium salt, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT), by the mitochondrial 
dehydrogenase of the viable cells (Mosmann, 1983; Sieuwerts at al., 1995). The amount 
of formazan crystals formed is directly proportional to the metabolic activity and the 
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water-soluble yellow MIT was reduced to a water insoluble dark purple 
coloured 'l'1'\1"1'1"1'.!1o',,'!lI.n product in viable cells. The amount of formazan formed was 
spectrophotometrically after dissolving the dark purple crystals in dimethyl 
sulphoxide (DMSO) (Stieuwerts 1995). 
After incubating plates for 48h, 25fJI of a MIT stock solution of 5.0 mg/ml was added 
into well of ""............. which were allowed to incubate for a further 4h. The 
were then centrifuged rpm for 10 min and followed by medium removal from 
well ht::01'.nrt::o 
monitored a wavelength 
basis 
to the formazan salts formed by viable cells. 
on a 
nm with a 
for 5 min. Absorbance was 
Microplate reader from Cambridge 
viable mammalian cells was thus calculated on the 
% Cell viability = 
[
AA540 well (cells+ drug) - AA.540 Blank well (medium) 
A"540 Control well (cells only)-AA54o Blank well 
x100 
The experimental data was transformed into percentage cell viability with 
calculated mean values and standard errors of the mean by Sigmaplot software. A 
non-linear regression analysis was using GraphPad Prism software. 
3.4 Cen proUferationl Substrate specificity 
Three isogenic strains of ...-"",,.."',.,,"",., ... ,,..,,,,"'''',,,, CjQrR'VI.O;;;IRR were purchased from Euroscarf. 
The S. cerevisiae was cultured in + 1 % Bactopeptone 
(Bacto) +1 % Dextrose (Sigma» 
change was performed at frequent intervals by 
than two-week old) YPD (pH6.4). 
200 rpm (Table 3.4). Medium 
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Table 3.4. S. cerevisiae yeast strains used in this study. 
Wild 
AD1 AYOR1 
AD1-3 A YOR1. ASNQ2, APDRS 
AD1,2,4-7 
AYOR1. ASNQ2, APDR10, APDR11, 
A YCF1. APDR3 
SuperYor 
A YOR1. ASNQ2, APDRS, APDR10, 
APDR11, AYCF1, APDR3 
BY4742w BY4742 Wild 
YGR281w YOR1 AYOR1 
YDR135c YCF1 AYCF1 
-Res.pectiivewild type strain for AD1. AD1-3. AD1.2.4-7 and Super Yor. 
bRespective wild type strain for YOR1and YCF1. 
Cell concentrations were determined spectrophotometrically at A600 (absorbance 
between 3-5 units) and harvested the day before starting the experiment to ensure cells 
are at their exponential growth. Test compounds and drug concentrations were prepared 
as in dose response curve experiments. 
3.4.1 Solid medium assay 
Sterile YPD agar plates (1 % Yeast Extract (Bacto) + 1 % Bactopeptone (Bacto) + 1 % 
Dextrose (Sigma) + 4% glycerol (Sigma, cell culture grade» were freshly prepared (less 
than one-week old) and stored at -4°C. Yeast cells were harvested from continuous 
cultures and centrifuged at 5000 rpm for 5 min followed by pellet resuspension with 5 ml 
Y.Gly medium (1 % Yeast Extract + 4% Glycerol) pre-warmed at 28°C. The harvested 
cells were then incubated at 28°C 200 rpm for 2h. 
Optical densities at A600 were monitored and 10D/ml yeast cell concentration were 
prepared before serially diluted to 1110, 1/100, 1/1000, 1/10,000 and 1/100,000. These 
yeast cells at various concentrations in YPD medium were suspended well before being 
applied onto the YPD agar plates. The agar plates were then incubated at 28°C for 3 
days to allow cell growth. Upon maturation, cell colonies were determined visually and 
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3.4.2 Drug susceptibility testing 
Cadmium chloride (CdCI2·2H20) was used as a positive control for the assay. In addition 
to the cadmium chloride,various desired drug concentrations were prepared on the day 
before commencing the experiment. S: cerevisiae was harvested during the exponential 
growth development and incubated in YGly medium containing varibus compounds of 
interest at 28°C and 200 rpm. Microtitre plates were designed, aqjusted and prepared in 
a similar manner to dose response curve experiments. The cell proliferation process (cell 
suspension) was monitored at regular intervals at A.620 on a 7520 Microplate reader from 
Cambridge Technology Inc. Data analysis of the experimental data was carried out using 
SigmaPlot and GraphPad Prism softwares to obtain the estimated inhibitory 
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4. Synthesis and characterization of target compounds 
4.1 Introduction 
In attempts to exploit structural molecular diversity, the general methods of classical 
solution phase synthesis and pOlymer-assisted synthesis in solution were used to 
generate various classes of compounds. The traceable synthetic routes, isolations as 
well as the characterizations of the potential CQ resistance modulators are described in 
this chapter. 
4.2 Polymer-assisted synthesis in solution 
Pioneering work by Merrifield on the use of polymeric supports in organic synthesis has 
led to considerable interest in this technology. The need to rapidly generate libraries of 
compounds has driven a conceptual revolution into solid-phase synthesis (Fig. 4.2; 
method A). Solid phase organic synthesis (SPaS) involves attachment of a reactant (A) 
onto a polymeric (solid) support via a bifunctional protecting group (linker). The 
polymer-bound reactant A is then treated with a large excess of a second reactant (B) to 
produce polymer-bound product (A-B), which upon cleavage from the solid support 
delivers A-B in solution. Purification and isolation is often by simple washing and filtration, 
which is facilitated by the general lack of solubility of most polymers in common organic 
solvents. The optimization of solid-phase synthesis, coupled with the evolution of 
medicinal chemistry has resulted in the development of a new methodology of 
polymer-assisted solution-phase organic synthesis for expediting the drug discovery 
process (Fig. 4.2; methods B - D). In the process where functional polymers are used as 
reagents and catalysts (Fig. 4.2; method B), the substrates do not remain attached to the 
solid support during multi-step sequences in solution. Instead, the polymer-bound 
reagents and/or catalysts promote a chemical transformation of a substrate which is 
cleaved from the support in the final step. Other new fundionalized polymers are 
polymer scavengers which are the resins added after a chemical reaction to remove the 
excess of reactants and/or by-products (method C). In addition, the molecule to be 
removed can also be "tagged" (Le. derivatized and fundionalized) to facilitate its removal 
by polymer-supported scavengers. Moreover, a subset of fundionalized polymers is able 
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remove the soluble by-products, the intermediate then "releases" the products back into 
the solution (method D). In multi-step syntheses, polymer-supported reagents and 
catalysts, along with the use of scavenging reagents and resin "capture-release" 
methods, can be combined to generate even more complex molecules (Kirschning et al., 
2001). 
Polymer-assisted solution-phase synthesis provides several advantages over the 
conventional solution-phase chemistry, such as the improved methods of· reaction 
workups and purifications by simple filtration and washing, the ability to use an excess of 
reagents to drive the reaction to completion without causing workup complications, the 
adaptation of continuous-flow processes (i.e. automated synthesis) and reuse of a 
catalyst or a supported reagent after regeneration (Kirschning et al., 2001). 
Method A: Solid phase synthesis 
~ Linker Linker 
A ----....... (ijl---->--A 
B Linker 
... Q)----A-B ---II ...... A-B 
Method B: Polymer-bound reagents and catalysts 
A B C 
Method C: Polymer-bound scavenging reagents 
C (excess) 
A ... + C 
@-D 
--"-......... ~D-C + B B 
("T agging.
E 
",age"") 1 .F 
B + C-E --.......... .F-E-C + B 
Method 0: "Capture-Release" method 
~B A ..... B-A 
C 
--II ...... A-C 
Figure 4.2. Various uses of polymer supports in organic synthesis. (Adapted from Kirschning et al., 
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I .Q P7 
In the first step of the multi-step synthesis (Scheme 1), a polymer-assisted O-alkylation 
of the phenolic benzaldehyde (I) was carried out using a polystyrene-supported base 
PTBD (1, 5, 7- triazabicyclo[4,4,O]dec-5-ene) (Fig. 4.3). This polymer-bound reagent 
served as a base in the phenol deprotonation step as well as a scavenger to mop up the 
liberated HBr and the excess unreacted starting phenol. The resulting products (II) were 
isolated and purified in high yields by simple filtration and evaporation (Xu et al., 1997). 
The second step involved a borohydride resin-mediated reductive amination of the 
aromatic aldehydes. Excess amine relative to the carbonyl intermediate (II) was used 
and the subsequent imine adduct was formed readily in methanol. Reduction was then 
performed using polymer-bound borohydride while the polymer-supported aldehyde (Fig. 
4.3) functioned to selectively separate the desired secondary product and the excess 
starting primary amine by imine formation (Kaldor et al., 1996). Subsequent filtration and 
evaporation afforded the secondary amines (P4-P7) in excellent yields (Table 4.3). Since 
both polymer-supported reagents act at different sites, the on- and off- polymer reactions 
allow this convenient one pot experimental procedure. The mechanism of this reductive 
amination is depicted in scheme 2. 
~CHO 
PTBD borohydride resin PS-CHO 


















(i) H2N~N/ (1.2 equiv.) 
I . 
borohydride resin (2.0 equiv.) 
(ii) PS-CHO (1.06 equiv.) 
CH2CI2 
(iii) filtration 
lfN~N/ I H I R'~O :::::...... 
III, (P4-P7) 90% - quantitative 
Scheme 1. Chemical synthesis of potential chemosensitizers. 
~ 
80 H 
. I if 
Ar~N~N/ 
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Proton transfer 
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4.3.1 Synthesis of polyamines P4-P7 
Synthesis of the polyamines P4-P7 involved the generation of aldehyde intermediates by 
alkylation using polymer-supported reagents with appropriate bromides, followed by a 
reductive amination of the aldehyde intermediates with 3-dimethyaminopropylamine to 
give the corresponding products. The NMR spectra, IR measurements, mass spectra 
and melting points for compounds P4-P7 are in section 4.5. 
4.3.1.1 General procedure A: Alkylation using PTBD 
4-Hydroxybenzaldehyde (86 mg, 1.2 eq.) and benzyl bromide (0.07 cm3 , 1.0 eq.) were 
added to a 20 cm3 sealed glass vial containing the PTBD resins (0.10m equiv.) in 7 cm3 
acetonitrile. The reaction was vortexed vigorously at room temperature under nitrogen 
atmosphere until the halide was completely consumed. After 18h, the reaction was 
filtered free of polymeric material. The filtrate was purified by chromatography on silica 
gel. 
Benzyl bromide -7 Intermediate 1 (0.58 mmol scale), 64 mg, 43% 
3-Methoxybenzyl bromide -7 Intermediate 2 (0.75 mmol scale), 139 mg, 77% 
2-Phenyl benzylbromide -7 Intermediate 3 (0.61 mmol scale), 144 mg, 82% 
4.3.1.2 General procedure B: Reductive amination using borohydride resin 
3-Dimethylaminopropylamine (0.03 cm3, 0.27 mmol) and benzaldehydes (0.23 mmol) 
were dissolved in 1 cm3 MeOH in a medium screw-capped glass vial. The reaction vial 
was shaken on an orbital shaker for 4h to allow imine formation. The resulting reaction 
mixture was then treated with Amberlite® IRA-400 borohydride resin (2.5 mmol BH4- /g 
resin, 2.0 equiv.) (Aldrich). The slurry was then shaken for an additional 24h to effect the 
reduction to the secondary amine. lastly, the polystyrene-linked benzaldehyde resin 
(2.5-3.0 mmoll g resin, 1.06 equiv.) and 1 cm3 CH2CI2 was added to the reaction. After 
18h, the reaction slurry was filtered through a cotion plug and the residual solids were 
rinsed with MeOH. 
Compound P4 (O.23mmols scale), 76.2mg, 94% 
Intermediate 1 (64 mg, 43%) -7 Compound P5 (O.30mmols scale), 81.4mg, 90% 
Intermediate 2 (139 mg, 77%) -7 Compound P6 (0.46mmols scale), 178mg, quantitative yield 
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Table 4.3 Synthesized intermediates 11-13 and compounds P4-P7 during the initial exploratory 
d H H ~ 43 Vo~ I~ II (11) 
d H H cr- 77 yO~ 
II (12) OMe OMe 
~o ~ A lfH H 82 "'" 0 ~ II (13) IA 
0- P ~ I "'" ~/"/"'N"~' OMe 94 ~ A I 0 
III (P4) 
lf~~( 
H ~ era ~ 90 IA 
III (PS) 
y~~( ~ I"'" 0 H quantitative A 
OMe III (PS) 
OMI! 
~ b A lf~~i/ H 97 "'" a~ IA 
III (P7) 
4.4 Synthesis of biphenyl piperazinyl analogues via the Suzuki cross 
coupling reaction 
4.4.1 Suzuki cross coupling 
In view of the tremendous importance of the biaryl subunit, several methods for 
generating these molecules have been developed over the past two decades. The most 
commonly used catalytic biaryl cross couplings are the Kharasch, Negishi, Stille and 
Suzuki reactions (Stanforth, 1997). These reactions utilize either nickel or palladium (Pd) 
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In the mid to late 1970's the Kharasch reaction achieved such cross-couplings when an 
aryl Grignard reagent reacted with an aryl halide while the Negishi reaction used arylzinc 
reagents and aryl halides. This was followed by the discovery of the more versatile Stille 
reaction which utilized arylstannanes and aryl halides as coupling partners. This reaction 
was more compatible and tolerant than the Kharasch and Negishi reactions. However, 
the major disadvantage of the Stille coupling is the toxicity of organotin reagents and 
their byproducts (Stanforth, 1997). In the early 1980's, the Suzuki reaction, in which 
boronic acids reacts with aryl halides, was developed and has since proved to be as 
extremely versatile as the Stille reaction. 
The catalytic process of both modified Suzuki coupling protocols using Pd is presented 
in scheme 3. The biaryl synthesis starts with an oxidative addition of the catalyst to the 
aryl halide (A~X, X ::: halogen) to afford the A~[Pd(II)]X intermediate before 
transmetallation to give a diarylated Pd moiety, A~[Pd]Ar1. Lastly, the biaryl product 
A~Ar1 and Pd(O) are formed by a reductive elimination reaction of the diarylated 








Ar2[Pd]OH + Ar"[Pd]Ar' 
Ar1B(OHh 
Pd(O) 
) ... Ar2-Ar1 
Scheme 3. Catalytic Suzuki reaction by palladium. Ar = aryl; x::: halogen. (Adapted from Stanforth. 1997. 
Tetrahedron). 
In this study, the synthesis of unsymmetrical biaryl motifs was carried out via the Suzuki 
reaction in three general reaction schemes (Scheme 4) to produce an analogous library. 
In the general reaction Scheme 4-A, 4-bromobenzaldehyde underwent Suzuki couplings 
with mono-, bi- and tri-methoxy boronic acids to produce the biphenyl intermediates II in 
high yields (80-94%). Formation of these intermediates was confirmed by 1H NMR. The 
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3.8-3.9 ppm were cleanly identified. Reductive amination of the aldehydes afforded the 
biphenyl polyamine products III (P11-P20). The 1H NMR revealed signals from the 
piperazinyl unit at 0 2-3 ppm, which differentiates the intermediates II (18-110) and 
polyamine products III (P11-P20) (details in section 4.5 experimental). Products were 
obtained in higher yields (63-95%) when dichloromethane was used in the reductive 
amination step compared to the corresponding reactions in methanol (23-35%). 
MeO MeO 
MeO P15 MeO 






III, 23% - 95% 
ArB(OH)2 
Pd(OAch ,PPh3 
Scheme 4-A. Synthesis of biphenyl compounds. 
r(YCHO 
~ Ar 
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4.4.2 Synthesis of biphenylamines P11·P20 
Synthesis of biphenylamines P11-P20 involved the generation of mono- bi-, tri-
methoxy-biphenyl -4-carbaldehyde intermediates, which were derived from 
4-bromobenzaldehyde with different boronic acids using Suzuki cross coupling reactions, 
followed by a reductive amination with appropriate piperazines to give the corresponding 
products. The NMR spectra, IR measurements, mass spectra and melting points for 
compounds P11-P20 are in section 4.5. 
4.4.2.1 General procedure C: Suzuki cross coupling reactions 
A tube equipped with a magnetic stirring bar and nitrogen inlet was charged with 
4-bromobenzaldehyde (300 mg, 1.62 mmol) and mono-, bi- or tri-methoxyphenylboronic 
acid (1.70 mmol) in 3.0 cm3 isopropanol under a N2 purge. The mixture was stirred at 
room temperature for 30 min, allowing solids to dissolve. The resulting solution was 
treated with palladium acetate (1.09 mg, 0.005 mmol), triphenylphosphine (3.83 mg, 
0.015 mmol). 0.98 cm3 of 2M NaHC03 and 0.6 cm
3 of water under N2. The reaction was 
brought to reflux for 18h before the heat was removed. An additional 2.5 cm3 of water 
was added to the reaction while hot followed by removal of N2. The reaction was then 
allowed to stir open to the atmosphere for 2.5h while cooling to room temperature. The 
darkened mixture was then diluted with 5 cm3 ethyl acetate and transferred to a 
separating funnel. The 2 phases were separated and the aqueous phase was washed 
with 2 x 5.0 cm3 ethyl acetate. The combined organic layer was washed with 5.0 cm3 of 
aqueous 5% NaHC03 followed by 2 x 5.0 cm
3 of saturated brine. The organic layer was 
placed in a flask with a magnetic stirring bar, treated with activated carbon (0.15 mg) and 
stirred at room temperature for 30 min before Na2S04 (0.30 mg) was added to the 
mixture and stirring was continued for an additional 30 min. A BOchner funnel was 
charged with Celite to a depth of 1 cm, and the resulting reaction mixture was filtered 
through this pad of filter aid, which was rinsed with 2 x 5 cm3 of ethyl acetate. The 
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4-Methoxyphenylboronic acid ~ Intermediate 8 (1.62 mmol scale), 272.5 mg, 81% 
3,4-Dimethoxyphenylboronic acid ~ Intermediate 9 (1.38 mmol scale), 312.5 mg, 94% 
2,3,4-Trimethoxyphenyiboronic acid ~ Intermediate 10 (1.62 mmol scale), 401.0 mg, 91% 
4-Methoxyphenylboronic acid 
3,4-Dimethoxyphenylboronic acid 
~ Intermediate 28 (1.38 mmol scale), 275.0 mg, 63% 
~ Intermediate 29 (1.38 mmol scale), 321.4 mg, 67% 
2,3,4-Trimethoxyphenylboronic acid ~ Intermediate 30 (1.38 mmoi scale), 175.0 mg, 34% 
4.4.2.2 General procedure 0: Reductive amination using sodium 
triacetoxyborohydride 
Mono-, bi- or tri-methoxy-biphenyl-4-carbaldehyde (0.41 mmol), amines (0.05 cm3, 0.45 
mmol) and 2 cm3 MeOH were added to a 20 cm3 sealed glass vial. The reaction was 
allowed to stir at room temperature for 16h. After monitoring by TLC, imine formation was 
confirmed and sodium triacetoxyborohydride (114 mg, 0.54 mmol) was added to the 
reaction mixture. The resulting reaction was left on the shaker for an additional 24h 
before it was quenched by adding 3.5 cm3 saturated NaHC03 followed by extraction with 
EtOAc. The resulting reaction extracts were combined and chromatographed. 
Intennediate 8 (272.5 mg, 81%) 
Compound PiS (0.38mmols scale), 100.1mg, 89% 
Compound Pi9 (0.29mmols scale), 91.4mg. 88% 
Compound P20 (0.47mmols scale), 114.7mg, 66% 
Intennediate 9 (312.3 mg, 94%) 
Compound Pii (0.41mmols scale), 36.5mg, 27% 
Compound Pi2 (0.41mmols scale), 4p.Omg, 29% 
Compound Pi3 (0.33 mmols scale), 125.3 mg, 95% 
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Intermediate 10 (401 mg, 91 %) 
Compound P15 (0.37mmols scale), 109.6mg, 83% 
Compound P16 (0.37mmols scale), 113.0mg, 73% 
Compound P11 (0.23mmols scale), 61.3mg, 63% 
Intermediate 28 (275 mg, 63%) ~ Compound 31 (0.16mmols scale), 25.1mg, 39% 
Intermediate 29 (321 mg, 67%) ~ Compound 32 (0.26mmols scale), 40.8mg, 36% 
Intermediate 30 (175 mg, 34%) ~ Compound 33 (0.24mmols scale), 60.1mg, 58% 
Table 4.4.1-A. Synthesized compounds and intermediates from reaction scheme 4-A. 
~CHO 
£) 80 '" b II I MeO h MeO~ II (18) 
d7'"O MeoxY MaO '" b 94 
II b 
MaO II (19) 
MeO 
OMe 
OMe ; "" 
CHO 
MeO~ ~ MoOxY 91 
II 
II (110) MeO h MaO ~ 
~'l Me0x;r-MeO '" "'- I ~N" Me MeOH 23 I . MeO h 
MeO' /- III (P11) 
~N~ Me0yY ~ MeO, '" '" ~NO Ih MeOH 27 I I " M.O~h ~ MeO 
III (P12) 
-_ .._-_ ... 
offNl Meo~ u L MOO '" '", I ~N CH2CI2 95 MOO I h ~ MeO h 
'" /, III (P13) 
~Vl Meo)~ ~ 
I I 
MeO I "" '" ~N I ' MeOH 35 
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Table 4.4.i-A. (Continued) Synthesized compounds and intermediates from reaction scheme 4-A. 
if-l oMi! MaO "" "" ~N Meoij Me CH2CI2 83 I "- Ih 
MaO h' III (PiS) MeO 
OMe :&U'l cr-MaO "" "" ~N Meoij CH2Cb 79 I I ~ ~ 
I MeO b '0 III (P16) MeO h 
:&U'l OMe ~ I: ~ "'-a M~ij ~ CH2Cb 63 MeO ~ MeO 0 
~ !. III (Pi7) 





~'l . "" "" ~N JYIcr- . I 7 ~ I 0 I I I CH2CI2 86 
IMeo ~ '0 III (P19) I M~ i A i 
I 
~'l JY ~ "" "" ~N CH2CI2 66 IM.O I "" "0 MeO h 
I ~ I. III (P20) • 
L ------1 
Amino alcohols (P23-P25) (Fig. 4.4.1-8) were synthesized in three steps, Scheme 4-8. 
Firstly, the starting material 4-bromophenol IV was alkylated with an epoxide in the 
presence of sodium hydride, as a base, followed by Suzuki coupling and piperazine 
amine alkylation reactions (epoxide ring opening) to afford the polyamine products 
P23-P25. The first alkylation reaction was completed with ease using epichlorohydrin to 
give a 96% yield of V. However, the Suzuki coupling of the epoxide was not very 
successful, yielding only 22% of the biarylepoxide VI. This could be due to sOme of the 
epoxide intermediate may have hydrolysed in the presence of the water used in the 
aqueous Suzuki protocol. The process of epoxide hydrolysis or ring opening would 
compete with the Suzuki cross coupling reaction. Purified VI then underwent a second 
alkylation reaction with piperazines to give the final products Vir (31-47%). In contrast, a 
70% yield of P26 was produced from the alkylation of N-methylpiperazine with 

















1 ___ .. ________________________________ ----' 
figure 4.4.1-B. Target compounds for scheme 4-8. 
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4.4.3 Synthesis of biphenylamines P23-P26 
Synthesis of the biphenylamines P23-P25 involved the generation of epoxide 
intermediates 121 and 122. The epoxide intermediate 121 was produced from a 
nucleophilic substitution reaction of the 4-bromophenol with epichlorohydrin. This was 
followed by Suzuki coupling on 121 to give the biphenyl epoxide intermediate 122. Lastly, 
the desired polyamines were produced by epoxide ring opening. 
4.4.3.1 Alkylation of bromophenol 
4-Bromophenol (2.0 g, 11.52 mmol) was dissolved in 56 cm3 of DMF in a 250 cm3 
round-bottomed flask at O°C. Upon dissolution, sodium hydride (0.42 g, 17.34 mmol) was 
added to the flask with stirring at O°C for 10 min. Epichlorohydrin (1.36 cm3, 17.34 mmol) 
was then added to the reaction mixture over 3 min at O°C. The resulting suspension was 
allowed to warm to 25°C and left stirring for 18h. The reaction was monitored by TLC Rf 
(EtOAc-hexane, 20:80) 0.20; 110 cm3 distilled water was used to quench the reaction, 
followed by extraction with EtOAc (2 x 110 cm3). The yellowish oil-like organic phase 
was dried over Na2S04 and concentrated under reduced pressure. This first step of 
alkylation was thus completed and gave 96% of the epoxide intermediate 21. 
4.4.3.2 Suzuki cross coupling 
Intermediate 121 (1.32 g, 5.76 mmol) then underwent the Suzuki reaction with 
2,3,4-trimethoxyphenylboronic acid (2.44 g, 11.53 mmol) in dry toluene. To this 
suspension, the base of K2C03 (2.36 g, 17.29mmol) was added under inert environment 
and stirred at 25 °C for 20 min. Tetrakis{triphenylphosphine}paUadium(O) (0.20 g, 0.17 
mmol) was then introduced as the catalyst while the reaction temperature was brought 
up to 88-92 oC, and the reaction mixture was refluxed for 3h before diluting with EtOAc 
(80 cm3). The crude product was then washed sequentially with saturated NaHC03 (1 x 
115 cm\ distilled water (1 x 115 cm3), 10% citric acid (1 x 115 cm3), distilled water (1 x 
115 cm3) and lastly saturated brine (1 x 115 cm3). The resulting organic phase was then 
collected, dried over MgS04, concentrated under reduced pressure and purified by 
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4.4.3.3 General procedure E: Ring opening of epoxide intermediate 122 
The epoxide intermediate 22 (150 mg, 0.59 mmol) (Scheme 4-8) was dissolved in 5 cm3 
MeOH together with amines (0.70 mmol) in a 20 cm3 sealed glass vial. The resulting 
reaction mixture was left stirring at 25°C for 4h before filtering and washing with MeOH. 
The mother liquor was concentrated and chromatographed. 
Compound P23 (0.59mmols scale), 76.2mg, 31 % 
Compound P24 (0.59mmols scale), 132.7mg, 47% 
Compound P25 (0.59mmols scale), 95.9mg, 33% 
Compound P26 (1.0 mmols scale), 187mg, 70% 
Table 4.4.1-8. Synthesized compounds from reaction scheme 4-8. 
OH r'N/ 
r O~N~ 
Me MeOH MeO "",I 
VII (P23) 




MoO L"" VII (P24) 
OH rNJ) 
~ OM. r O~N~ L MeOH MoO, "': "'" 
I 
VII (P25) MoO L 
~ 
""I 
r Nl Me MeOH 
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Similarly, the starting material 4-hydroxybenzaldehyde VIII underwent alkylation to form 
the intermediate IX before Suzuki coupling took place to afford X in reaction scheme 4-C. 
Reductive amination of the biaryl intermediate aldehyde X completed the synthesis of 
products XI (36-58%). 
Figure 4.4.1-C. Target compounds for scheme 4-C. 
c. ~Br 
~ Br (yCHO 
HO~ --------------~. 




~ Br· IX 91% . 
(I) c: i ~ +ArB(OHh 
/\ 
HN N-
... (J) j 
~CHO 
~O~ "--I 
II ~ Ar 
X,34-67% 
Scheme 4-C. Synthesis of biphenyl compounds. 
4.4.4 Synthesis o'f biphenylamines P31-P33 
Synthesis of the biphenylamines P31-P33 involved 3 reaction steps. First, an alkylation 
reaction took place to 4-hydroxybenzaldehyde to give 127, followed by Suzuki couplings 
with different boronic acids to produce the corresponding biphenyl intermediates 
128-130. The desired products P31-P33 were produced from the reductive amination of 
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4.4.4.1 Alkylation of 4-bromobenzylbromide 
4-Bromobenzylbromide (2.23 g. 8.94 mmol) was added to a stirred solution of powdered 
anhydrous sodium hydride (0.27 g, 11.1 mmol) and 4-hydroxybenzaldehyde (1.04 g, 
8.52 mmol) in DMF (25 cm3) at O°C under an inert atmo~phere. The resulting light yellow 
suspension was allQwed to warm to 25°C and stirred for an additional 18h. The reaction 
was then diluted with water (500 cm3) and' the yellow precipitate was collected by 
filtration and subsequent washing with water. Further drying under vacuum afforded the 
aldehyde 127 (2.25 g, 91 %); Rf (MeOH-CH2CI2, 5:95) 0.23. 
Table 4.4.1-C. Synthesized compounds and intermediates from reaction scheme 4-C. 
OCHO 
~,~I ff 63 "" "'- MeO 0 
MeO I A- . X (128) 
[ 0'" v 0 "" Meo~ 67 i~~ X (129) Mea 0 
LflRe() ---~--
Elf'O~ OMe Me0xY 34 
MeO "" "" 10 I X (130) MeO A MeO . 
. ,(Y'Nl 
~,~I ~"' ff MeOH 39 I '" "'- MaO 0 
Meo I A- XI (P31) 
lfNl 
~o~ ~" Meo~ MeOH 36 
MeO "" "" I 
I A- . Mea 0 
MeO XI (P32) 
lfNl OMe Elf' ~ ~" Me0xY MeO "" "'- I MeOH 58 
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All the synthesized compounds possess biphenyl derivatives possessing ortho and para 
substituents. The small library of synthesized compounds and the structural variations of 
the amines were evaluated in vitro. This led to a few generalizations on the 
structure-activity relationships for potential lead development (Chapter 5 and 6). 
4.5 Characterization of synthesized compounds 
The novel products (Table 4.5) were characterized by infrared spectroscopy (IR), 1H, 13C 
NMR, mass spectrometry and microanalysis. The uncorrected melting points were also 
recorded. The formulae, molecular weights, melting points, microanalysis and IR data 
and the respective % yields are reported in Table 4.5. IR gives the information about the 
functional groups present in the compound's structure. For example, the -OH group of 
alcohols absorbs strongly at 3200-3600 cm-1; N-H group of amines at 3300-3500 cm-1; 
C-N group of amines at 1180-1360cm-1. The 1H and 13C NMR show the proton and 
carbon absorption peaks, whose relative positions, reflecting their differences in 
environments of protons and carbons, can give the detailed molecular information about 
molecular structure. For example, the characteristic 1 H signals for the biaryls are at 8 
7-7.5 ppm and -CH3 at 82-3 ppm. The characteristic 13C signals of aromatic C=C are at 
8100-150 ppm. The 1H, 13C NMR, and mass spectra of the synthesized compounds can 
be found in Appendix 1. 
75 
University of Cape Town
Table 4.5. Summary of chemical formula, moiecular weight, melting pOints,clogP and IR data of the intermediates'$~d products: 
,~ .('1) .... 
~ 
11 C14H1202 . 212.2468 
-. .. 12 C15H1403 242.2726 
13 C2oH1S02 288.3444 
P4 C1sH30N202 306.4430 3.89 1136.2, 1345~8,,1662.9, 3402.3 
P5 C19H2SN20 298.4225 3.86 1136.2,,1345.8,3402.3 
. P6 ' C2oH2SN202 328.4485 3.78 1136.2, 1345.8, 3402.3 
(") 
P7 C25H30N20 347.5185 5.45 1136.2, 1345.8, 3402.3 :::r ('I) 
3 
IS C14H1202 ' 212.2468 3.37. 
iii' ..... 
-< 
.):~ C15H1403 242.2726 3.07 
110 G1SH1S0 4 272:2984 2 .. 13 
P11 C2oH2SN202 .3260432,7 96-98 3.88 1148.3, 1347.5 
P12' C25H2SN202 388.501:2 120 - 123 4.86 1148.3, 1347.5 
P13 I C2sHsoN202 402.5287 105 -108 5.72 1148.3,1347.5. 
P14 C30H3SN202Fe 514.4641 110 - 112 1136.1,1372.2 
P15 C21H~6N203 536.4586 2.96 1148.3. 1347.5 
P16 C2sH30N203 418:5280 65-68 3,94 1148.3, 1347.5 
I = intermediates 
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Table 4.5. (Continued) Summary of chemical formula, molecular weight, melting points, clogP and IR data of the intermediates and 
produ~. . 
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I :: intermediates. 
P :: products. 
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4.5.1 Chemical synthesis during hit development 
4.5.1.1 Synthesis of intermediate 11-13 (Scheme 1) 
11 12 
4-Benzyloxybenzaldehyde 11 
The conditions employed for the preparation of this compound were those described in 
General Method A. Column chromatography (Si02, EtOAc-hexane, 10:90) afforded the 
intermediate 1 C14H1202 (64 mg, 43%); RdEtOAc-hexane, 10:90) 0.22; bH(200 MHz; 
CDCb) 9.89 (1 H, s, -CHO), 7.85 (2H, d, J 8.7, H1 and H2), 7.42-7.21 (5H, m, H3, H4, H5, 
Hs and H7), 6.92 (2H, d, J 8.7, Hs and Hg) and 5.10 (2H, s, Ar-CH2-0-). 
4-(3-Methoxy-benzyloxy)-benzaldehyde 12 
The conditions employed for the preparation of this compound were those described in 
General Method A. Column chromatography (Si02, EtOAc-hexane, 30:70) afforded the 
intermediate 2 C15H1403 (139 mg, 77%); Rf (EtOAc-hexane, 30:70) 0.35; bH(200 MHz; 
CDCb) 9.89 (1H, s, -CHO), 7.85 (2H, d, J 8.7, H1 and H2), 7.32 (1H, dd, J 8.7 and 2.4, 
H3), 7.10-6.98 (4H, m, H4, H5, Hs and H7), 6.91 (H, t, J 8.7, Hs), 5.13 (2H, s, Ar-CH2-0-) 
and 3.83 (3H, S, -OCH3). 
4-(Biphenyl.2.ylmethoxy)·benzaldehyde 13 
The conditions employed for the preparation of this compound were those described in 
General Method A. Column chromatography (Si02, EtOAc-hexane, 30:70) afforded the 
intermediate 3 C2oH1S02 (144 mg, 82%); Rf (EtOAc-hexane, 30:70) 0.43; bH(200 MHz; 
CDCh) 9.87 (1 H, s, -CHO), 7.78 (2H, d, J 8.7, H1 and H2), 7.65-7.61 (1 H, m, H3), 
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4.5.1.2 Synthesis of product P4-P7 (Scheme 1) 
N'-[2-Methoxy-4-(3-methyl-but-2-enyloxy)-benzyl]-N,N-dimethyl-propan-1,3-diamine P4 
OMe "'"hl H2 N N/ Jy(' He H H10 H'2 "-.. ~ 0 H14 H, . 
Hs 
H4 H3 P4 
The conditions employed for the preparation of this compound were those described in 
General Method B. Simple filtration with MeOH gave the product P4 (76.2mg, 94%) as a 
yellowish oil; RdMeOH-CH2Cb, 10:90) 0.22; oH(300 MHz; CDCb) 7.12 (1H, d, J 8.0, H1), 
6.47-6.40 (2H, m, H2 and H3), 5.48 (1 H, t, J 7.5, H4), 4.48 (2H, d, J 8.0, Hs and Hs), 3.79 
(3H, s, -OCH3), 3.70 (2H, s, -Ar-CH2-N-, H7 and He), 2.63 (2H, t, J 7.5, He and H1O), 2.30 
(2H, t, J 7.5, Hii and H12), 2.20 (3H, s, -N-CH3), 2.15 (3H, s, -N-CH3), 1.79 (3H, s, 
CHs-CH-CH3), 1.74 (3H, s, CH3-CH-CH3) and 1.64 (2H, quintet, J 7.5, H13 and H14); 
oc(75 MHz; CDCb)130.6 (2C), 119.6 (2C), 104.6 (2C), 99.3 (2C), 64.8, 58.2, 55.3, 48.5, 
47.5,45.4, 30.8, 27.2, 25.8 and 18.1; ElMS mlz (50 eV) 306 [Mr, 220 [C13H1 SN02t, 205 
[C13H1702t, 85 [CsHeOt, 30 [CH20t MS found: M+, 306. CisH30N202 requires M, 
306.4430. 
N'-(4-Benzyloxy-benzYI}-N,N-dimethyl-propan-1,3-diamine P5 
The conditions employed for the preparation of this compound were those described in 
General Method B. Simple filtration with MeOH gave P5 (81.4mg, 90%) as a yellowish oil; 
RdMeOH-CH2CI2, 10:90) 0.22; oH(300 MHz; CDCI3) 7.46-7.21 (7H, m, aromatic), 6.93 
(2H, d, J 8.7, Hi and H2), 5.05 (2H, S, H3 and H4), 3.72 (2H, s, Hs and Hs), 2.65 (2H, t, J 
7.5, H7 and Hs), 2.31 (2H, t, J 7.5, He and Hi0), 2.23 (3H, s, -N-CH3), 2.21 (3H, S, -N-CH3) 
ami 1.72 (2H, quintet, J7.5, Hii and Hi2); oc(75 MHz; CDCb) 157.8, 137.1, 133.0, 129.2 
(2C), 128.5, 128.0, 127.9 (2C), 127.4, 114.9, 114.8, 70.1, 58.0, 53.4, 47.8, 45.5 (2C), 
28.1; ElMS mlz (50 eV) 298 [Mr, 212 [C14H14NOr, 197 [C14H130r, 107 [C7H70r. 30 
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• N'-[4-(3-Methoxy-benzyloxy)-benzylJ-N,N-dimethyl-propane-1,3-diamine P6 
The conditions employed for the preparation of this compound were those described in 
General Method B. Simple filtration with MeOH gave P6 (178mg, quantitative yield) as a 
yellowish oil; Rf(MeOH-CH2Cb, 10:90) 0.20; cH(300 MHz; COCh) 7.32-7.21 (3H, m, H1, 
H2 and H3), 7.03-6.91 (4H, m, H4• Hs, H6 and H7), 6.95 (1 H, dd, J 3.0 and 9.0, Ha), 5.02 
(2H, s, Hg and H10), 3.81 (3H, s, -OCH3), 3.76 (2H, S, H11 and H12), 2.73 (2H, t, J 7.5, H13 
and H14), 2.37 (2H, t, J 7.5, H15 and H16), 2.25 (3H, s, -N-CH3), 2.23 (3H, S, -N-CH3) and 
1.74 (2H, quintet, J 7.5, H17 and H1a); cc(75 MHz; COCh) 159.9, 158.0, 138.6, 131.5, 
129.6, 129.5, 128.5, 119.6, 114.9 (2C), 113.5, 112.9,69.9,58.0,55.2,52.7,47.4,45.1 
(2C), 26.6; ElMS m/z (50 eV) 328 [Mt, 242 [C1sH16N02t, 227 [C1SH1s02t, 121 [CsHgOr, 
107 [C7H70r, 30 [CH20t MS found: M+, 328. C2oH2aN202 requires M, 328.4485. 
N'-[4-(Biphenyl-2-ylmethoxy)-benzylJ-N,N-dimethyl-propane-1 ,3-diamine P7 
The conditions employed for the preparation of this compound were those described in 
General Method B. Simple filtration with MeOH gave P7 (139 mg, 97%) as a yellowish oil; 
Rf (MeOH-CH2CI2, 10:90) 0.38; cH(300 MHz; COCh) 7.61-7.58 (1H, m, H1), 7.39-7.20 
(10H, m, aromatic), 6.79 (2H, d, J 9.0, H3 and H4), 4.89 (2H, S, H4 and Hs), 3.73 (2H, S, 
H6,and H7), 2.67 (2H, t, J 7.5, He and Hg), 2.39 (2H, t, J 7.5, H10 and H11), 2.26 (3H, s, 
-N-CH3), 2.25 (3H, S, -N-CH3) and 1.73 (2H, quintet, J 7.5, H12 and H13); cc(75 MHz; 
COCI3) 157.8,141.8,140.5,134.1,130.0,129.5 (2C), 129.2, 129.1, 128.2, 128.0, 127.6 
(2(;;), 127.3 (3C), 114.8 (2C), 68.1, 57.7, 53.0,47.3,45.2 (2C), 27.1; ElMS m/z (50 eV) 
I 
37~ [Mr. 288 [C2oH1SNOr, 167 [C13H11r, 29 [C2Hst MS found: M+, 374. C2sH30N20 
I 
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4.5.2 Chemical synthesis for hit modification 
4.5.2.1 Synthesis of intermediate IS-I10 (Scheme 4-A) 
H1 H1 H I 
H3 CHO ,CHO cN
CHO OMe Y , Hs I i 
H7 MeO MeO~~ '0-.' H2 
I H 
H2 I H2 
H4 ~H MeO/' MeO/' y"Hs 4 MeO h H 4 He I 5 
He H He 18 7 19 110 
4' -Methoxy-biphenyI4-carbalcJehycJe 18 
The conditions employed for the preparation of this compound were those described in 
Gen~ral Method C. Column chromatography (Si02, EtOAc-hexane, 20:80) afforded the 
aldehyde 18 (272.5 mg, 80%) as yellow plates; Rf (EtOAc-hexane, 20:80) 0.40; ()H(300 
MHz; COCb) 10.04 (1H, s, -CHO), 7.93 (2H, d, J 8.4, H1 and H2), 7.72 (2H, d, J 8.4, H3 
and H4), 7.60 (2H, d, J 9.3, Hs and Hs), 7.01 (2H, d, J 9.3, H7 and He) and 3.87 (1 H, s, 
-OCIi-h). (Found: C, 78.86; H, 5.77. C14H1202·0.1 H20 requires C, 78.56; H, 5.70%). 
3,4' -Dimethoxy-biphenyI4-carbalcJehycJe 19 
The conditions employed for the preparation of this compound were those described in 
General Method C. Column chromatography (Si02, EtOAc-hexane, 15:85) afforded the 
aldehyde 19 (312.3 mg, 94%) as white cubes; RdEtOAc-hexane, 15:85) 0.30; ()H(300 
MHz; COCh) 10.04 (1H, s, -CHO), 7.93 (2H, d, J 8.4, H1 and Hz), 7.72 (2H, d, J 8.4, H3 
and H4), 7.15-6.96 (3H, m, Hs, Hs and H7), 3.97 (3H, s, -OCH3) and 3.94 (3H, s, -OCH3) 
(Found: C, 73.93; H, 5.68. C1sH 140 3 requires C, 74.36; H, 5.82%). 
2' ,3' ,4' -Trimethoxy-biphenyI4-carbalcJehycJe 110 
The conditions employed for the preparation of this compound were those described in 
General Method C. Column chromatography (Si02, EtOAc-hexane, 20:80) afforded the 
aldehyde 110(401 mg, 91%) as yellowish-brown needles; RdEtOAc-hexane, 15:85) 0.25; 
()H(400 MHz; COCh) 10.04 (1H, s, -CHO), 7.93 (2H, d, J 8.4, H1 and H2), 7.72 (2H, d, J 
8.4, H3 and H4), 7.07 (1 H, d, J 8.4, Hs), 6.78 (1 H, d, J 8.4, H6), 3.94 (3H, s, -OCH3), 3.92 
(3H, s, -OCH3), and 3.69 (3H, s, -OCH3) (Found: C, 70.74; H, 5.88. C16H1S04 requires C, 
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4.5.2.2 Synthesis of product P11·P20 





The conditions employed for the preparation of this compound were those described in 
General Method D. Column chromatography (Si02, EtOAc-hexane, 60:40) gave the 
biaryl piperazine P11 (36.5mg, 27%) as yellow needles; m.p. 96-98 °C; Rr 
(EtOAc-hexane, 60:40) 0.42; oH(300 MHz; CDCh) 7.45 (2H, d, J 8.4, H1 and H2), 7.37 
(2H, d, J8.4, H3and H4), 7.12-7.10 (2H, m, Hs and Hs), 6.94 (1H, d, J8.7, H7), 3.94 (3H, 
s, -OCH3), 3.92 (3H, s, -OCH3), 3.54 (2H, s, Ar-CH2-N-). 2.47 (8H, broad s, 4 x -N-CHr) 
and 2.29 (3H, S, -N-CH3); oc(100 MHz; CDCb) 149.2,148.6,139.9,136.8,134.1,129.6 
(2C), 126.6 (2C), 119.3, 111.6, 110.5,62.7,56.0 (2C), 55.1 (2C), 53.0 (2C) and 46.0; 
LC-MSfound: M+, 327.05. C20H26N202 requires M, 327.068. (Found: C, 71.94; H, 8.17; N, 
8.54. C2oH2SN202·0.4H20 requires C, 72.00; H, 7.98; N, 8.40%). 
1-(3' ,4' -Dimethoxy-biphenyl-4-ylmethyl)-4-phenyl-piperazine P12 
P12 
The conditions employed for the preparation of this compound were those described in 
General Method D. Column chromatography (Si02, EtOAc-hexane, 60:40) gave the 
triaryl piperazine P12 (46 mg, 29%) as yellow needles; m.p. 120-123 °C; Rf 
(EtOAc-hexane, 30:70) 0.20; oH(400 MHz; CDCb) 7.54 (2H, d, J 8.0, H1 and H2), 7.41 
(2H, 1, J 8.0, H3 and H4), 7.27-7.24 (3H, m, Hs, Hs and H7), 7.08-7.05 (2H, m, Hs and H9), 
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s, Ar-CH2-N-), 3.24-3.21 (4H, m, 2x -CH2""N-CH2) and 2.69-2.66 (4H, m, 2x -CH2-N-CH2""); 
Bc(100 MHz; CDCb) 149.6 (3C), 139.0, 136.8, 134.2, 129.6 (2C), 129.1 (3C), 126.7 (2C), 
119.5, 116.0, 111.8 (2C), 110.5, 62.7, 56.0 (2C), 53.1 (2C) and 49.1 (2C); LC-MS found: 
M+, 389.13. C2sH2SN202 requires M, 389.118. (Found: C, 77.32; H, 6.94;N, 7.61. 
C2sH28N202 requires C, 77.29; H, 7.26; N, 7.21 %). 
i-Benzyl-4-(3' ,4' -dimefhoxy-biphenyl-4-ylmefhyl)-piperazine Pi3 
MeO 
P13 
The conditions employed for the preparation of this compound were those described in 
General Method D. Column chromatography (Si02,EtOAc-hexane, 60:40) gave the 
triaryl piperazine P13 (125.3 mg, 94.5%) yellowish-brown plates; m.p. 105-108 °C; Rf 
(EtOAc-hexane, 60:40) 0.28; BH(300 MHz; CDCb) 7.49 (2H, d, J 8.4, H1 and H2), 
7.37-7.30 (7H, m, aromatic), 7.11-7.09 (2H, m, H3 and H4), 6.94 (1H, d, J 8.4, Hs), 3.94 
(3H, s, -OCH3), 3.92 (3H, s, -OCH3). 3.55 (2H, s, Ar-CH2-N-), 3.53 (2H. s, Ar-CH2-N-) 
and 2.51 (8H, broad s, 4 x -N-CH2-); Bc(100 MHz; CDCh) 149.5 (2C), 139.0, 137.0, 
134.2, 129.7 (3C), 129.3 (2C), 128.2 (2C), 126.6 (3C), 119.5, 111.8, 110.5, 62.7 (2C), 
56.0 (2C) and 53.0 (4C); LC-MS found: M+, 403.13. C2sH30N202 requires M, 402.504. 
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H4 He H11 
He 
P14 Hg 
The conditions employed for the preparation of this compound were those described in 
General Method D. Column chromatography (Si02, EtOAc-hexane, 60:40) gave the 
organometallic compound Pi4 (73.2 mg, 35%) as orange plates; m.p. 110-112 °C; Rf 
(EtOAc-Hex, 30:70) 0.40; 8H(300 MHz; CDCb) 7.50 (2H, d, J 9.0, H1 and H2), 7.35 (2H, d, 
J 9.0, H3 and H4), 7.17-7.10 (2H, m, H5 and Hs), 6.93 (1H, d, J 9.0, H7), 4.18 (4H, s, Ha, 
Hg, H10 and H11 ), 4.10 (5H, s, C5H5), 3.94 (3H, s, -OCH3), 3.92 (3H, s, -OCH3), 3.51 (2H, 
S, H12 and H13), 3.40 (2H, S, H14 and H15) and 2.49 (8H, broad s, 4 x -NCH2); 8c(1 00 MHz; 
CDCI3) 148.7, 139.9, 136.7, 134.4, 129.6 (9C), 126.6 (4C), 119.4,111.8, 111.0,70.3, 
68.5, 68.0 (2C), 63.1 (2C), 58.7, 56.1, 52.9, and 52.5; LC-MS found: M+, 511.09. 
C30H34N202Fe requires M, 511.065. (Found: C, 70.59; H, 6.71; N, 5.49. C30H3sN202Fe 
requires C, 70.90; H, 6.71; N, 5.24%). 
1-MethyI4-(2' ,3' ,4' -trimethoxy-biphenyI4-ylmethyl)-piperazine P15 
MeO 
MeO 
The conditions employed for the preparation of this compound were those described in 
General Method D. Column chromatography (Si02, EtOAC-hexane, 50:50) gave the 
biaryl piperazine PiS (109.6 mg, 83%) as yellow oil; RdEtOAc-hexane, 30:70) 0.25; 
8H(300 MHz; CDCb) 7.44 (2H, d, J 8.4, H1 and H2), 7.34 (2H, d, J 8.4, H3 and H4), 7.02 
(1H, d, J 8.4, H5), 6.73 (1H, d, J 8.4, Hs), 3.92 (3H, s, -OCH3), 3.89 (3H, s, -OCH3), 3.67 
(3H, s, -OCH3), 3.54 (2H, s, Ar-CH2-N-), 2.51 (8H, broad s, 4 x -N-CH2-) and 2.29 (3H, S, 
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(2C), 124.8 (2C), 107.5,62.8,61.0 (2C), 56.1 (3C), 53.1 (2C) and 46.0; lC-MS found: M+, 
357.14. C21H2SN203 requires M, 357.062. (Found: C, 70.45; H, 7.88; N, 7.76. C21H2SN203 
requires C, 70.76; H, 7.92; N, 7.86%). 
1-Phenyl-4-(2' ,3' ,4' -trimethoxy-biphenyl-4-ylmethyl)-piperazine P16 
Hl 
MeO o Hs 
H2 Ny~H3 
H Hs MeO Hey 7 
H10 H4 
P16 
The conditions employed for the preparation of this compound were those described in 
General Method D. Column chromatography (Si02, EtOAc-hexane 30:70) gave the 
triaryl piperazine P16 (113.0 mg, 73%) yellow cubes; m.p. 65-68 °C; Rf(EtOAc-hexane, 
30:70) 0.32; ()H(400 MHz; CDCb) 7.48 (2H, d, J 8.4, Hi and H2), 7.38 (2H, d, J 8.4, H3 
and H4), 7.28 (2H, d, J 8.4, Hs and Hs), 7.04 (1 H, d, J 8.4, H7), 6.95 (2H, d, J 8.4, Hs and 
Hg), 6.87 (1 H, t, J 7.5, H10), 6.74 (1 H, d, J 8.4, H11), 3.93 (3H, s, -OCH3), 3.90 (3H, s, 
-OCH3), 3.70 (3H, s, -OCH3), 3.61 (2H, s, Ar-CH2-N-), 3.25-3.20 (4H, m, 2 x CHr N-CH2-) 
and 2.65-2.61 (4H, m, 2 x -CH2-N-CHr ); ()c(100 MHz; CDCb) 153.1, 151.4, 142.6, 137.0, 
136.5 (2C), 129.3 (2C), 129.2 (2C), 125.0 (2C), 119.8 (2C), 116.3 (3C), 107.7,63.0,61.0 
(2C), 56.3 (2C), 53.4 and 49.4 (2C); lC-MS found: M+, 419.10. C2sH30N203 requires M, 
419.112. (Found: C, 74.52; H, 7.27; N, 6.37. C2sH30N203requires C, 74.61; H, 7.22; N, 
6.69%). 
1-Benzyl-4-(2' ,3' ,4'-trimethoxy-biphenyl-4-ylmethyl)-piperazine P17 
MeO 
MeO 
The conditions employed for the preparation of this compound were those described in 
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triaryl piperazine P17 (61.3 mg, 63%) as orange oil; Rf (EtOAc-hexane, 60:40) 0.30; 
8H(300 MHz; CDCb) 7.43 (2H, d, J 9.0, H1 and H2), 7.31-7.30 (7H, m, aromatic), 7.02 (1 H, 
d, J 9.0, H3). 6.72 (1 H, d, J 9.0, H4), 3.92 (3H, s, -OCH3), 3.89 (3H, s, -OCH3), 3.67 (3H, 
s, -OCH3), 3.55 (2H, s, Ar-CH2-N-), 3.53 (2H, s, Ar-CH2-N-), and 2.52 (8H, broad s, 4 x 
-N-CH2-); 8c(100 MHz; CDCb) 153.1,151.4,143.6,137.0.136.5 (2C). 129.2 (2C), 129.0 
(2C), 128.2 (2C), 127.0 (3C), 124.7. 115.5, 107.6,63.1,62.8,60.9 (3C), 56.1 (2C) and 
53.1 (2C); LC-MS found M+, 433.10. C27H32N203 requires M, 433.142. (Found: C, 72.68; 
H, 6.93; N, 6.28%. C27H32N203·0.8H20 requires C, 72.55; H, 7.57; N, 6.27%). 




The conditions employed for the preparation of this compound were those described in 
General Method D. Column chromatography (Si02, EtOAc-hexane, 50:50) afforded the 
biaryl piperazine P18 (100.1 mg, 89%) as yellow plates; m.p. 106-108 °C; Rf 
(EtOAc-hexane, 50:50) 0.15; 8H(300 MHz; CDCb) 7.53-7.7.48 (4H, m, H1, H2, H3 and H4), 
7.36 (2H, d, J 8.7, H5 and H6), 6.97 (2H, d, J 8.7, H7 and Ha), 3.84 (3H, s, -OCH3), 3.54 
(2H, s, Ar-CH2-N-), 2.62 (8H, broad s, 4 x -N-CH2-) and 2.29 (3H, S, -N-CH3); 8c(100 
MHz; CDCb) 159.1, 139.6, 136.6, 133.6, 129.6 (2C). 128.0 (2C). 126.5 (2C). 114.2 (2C). 
62.7,55.3,55.2,53.1 (3C) and 46.0; LC-MS found: M+, 297.04. C19H24N20 requires M, 
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1-(4' -Methoxy-biphenyl-4-ylmethyl)-4-phenyl-piperazine P19 
The conditions employed for the preparation of this compound were those described in 
General Method O. Column chromatography (5i02, BOAc-hexane, 30:70) afforded the 
triaryl piperazine P19 (91.4 mg, 88%) as orange crystals; m.p. 123-127 °C; Rf 
(BOAc-hexane, 30:70) 0.45; oH(400 MHz; COCb) 7.55-7.51 (4H, m, Hi, H2, H3 and H4), 
7.40 (2H, d, J 8.4, Hs and Hs), 7.29-7.23 (2H, m, H7 and H 8), 7.00-6.91 (5H, m, Hg, H1Q, 
H11 , H12 and H13), 3.86 (3H, s, -OCH3), 3.61 (2H, s, Ar-CH2-N-), 3.24-3.21 (4H, m, 2 x 
-CHrN-CH2-) and 2.67-2.64 (4H, m, 2 x -CH2-N-CH2); oc(100 MHz; COCh) 159.1,151.4, 
139.7,136.4,133.5,129.6 (2C), 129.1 (2C), 128.0 (2C), 126.6 (2C), 119.6,116.1 (2C), 
114.2 (2C), 62.7, 55.3 (2C), 53.1 and 49.2 (2C); LC-M5 found: M+, 359.06. C24H2SN20 
requires M, 359.124. (Found: C, 77.53; H, 7.31; N, 6.20. C24H2SN20·O.7H20 requires C, 
77.67; H, 7.43; N, 7.55%). 
1-Benzyl-4-(4' -methoxy-biphenyl-4-ylmethyl)-piperazine P20 
The conditions employed for the preparation of this compound were those described in 
General Method O. Column chromatography (5i02, BOAC-hexane, 60:40) gave the 
triaryl piperazine P20 (114.7 mg, 66%) as yellow needles; m.p. 117-120 °C; Rf 
(BOAc-hexane, 60:40) 0.27; oH(300 MHz; COCb) 7.53-7.48 (4H, m, Hi, H2, H3, and H4), 
7.36-7.30 (7H, m, aromatic), 6.97 (2H, d,J 9.0, H5 and Hs), 3.85 (3H, s, -OCH3), 3.54 (2H, 
s, Ar-CH2-N-), 3.51 (2H, s, Ar-CH2-N-) and 2.50 (8H, broad s, 4 x -N-CH2-); oc(100 MHz; 
CDCh) 159.1, 139.6, 138.2, 136.6, 133.6, 132.2, 132.0, 129.6, 129.2, 128.6, 128.4, 
128.2, 128.0, 127.0 (2C), 126.5, 114.2 (2C), 63.1,62.7,55.3 (3C) and 53.1 (2C); LC-M5 
found: M+, 373.15. C25H2SN20 requires M, 373.154. (Found: C, 79.41; H, 7.20; N, 6.54. 
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4.5.2.3 Synthesis of product P23-P26 
1-(4-Methyl-piperazin-1-yl)-3-(2' ,3',4' -trimethoxy-biphenyl-4-yloxy-propan-2-ol P23 
MeO 
P23 
The conditions employed for the preparation of this compound were those described in 
General Method E. Column chromatography (Si02, MeOH-CH2CI2, 10:90) afforded the 
biaryl piperazine P23 (76.2 mg, 31%) orange cubes; m.p. 103-106 °C; Rf (MeOH-CH2CI2, 
10:90) 0.21; <>H(400 MHz; CDCh) 7.42 (2H, d, J 8.0, Hi and H2), 7.01-6.95 (3H, m, H3, H4 
and H5), 6.72 ('I H, d, J 8.0, H6), 4.11 (1 H, quintet, J 7.5, Ha), 4.02 (2H, d, J 8.0, H7 and 
He), 3.92 (3H, s, -OCH3), 3.88 (3H, s, -OCH3), 3.65 (3H, s, -OCH3), 2.58-2.56 (2H, m, Hg 
and H1O), 2.46 (8H, broad s, 4 x -N-CH2-) and 2.29 (3H, S, -N-CH3); <>c(100 MHz; CDCb) 
158.8,153.5,152.1,142.6,131.3,130.4,129.2,128.2, 124.7, 114.5 (2C), 107.8,70.6, 
65.9,61.0,60.7,56.3 (2C), 55.4, 53.6 (2C) and 46.2 and 29 .. 9; lC-MS found: M+, 417.05. 
C23H32N205 requires M, 417.050. (Found: C, 64.96; H, 8.64; N, 5.31. C23H32N205·0.5H20 
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I ~ H2 
Hs 
H11 P24 
The conditions employed for the preparation of this compound were those described in 
General Method E. Column chromatography (Si02, MeOH-CH2CI2, 5:95) afforded the 
triaryl piperazine 24 (76.2 mg, 47%) as white needles; m.p. 105-108 °C; Rf (5% 
MeOH-CH2CI2) 0.37; oH(400 MHz; COCh) 7.43 (2H, d, J 8.0, Hi and H2), 7.27-7.23 (3H, 
m, H3, H4 and H5), 7.01-6.92 (4H, m, H6, H7, Hs and Hg), 6.89-6.85 (1 H, m, H10), 6.74 (1 H, 
d, J 8.0, H11 ), 4.18 (1 H, quintet, J 7.5, Ha), 4.03 (2H, d, J 8.0, H12 and H13), 3.93 (3H, s, 
-OCH3), 3.89 (3H, s, -OCH3), 3.66 (3H, s, -OCH3), 3.24-3.20 (4H, m, 2 x -CHr N-CH2-), 
2.90-2.84 (2H, m, H14 and Hi5) and 2.66-2.62 (4H, m, 2 x CH2-N-CHr ); oc(100 MHz; 
COCh) 158.0, 153.2, 152.1, 131.3, 130.4, 129.4 (2C), 128.2 (3C), 124.8, 120.1, 116.4 
(3C), 114.5 (2C), 107.8, 70.6, 66.0, 61.2, 61.0, 60.9, 56.3 (2C), 53.6, 49.5 and 29.9; 
LC-MS found M+, 479.10. C2sH34N20s requires M, 479.100. (Found: C, 70.62; H, 7.72; N, 
5.42. C2sH34N205 requires C, 70.27; H, 7.16; N, 5.85%). 
1-(4-Benzyl-piperazin-1-yl)-3-(2' ,3' ,4' -trimethoxy-biphenyl-4-yloxy)-propan-2-ol P25 
The conditions employed for the preparation of this compound were those described in 
General Method E. Column chromatography (Si02, MeOH-CH2CI2, 5%) afforded the 
triaryl piperazine P25 (95.9mg, 33%) as yellow needles; m.p. 76-79 °C; Rf (5% 
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m, H3, H4, H5, Hs and H7),7.00-6.94 (3H, m, He, Hg and H10), 6.70 (1 H, d, J 8.0, H11 ). 4.13 
(1 H, quintet, J 7.5, Ha), 4.02 (2H, d, J 8.0, H12 and H13), 3.92 (3H, s, -OCH3), 3.89 (3H, s, 
-OCH3), 3.65 (3H, s, -OCH3), 3.51 (2H, S, H14 and H1S), 2.73 (2H, m, H16 and H17) and 
2.51 (8H, broad s, 4 x -N-CH2-); De(100 MHz; CDCb) 158.0, 152.6, 151.8, 138.5, 131.2, 
130.4,129.4 (2C), 128.4 (5C). 127.3, 124.8, 114.5 (2C). 107.8.70.6,65.8,63.2,61.2. 
61.0, 60.7; 56.3 (2C), 53.6, 53.3 and 29.9; lC-MS found: M+, 493.16. C29H36N20S 
requires M, 493.130. (Found: C, 69.37; H. 7.51; N, 5.49. C29H36N20s·0.5H20 requires C, 
69.44; H, 7.43; N, 5.58%). 
1-Biphenyl-2-ylmethyl-4-methyl-piperazine P26 
P26 
N-Methylpiperazine (0.11 em3, 1.0 mmol) and 2-phenylbenzyl bromide (0.22 cm3, 1.2 
mmol) were dissolved in a minimum amount of dry toluene in a 25 cm3 round-bottomed 
flask. After stirring at 25°C under a N2 purge for 10 min, the water soluble base 
1,1,3,3-tetramethylguanidine (1.0 cm3, 8.0 mmol) was added to the reaction mixture 
which was brought to reflux. 18h later, the resulting reaction mixture was removed and 
extracted with EtOAc and distilled water. The organic phase was collected and 
chromatographed (Si02, MeOH-CH2CI2, 15:85) yield the biphenyl piperazine P26 (187 
mg, 70%) as yellow cubes; m.p. 56-58°C; Rf(15% MeOH-CH2CI2) 0.42; DH(400 MHz; 
CDCb) 7.50 (1 H, d, J 8.8, H1), 7.34-7.22 (8H, m, aromatic), 3.4i (2H, s, Ar-CH2-N-), 2.43 
(8H, broad s, 4 x -N-CH2-) and 2.29 (3H, S, -N-CH3); De(100 MHz; CDCb) 130.1, 130.0, 
129.4 (2C), 127.8 (2C), 127.0 (4C), 126.8 (2C), 59.6 (2C). 55.0 (2C), 52.3 and 45.7; 
lC-MS found: M+, 267.08. C1sH22N2 requires M, 267.080. (Found: C, 72.44; H, 8.29; N, 
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4.5.2.4 Synthesis of intermediate 21-30 (Scheme 4-C) 
4-(4-Bromo-benzyloxy)-benzaldehyde 127 H1 
Hs H7yyCHO 
H3*=O~YH2 I ' 




4-Bromobenzaldehyde (2.23 g, 8.94 mmol) was added to a stirred solution of powdered 
anhydrous sodium hydride (0.27 g, 11.1 mmol) and 4-hydroxybenzaldehyde (1.04 g, 
8.52 mmol) in DMF (25 cm3) at O°C under an inert atmosphere. The resulting light yellow 
suspension was allowed to warm to 25°C and stirred for an additional 18h. The reaction 
was then diluted with water (500 cm3) and the yellow precipitate was collected by 
filtration and subsequent washing with water. Further drying under vacuum afforded the 
aldehyde 127 (2.25 g, 91%) as yellow cubes; Rf (MeOH-CH2CI2, 5:95) 0.23; bH(400 MHz; 
CDCI3) 9.89 (1 H, s, -CHO), 7.84 (2H, d, J 8.8, H1 and H2), 7.53 (2H, d, J 8.8, H3 and H4), 
7.23 (2H, d, J 8.8, Hs and Hs), 7.05 (2H, d, J 8.8, H7 and Hs) and 5.10 (2H, s, Ar-CH2-) 
(Found: C, 57.72; H, 3.60. C14H1102Br requires C, 57.76; H, 3.81%). 
4-(4'-Mefhoxy-biphenyl-4-ylmefhoxy)-benzaldehyde 128 
The conditions employed for the preparation of this compound were those described in 
General Method C. The product was recrystalized uSing ethyl acetate. The pure white 
needles were separated from the yellow impurities to yield the aldehyde 128 (275 mg, 
63%); Rf (EtOAc-hexane, 10:90) 0.27; bH(400 MHz; CDCb) 9.90 (1H, s, -CHO), 7.86 (2H, 
d, J 8.7, H1 and H2), 7.60-7.46 (6H, m, aromatic), 7.11 (2H, d, J 8.7, H3 and H4), 6.99 (2H, 
d, J 8.7, Hs and Hs), 5.18 (1 H, s, Ar-CH2-0-) and 3.85 (3H, s, -OCH3) (Found: C, 77.76; 
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MeO Hll 6 
Hs 129 
The conditions employed for the preparation of this compound were those described in 
General Method C. The aldehyde 129 was chromatographed (Si02, EtOAc-hexane, 
15:85) as white cubes (321.4 mg, 67%); RdEtOAc-hexane, 15:85) 0.19; bH(400 MHz; 
CDCb) 9.94 (1 H, s, -CHO), 7.84 (2H, d, J 8.8, H1 and H2), 7.61 (2H, d, J 8.8, H3 and H4), 
7.44 (2H, d, J 8.8, Hs and Hs), 7.16-7.10 (4H, m. H7• Ha. Hg and H1O), 6.97 (1 H, d, J 8.8, 
H11), 5.20 (2H, s, Ar-CH2-0-) and 3.95 (3H, s, -OCH3), 3.93 (3H, s, -OCH3) (Found: C, 
75.54; H, 5.64. C22H2004"0.1 H20 requires C, 75.46; H, 5.81 %). 
4-(2' ,3',4' -Trimethoxy-biphenyI4 .. ylmethoxy)-benzaldehyde 130 
MeO 
MeO 
The conditions employed for the preparation of this compound were those described in 
General Method C. The benzaldehyde 130 was purified by chromatography (Si02, 
EtOAc-hexane, 15:85) as yellow cubes (175 mg, 34%) Rf (EtOAc-Hex, 15:85) 0.30; 
bH(400 MHz; CDCh) 9.94 (1H. s. -CHO). 7.85 (2H. d. J 8.8, H1 and H2). 7.55 (2H. d. J 8.8, 
H3 and H4), 7.47 (2H, d, J 8.8, Hs and Hs), 7.11 (2H, d, J 8.8, H7 and Ha), 7.02 (1 H, d, J 
8.8, Hg), 6.86 (1 H, d, J 8.8, H10). 5.20 (2H, s, Ar-CH2-0) and 3.93 (3H, s, -OCH3), 3.90 
(3H, s, -OCH3), 3.70 (3H, S, -OCH3) (Found: C, 72.90; H, 5.79. C23H2205 requires C, 
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4.5.2.5 Synthesis of product P31-P33 
1-[4-(4' -Methoxy-biphenyl-4-ylmethoxy)-benzyl]-4-methyl-piperazine P31 
The conditions employed for the preparation of this compound were those described in 
General Method D. Column chromatography (Si02, MeOH-CH2CI2, 5:95) afforded the 
triaryl piperazine P31 (25.1 mg, 39%) as yellow needles; m.p. 127-130 °C; Rf (5% 
MeOH-CH2Cb) 0.30; oH(400 MHz; CDCb) 7.59-7.46 (6H, m, Hi. H2• H3• H4• Hs and Hs). 
7.23 (2H, d, J 8.8, H7 and Hs), 6.99-6.93 (4H, m, Hg , HiQ, H11 and H12), 5.10 (2H, s, 
Ar-CH2-0-), 3.85 (3H, s, -OCH3), 3.47 (2H, s, Ar-CH2-N-), 2.46 (8H, broad s, 4 x -N-CH2-) 
and 2.28 (3H, s, N-CH3); oc(100 MHz; CDCb) 159.3, 158.0, 140.6, 135.5, 133.4, 130.5, 
130.4,128.1 (3C), 128.0 (2C), 126.9 (4C). 114.6, 114.3,69.9,62.4,55.3 (2C). 55.1, 53.0 
(2C) and 46.0; LC-MS found: M+, 403.10. C2sH30N202 requires M, 403.148. (Found: C, . 
72.48; H, 7.74; N, 6.07. C2sH30N202·1.6H20 requires C, 72.38; H, 7.75; N; 6.49%). 
1-[4-(3' ,4' -Dimethoxy-biphenyl-4-ylmethoxy)-benzyl]-4-methoxy-piperazine P32 
The conditions employed for the preparation of this compound were those described in 
General Method D. Column chromatography (Si02, MeOH-CH2CI2, 5:95) afforded the 
triaryl piperazine P32 (40.8 mg, 36%) as white cubes; m.p. 112-114 °C; Rf (5% 
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8.8, H3 and H4), 7.23 (2H, d, J 8.8. H5 and Hs). 7.15-7.10 (2H, m, H7 and He), 6.96-6.94 
(3H, m, Hg, H10 and H11 ), 5.10 (2H, s, Ar-CH2-0-), 3.94 (3H, s, -OCH3). 3.92 (3H. 
s, -OCH3), 3.46 (2H, s, Ar-CH2-N-), 2.44 (8H, broad s, 4 x -N-CH2-) and 2.27 (3H, s, 
-N-GH3);8c(100 MHz; COGh) 158.0, 149.2, 148.8, 140.8, 135.7, 133.9, 130.6, 130.4, 
128.0 (2C). 127.0 (3C), 119.4, 114.5 (2C). 111.6, 110.5, 69.8, 62.4, 56.0 (2C). 55.1 (2C), 
53.4.53.0 and 46.0; LC-MSfound: M+, 433.10. C27H32N203 requires M, 433.142. (Found: 
C, 72.28; H, 6.72; N, 5.83. C27H32N203·0.9H20 requires C, 72.26; H. 7.58; N, 6.24%). 
1-Methyl-4-[4-(2' ,3',4' -trimethoxy-biphenyl-4-ylmethoxy)-benzyl-piperazine P33 
MeO 
MeO 
The conditions employed for the preparation of this compound were those described in 
General Method O. Column chromatography (Si02, MeOH-CH2CI2, 5:95) afforded the 
triaryl piperazine P33 (60 mg, 58%) as yellowish needles; m.p. 68-70 °C; Rf (5% 
MeOH-CH2CI2) 0.20; 8H(300 MHz; COCh) 7.52 (2H, d, J 8.8, H1 and H2), 7.46 (2H. d, J 
8.8, H3 and H4), 7.24 (2H, d, J 8.8, H5 and Hs), 7.01 (1 H, d, J 8.8, H7), 7.96 (2H, d, J 8.8, 
He and Hg), 6.75 (1 H, d, J 8.8, H1o), 5.08 (2H, s, Ar-CH2-0..;), 3:93 (3H, -s, -OCH3), 3.90 
(3H. s, -OCH3), 3.68 (3H, s, -OCH3), 3.45 (2H, s, Ar-CH2-N-), 2.44 (8H, broad s, 4 
x -N-CH2-) and 2.28 (3H, S, -N-CH3); 8c(100 MHz; COCh) 158.1, 153.2, 142.6, 138.0, 
135.5,130.5,130.4,129.3,128.3 (2C), 127.3 (3C), 124.8, 114.6 (2C), 111.8, 107.6,70.0, 
62.4, 61.0 (2C), 56.1 (2C), 55.1, 53.0 (2C) and 46.0; LC-MS found: M+, 463.12. 
C2sH34N204 requires M, 463.136. (Found: C, 70.10; H, 6.64; N, 5.32. C2eH34N204·0.9H20 
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5. In Vitro Screening against P. falciparum 
5.1 Introduction 
Drug resistance in malaria has been defined as "ability of a parasite strain to survive 
and/or to multiply despite the administration and absorption of a drug given in doses 
equal to or higher than those usually recommended but within the limits of tolerance of 
the subject." (WHO, 1965, 1973; Bruce-Chwatt et a/., 1981). However, the term CO 
resistance could be misleading. It has been considered as an in vitro phenotype; the 
ability of malaria parasites to survive CO at a therapeutic serum concentration in vivo 
and even the outcome of a clinical CO therapy (Wellems and Plowe, 2001). CO 
resistance throughout the in vitro investigation in this research is therefore defined to 
have two distinguishing features: (1) the ability of the parasites to survive and/or multiply 
at 0.1 IJM (33 ng/ml) of CO based on standard conditions of continuous culture and (2) 
the characteristic of chemosensitization by verapamil present at 1.0 1l1Vl. 
The characteristic features of classical resistance modulators include the ability to 
modulate CO resistance when used in combination with CO. However, the factor limiting 
achievement of effective concentrations is the intrinsic side-effects. In the search for a hit 
compound as the basis of a CO resistance reverser, a small group of rationally designed 
compounds generated were studied in vitro against P. falciparum. The intrinsic 
antiplasmodial activity, resistanc  reversal effect, effect in CO accumulation as well as 
cytotoxic screening are reported and discussed in this chapter. 
5.2 Hit development 
In the early stage of drug discovery, it is essential to discover hits, which are prototype 
compounds possessing desired pharmacological activities, before any chemical 
modifications to improve their clinical features into lead molecules and ultimately fulfil the 
criteria for a pre-clinical candidate (see Table 2.1 - Rational drug design, P32). On the 
basis of known structure-activity relationship studies for MDR reversal agents, and 
inspection Of the chemical structures of known chemosensitizers in malaria, a small 
number of compounds was designed and synthesized for preliminary exploratory 











Chapter 5 Hit development: biological evaluation 
According to known SAR in malaria MDR chemosensitizers, a hydrophobic moiety is 
important for good resistance reversal effects in CO resistant parasites (see 2.2.2.1. 
SAR in chemosensitizers). In connection with the known SAR studies, the synthesized 
compounds possess different extended hydrophobic chemical features in their 
respective structures. Compound P4 differs from the others with only one aromatic ring 
in its structure while the others contain at least two' aromatic ring systems. The 
introduction of a methoxy group at position 3 on one of the hydrophobic rings of 
compound P5 distinguishes compound P6 from P5. In the structure of compound P7, a 
privileged biphenyl substructure was introduced. 
N~N/ 







Figure 5.2. Chemical structures of potential hits. 
The objective of this exploratory study was three-fold: 0) to extend and/or confirm the 
known structure-activity relationships of previously identified chemosensitizers in malaria 
with respect to the chemoreversal diamino propane pharmacophore hypothesis 
(Rasonaivo et al., 2004), (ii) to confirm our hypothesis that two basic nitrogens in the side 
chain (reminiscent of a polyamine backbone) will give rise to concentration-dependent 
dual acting antimalarial and resistance reversal agents and, (iii) to test our hypothesis 
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5.3 Results and discussions 
5.3.1 Antiplasmodial activity 
The K1 and RSA 11 strains of P. faiciparum are more resistant to CO than the sensitive 
strain, 010 (Appendix 2, Fig. 5.3.1-A(a), Fig. 5.3.1-8(a) and Fig. 5.3.1-C(a». The intrinsic 
antiplasmodial activities of the synthesized potential CO resistance reversing agents 
alone were studied on the South African caR strain RSA 11. For comparative purposes, 
the activities were also assessed in K1. The pLOH assay was carried out and the results 
were analysed as parasite percentage viability versus logarithm of the drug 
concentration in /-lM. Fig. 5.3.1-8 and Fig. 5.3.1-C (Appendix 2) show the results 
obtained. The degree of intrinsic antiplasmodial activity was measured by the 50% 
inhibitory concentrations (lCso) at which 50% of the parasites were killed (Table 5.3.1). In 
addition to the ICso values, the resistance index (RI :::: ICsl 1 orRsA11/1CsoD10) which gives 
an indication of the relative activity of the compounds in a drug resistant and sensitive 
strain of P. falciparum, is reported. For new compounds, this gives an indication of 
whether or not the compound will be active against caR strains. Le. the lower the RI 
value, the better. 
The small series of compounds synthesized all showed marked antiplasmodial activity 
against CO-sensitive and resistant strains of falciparum malaria (Table 5.3.1). Since the 
synthesized compounds are structurally unrelated to CO, comparisons were made within 
this series of compounds produced, in which a lower activity in P4 was observed (lCso > 
2/-lM while the others exhibited ICso < 2/-lM). This may be explained by the poly-aromatic 
substructure present in compounds P5, P6 and P7. All the compounds exhibited 
substantially lower antimalarial activity against the CO sensitive strain, 010 when 
compared to ca. However, the intrinsic activity of P7 was comparable to CO in the CO 
resistant strain K1 (CQ: ICSO
K1 =0.196 /-lM; P7: ICsO
K1 =0.148 /-lM), even though it was 3 
times less active than CO in the RSA11 strain (CQ: ICsORSA11=0.181 /-lM; P7: 
ICSORSA11=0.600 /-lM). Although the number of compounds synthesized for exploratory 
studies is very small, the superior activity of compound P7 relative to the others may be 
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Table 5.3.1. In vitro antiplsmodial activitl 
lf~~N' R ...... I '0 " ..... 
P5,P6,P7 
P4 2.45 2.29 0.93 2;57 1.05 3.88 
P5 ~ 1.10 1.58 1.43 1.86 1.69 3.86 
P6 ~ 0.977 0.830 0.85 1.32 1.35 3.78 
OMe 
~ P7 0.174 0.148 0.85 0.600 3.45 5.45 r l :::,... 
"Results are expressed as mean ICso (~) of three independent experiments performed in duplicate. 
In terms of the relative activity of the compounds in different strains of P. falciparum, 
compound P4 was equally active against cas and caR strains (RIK1:O.93; 
RIRSAll=1.05). Compound P5 was slightly less active in the CO resistant strains while P6 
(RIK1=O.85; RIRSAll=1.35) and P7 (RIK1=O.85; RIRSAll=3.45) showed better activity 
against K1 than RSA 11. This suggests that the hydrophobic structural feature 
incorporating substituents (methoxy group or another lipophilic aromatic ring) on the 
aromatic ring may improve their antiplasmodial activity against the K1 strain of malaria 
parasites as the more lipophilic compound, P7, (high clogP value) may be able to readily 
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5.3.2 Resistance reversal effects 
All the concentrations selected for combination studies in COR K1 and RSA11 isolates 
were derived from Fig. 5.3.1-8 and Fig. 5.3.1-C (Appendix 2), respectively. 
Concentrations were chosen which were sub-lethal to the parasite cultures, in order to 
be able to distinguish the resistance reversal from the antimalarial effect (Table 5.3.1). 
The concentration chosen for the compounds was 0.03 J.lM, which is much lower than 
any of the intrinsic antiplasmodial ICso values of the compounds tested. The CO 
resistance reversing effects of the single drug combined with CO on the resistant strains 
of K1 and RSA11 are illustrated in Fig. 5.3.2-A and Fig. 5.3.2-8, respectively. A 
dose-response curve of CO alone serves as a control of the experiment (shown in black). 
The result of combination of CO with each single compound is illustrated in colour. A shift 
of the curve to the left of the CO dose-response curve indicates resistance reversal 
activity. Any shifts to the right of the CO curve would suggest an antagonistic effect to the 
action of CO. 
As can be seen in Fig. 5.3.2-A, a slight shift of the CO+compound curve to the left of the 
CO alone on K1 strain was observed. This indicates weak resistance reversal effects on 
CO action for all synthesized compounds. On RSA11 (Fig. 5.3.2-8), curves of CQ+P4 
and CQ+P5 showed possible antagonistic effects while CQ+P6 demonstrated no 
significant resistance reversal effects. As with data obtained on K1, P7 showed little 
resistance reversal effects on RSA 11. The control curve of CO+VPL shows significant 
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For convenience, the ICso values of the synthesized compounds in combination with CQ 
in this study as well as the Response Modification Index (RMI) outlines, which indicate 
the susceptibility of the sensitive strain and resistant strains to CQ alone and in 
combination with a single drug, can also be found in Table 5.3.2.1. 
The RMI is defined as 
where 
R.M.I.= ICso{z*)/ICso (z) 
ICso(z*) = ICso of the combination of a particular drug with CQ 
ICso(z) ::: ICso of CQ alone 
If the index < 1, a synergistic effect and/or potentiation are/is suggested. Otherwise, an 
antagonistic result (RMI > 1) and an unbiased result (RMI :::'1) are stated. 
Table 5.3.2.1. Resistance reversal effect. 
OMe#~~OMe I eN I ...-::, 
OMe ~ h ~
~~N/ 
R "- I '0 , ...... 
OMe 
P5,PS,P1 VPL 
CQ+VPl 0.126 0.42 0;109 0.60 
CQ+P4 0.144 0.13 0.335 1.85 
CQ+P5 (jL 0.141 0.12 0.234 1.29 
CQ+PS ~ 0.148 0.1S 0.162 0.90 
OMe 
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In this exercise, all the compounds synthesized were found to be less potent resistance 
reversers than VPL. However, the marked antiplasmodial activity and moderate 
resistance reversal effect of compound P7 on both caR strains are noteworthy. The RMI 
indices in Table 5.3.2.1 confirm the dose-response relationship of the compounds 
tested. 
For resistance reversal effects, VPL showed the most potent ca resistance reversing 
activity among the drugs tested as its Ca+VPL dose-response curve shifts to the left of 
the ca curve in both caR strains of K1 and RSA11 (Fig. 5.3.2). This was confirmed with 
the resistance modification indexes which indicate good reversing activity when RMI <1 
(RMIK1= 0.42 and RMIRSA11= 0.60). All synthesized compounds showed moderate 
resistance modulating properties in the K1 isolate whereas compound P7 demonstrated 
the best resistance reversal effect in both caR strains (RMIK1 =0.67 and RMIRSA11=0.82). 
Compound P4 was shown to be the least potent resistance reverser although it exhibited 
the least intrinsic toxicity. When the alkyl chain was substituted with an aromatic ring (P4 
vs P5). the intrinsic antiplasmodial activity as well as the resistance reversal effect were 
improved, suggesting the importance of an aromatic hydrophobic moiety. Furthermore, 
when an additional methoxy group was attached to the substituted aromatic ring 
(compound P5 vs P6), further enhancement in resistance reversing properties was 
observed in addition to increased antiplasmodial activity. Lastly, the effect of the biphenyl 
substructure in compound P7 was evident since compound P7, the analogue of P4, 
showed significant chemosensitization as well as antimalarial effects. A tentative 
hypothesis is proposed that the poly-aromatic structural element is probably the 
pharmacophore that is responsible for interacting with proteins involved in the resistance 
mechanism. In addition, one possibility for the moderate chemosensitizing activities 
observed with the drugs investigated in this study could be that the chosen sub-lethal 
concentration of 0.03JlM was minimal. It is expected that the higher concentrations of 
these drugs would produce greater chemosensitization and antiplasmodial activity 
against ca resistant P. falciparum. However, it would not be possible to distinguish the 
antiplasmodial activity from resistance reversal effects at higher concentrations of the 
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5.3.3 Tritiated CQ accumulation with combinations of compounds 
Substantial literature on the accumulation of CO by falciparum infected erythrocytes has 
shown that the cytotoxic effect of CO is due to the increased uptake of CO within malaria 
parasites. In COR parasites, an effective chemosensitizer leads to a potentiation of CO 
uptake within the malaria-infected red blood cells. In efforts to establish a possible 
mechanism underlying resistance reversal effects of the novel products, radio-labelled 
CO was used in this accumulation assay. COs strain D10 standardized this assay as 
results reveal no potentiation effect against all the drugs tested in this strain 
(Fig.5.3.3-A). 
The results presented in combination studies were validated in accumulation 
experiments. Typical resistance reversal agents are characterized by increased CO 
accumUlation in addition to the shift in the CO curve. The concentrations of potential 
resistance reversers selected for the combination experiments were non-toxic to P. 
faiciparum and derived from Fig. 5.3.1-A, -B and -C. The results are presented in Fig. 
5.3.3 as fold increase versus the CO combination with different compounds at various 
concentrations. The parasitized red blood cell served as a control. Fold increase in 
uptake refers to the ratio of radio-labelled 3H-CO counts of the combination to the 3H-CO 
control. The data for all three strains tested are expressed below as three independent 
experiments performed in triplicate. 
In D10, none of the tested compounds significantly increased CO uptake when 
compared to the control of parasitized red blood cell (pRBC) at all the concentrations 
tested. This confirms the prediction that there are no significant differences in CO 
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Figure 5.3.3-(A). Fold increase in 3H-Ca uptake with combinations of drugs at different 
concentrations used on cas, D10. 
Against the COR strain, K1, the compounds potentiated CO uptake to an extent of 3 to 6 
fold with the control, VPL exhibiting a 6 fold increase in CO uptake at a drug 
concentration of 0.1 )lM in the same assay (Fig. 5.3.3-B). At a higher drug concentration 
of 1.0 )lM, compound P7 showed an improved 8-fold increase in CO uptake. In addition, 
the investigation at a concentration of 10 )lM (100 times more than the lowest 
concentration of 0.1 )lM tested) showed no further enhancement of CO accumulation 
among all the drugs tested; this suggested that there is a saturation point in 3H-CO 
uptake. This may be due to toxic effects as a result of the high concentration of the 
compounds used (approximately 100 times their ICso). Similarly, no significant difference 
in CO resistance reversal activity was found for all the drugs tested at a concentration of 
0.1 flM in RSA 11. However, at a concentration of 1 flM, compound P7 revealed a marked 
activity in potentiating CO uptake which was 4-fold higher than VPL (2-fold). No 
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Figure 5.3.3-(8). Fold increase in 3H-CO uptake with combinations of drugs at different 












Fig. S.3.3-(C). Fold increase in 3H-Ca uptake with combinations of drugs at different 
concentrations used on caR, RSA11. 
When the compounds are compared within caR strains, clearly compound P7 is the 
most probable candidate as a resistance reversal agent among all the synthesized 
compounds. This compound not only exhibited weak to moderate intrinsic antimalarial 
activity (Table 5.3.1), which is ideal for a chemosensitizer, but also enhanced CO action 
in a resistance reversal experiment (Table 5.3.2.1), a result confirmed in CO 
accumulation experiments (Fig. 5.3.3). Additionally, it is noteworthy that compound P7 
was shown to possess the highest antimalarial activity of all the compounds tested and it 












5.3.4 Cytotoxicity screening 
Despite the establishment of in vitro analyses against the infectious parasite cultures, it 
is also crucial to substantiate the cytotoxicity of a drug used at its therapeutic 
concentration. Cytotoxicity screening in vitro was achieved by the use of Chinese 
Hamster Ovarian (CHO) cells in MTT assays. Positive controls of daunomycin as well as 
the novel products synthesized were investigated. In this assessment, the same 
concentration range chosen to test resistance reversal assays was used on mammalian 
cells. The results are presented as percentage of viable CHO cells versus the logarithm 
of particular drug concentration in 11M shown in Fig. 5.3.4. 
The IC5D value of the standard, daunomycin, was 3.25±0.39 11M in CHO cell lines (Fig. 
5.3.4-A). Compounds P4, P5and P6 were shown to be non-toxic against the same cell 
line with 100% cell viability even at the highest concentration of 100 fLg/ml (Fig. 
5.3.4-B,-C and -D). Compound P7 demonstrated a cytotoxic effect at a concentration of 
125.89±3.15 11M which nevertheless was much higher than its antimaiariallC5D value « 
5 IlM) among the P. fa/ciparum parasites tested (Fig. 5.3.4-E). This indicates that 
compound P7 is selectively cytotoxic for P. falciparum. Therefore, compound P7 may be 
regarded as the hit molecule warranting further modifications and investigations as a 
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5.3.5 Further investigation of compound P7 using isobologram analysis 
In order to understand the interaction of compound P7 with ca, a modified isobologram 
analysis protocol from Chawira and Warhurst (1987) was employed. Isobologram 
analysis (Section 3.2.3.2) involves graphic representation using fixed ratios of 
predetermined concentrations to determine the interactions of two different 
chemotherapeutic agents (see introduction). If the effect is synergistic, the parasite 
viability values at the fixed ratios for both ca and P7 are illustrated below the line and 
antagonism is indicated by values above the line. 
In assessing the clinical potential of a combination of ca with compound P7, the 
isobologram method was used (Fig. 5.3.5). An additive effect was observed against both 
cas and caR strains when ca and P7 were used at their corresponding ICso 
concentrations (Fig. 5.3.5-A). This suggests that compound P7 and ca did not compete 
for the same binding site and there were no drug interactions. In addition, a more 
detailed assessment was made in a caR strain by mixing the cocktails of ca at its IC50 
and IC25 concentrations with the toxic dose of P7. Both studies showed synergistic 
effects against RSA 11. This indicated that there could be a drug interaction at the 
pharmacological site of action in falciparum malaria. In an attempt to realise a potential 
clinical combination, the IC1 and IC10 of both ca and P7 were combined and examined 
(Fig. 5.3.5-C). However, both combinations demonstrated no better than an antagonistic 
effect, suggesting that compound P7 and ca interacted with each other to compete for 
the same binding site in the RSA11 isolate. To sum up, the isobologram analyses 
revealed that the best combination of ca and compound P7 is at their corresponding 
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Comparing the antiplasmodial activities of compound P1 and amodiaquine (AQ), which 
is relatively active against CQ resistant parasites despite its structural analogy to CQ, the 
structural similarities observed are a tertiary nitrogen atom and the aromatic structural 
features. In addition, the major difference between CQ and AQ is the extra phenolic 
group that AQ contains. Collectively, this suggests that the highest antiplasmodial activity 
P1 possesses among the compounds tested may be due to the tricyclic hydrophobic 
chemical feature. The importance of the 4-amino-7-chloroquinoline moiety in binding to 
the haem may account for the superior antiplasmodial activity of CQ and AQ relative to 
compound P1. The tricyclic moiety of P1 may be involved in binding to haem, albeit 
presumably weakly, which may account for the superior antiplasmodial activity of P1 
relative to the other synthesized compounds. Possible binding to haem of compound P1 
may be enhanced by further structure-activity relationship studies focusing on the nature 
and relative position (relative to the side chain) of the tricyclic (or even bicyclic) moiety. 
~N~ «OH 
NH ~ " I m HN I ~ ~ N a AN" ~ (I c,AAN) ~
N~N/ 
I H I 
o ~ 
CQ amodiaquine (AQ) P7 
5.4 Conclusion 
This study demonstrated that novel exploratory compounds synthesized all possess 
intrinsic (albeit weak to modest) antiplasmodial· activity against CQ-sensitive 
and -resistant P. falciparum parasites. Further, in vitro studies of resistance reversal in P. 
falciparum and cytotoxicity on mammalian cells showed that compound P1 exhibited the 
greatest potential as a dual-acting antimalarial agent and CQ-resistance reverser. From 
a therapeutic point of view, it is infact an advantage to develop dual-acting antimalarial 
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6. Screening of a small library of compounds 
6.1 Introduction 
In light of the identification of a privileged biphenyl substructure as a potential 
chemoreversal pharmacophore, a first generation small library of compounds was 
generated around the basic structure of this potential pharmacophore. This initial SAR 
library focused on replacing the flexible alkyl chain with a piperazinyl moiety, Fig. 6.1. In 
search of potential lead compounds, the biological activity of the novel products will be 
studied and discussed in this chapter. The assessment of in vitro antiplasmodial activity, 
resistance reversing effect, validation of ca accumulation and selective cytotoxicity are 
also reported. 
In chapter 5, compound P7 was identified as being a worthwhile candidate for future 
investigation. In this chapter, a small library of novel products are developed based on 
the compound P7 as well as chemical features known to be exhibited in existing 
antimalarial and/or resistance reversers. The objective was to attempt to improve 
selective cytotoxicity against P. falciparum and/or resistance reversal activity from the hit. 
In vitro screenings for antiplasmodial activity, resistance reversing effects, cytotoxicity, as 
well as careful inspections of their structures are investigated. The structure-activity 
relationships to be revealed are of interest in order to better understand which 
substructural features of the molecule are responsible for the antimalarial activity and 
which for the resistance reversal. 
While this work was in progress, a series of dibenzosuberane-based amino alcohol 
piperazines were described as chemosensitizers active in vivo (Osa at al., 2003). 
Coupled with the identification of compound P7 during preliminary studies, this prompted 
the design of a preliminary SAR library. In addition, the methoxy substituent was chosen 
I 
on the basis of known SAR, which point to the importance of a hydrophobic moiety. a 
protonatable nitrogen and the presence of Lewis basic sites for effective 
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6.2 Results 
6.2.1 In vitro antiplasmodiai activity and cytotoxicity screening of modified 
compounds (Phase II) 
The details of the synthesis and structural elucidation of the novel compounds are 
recorded in chapter 4. 
The small library of compounds produced were firstly examined in vitro for intrinsic 
antimalarial activity against a CO-sensitive strain, 010, and two CO-resistant strains, K1 
and RSA11 , for comparison purposes. The results of dose-response curves for each 
strain are shown in Appendix 3 (Fig. 6.2.1.1 - Fig 6.2.1.3) and the corresponding ICso 
values as well as their chemical structures are listed in Table 6.2.1 and summarized in 
Fig. 6.2.2.4-A. The resistance index (RI), which is used to evaluate whether novel 
antimalarials are potential agents against CO resistant parasites, are also listed in the 
table and discussed in section 6.3.1. 
To measure cell chemosensitivity and selectivity of the modified compounds, concurrent 
cytotoxic analyses were conducted in a Chinese Hamster Ovarian cell line. Cell growth 
inhibition was monitored for the entire class of compounds (Fig. 6.2.1.4). However, no 
attempt was made to determine the ICso (CHO) at concentrations in excess of 100!Jgmr1 
as non-specific toxicity is often shown at such high concentrations. The ICso (CHO) can 
also be found in Table 6.2.1 for comparison purposes. 
The synthesized compounds displayed a range of antiplasmodial activity against P. 
faiciparum strains, 010 (CO-sensitive), K1 and RSA11 (CO-resistant). Compound P14, 
P17, P25, P26, P31, P32 and P33 possess the greatest antiplasmodial activity against 
COR parasites with the analogue P26 exhibiting a reduced activity towards 010, but 
greater activity against K1 and RSA11. In addition, all the novel products were shown to 
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6.2.2 In vitro resistance reversal effect in P. fa/ciparum 
The in vitro dose-response curves of the combination studies were conducted against 
010, K1 and RSA11 in a similar manner to the dose-response curve experiments 
(Section 3.2.3.1) and the subsequent results are shown in Appendix 3 (Fig. 6.2.2.1, Fig. 
6.2.2.2 and Fig. 6.2.2.3). The concentration for each potential resistance modulator used 
for the combination study was derived from Fig. 6.2.1.1, 6.2.1.2 and 6.2.1.3 (Appendix 3) 
for 010, K1 and RSA 11, respectively. A sub-lethal concentration of 1 JlM was selected for 
most of the compounds in this experiment against both CO-sensitive and -resistant 
malaria cell cultures. A concentration of 0.25 JlM was chosen for P14 and P26 which 
were toxic to the parasites at a concentration of 1.0 JlM. 
For comparison purposes, the corresponding IC50 values for each compound alone and 
in combination with CO are summarised in Table 6.2.1. In addition to the 50% inhibitory 
concentration (IC50), the resistance modification index (RMI ::: ICso (CO + drugjllC50 (CO alOne) 
(Section 5.3.2), which as mentioned before gives an indication of the relative activity of 
the compound in the CO-resistant isolates of falciparum malaria, are also recorded. 
Together with the tested candidates, the standard and the positive control of CO and 
verapamil can also be found in the table. 
The 50% inhibitory concentration of CO plus single compound in 010, K1 and RSA11 
are summarized in Fig. 6.2.2.4-8 (shown in histograms). For comparative purposes, the 
RMI for K1 and RSA11 isolates are also illustrated in connected purple and red lines, 
respectively. 
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Table 6.2.1 (Continued) In vitro antiplasmodial activity and resistance reversal effect of each drug alone and in combination with CO (Phase II) in D10, 
K1 and RSA11. 
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Figure 6.2.2.4. 
A. Summary of the IC5D values of the synthesized compounds against D10, K1 and 
RSA11. 
B. Summary of the IC5D of CQ plus each synthesized compound and the resistance 











Chapter 6 Screening of a small library of compounds 
6.2.3 Enhancement of radioactive CQ accumulation 
Incorporation of radiolabeled CO, 3H-CO, was used as the measured parameter of the 
response of the parasites to the drug in this study. For comparative purposes, 
stimulation of CO accumulation by the range of compounds, tested at both 5 ~M and 50 
~M is summarized in Fig. 6.3.3.1. 
Verapamil has been shown to increase CO accumulation by 3 - 5 fold within COR clones 
(Martin et a/., 1987; Adovelande et a/., 1998). In our hands, verapamil also reversed CO 
resistance by enhancing CO uptake within the parasites by 3 - 6 fold at concentrations 
of 5 ~M and 50~M. Moreover, the potentiation ability of verapamil was found to reach a 
saturation point when 50 ~M was tested which suggests that it is toxic to the parasites at 
this concentration so that no further enhancement of CO accumulation could be shown. 
7 
6 
DIO (+ 50 uM compound) 
c::::::J K I (+ 50 uM compound) 
0 5 c::::::JRSAII (+ 50 wVl compound) U C 
-'-DIO (+ 5 uM compound) .= .S? 
Q) .... 4 - KI (+ 5 wVl compound) I/).!!! 
ro :J 
--+-RSAII (+ 5 wVl compound) ~ E 
(.) :J 3 c (.) .- (.) 
u ro 
(5 2 u. 
1 
a 
CQ + Test Compound 
Figure 6.3.3.1. Summary of the fold increase in CO accumulation against CO plus single 
compound at 5 ~M and 50 ~M in 010, K1 and RSA 11 of P fa/ciparum. 
As illustrated in Fig. 6.2.2.4-8 (connected red line), all the synthesized compounds, 
except P13, showed improved CO resistance reversing ability as their resistance 
modification indexes (RMI) lay below 1. In addition, the ability of the compounds to 
stimulate CO accumulation in the COR strain RSA 11 was studied. The control, 











Chapter 6 Screening of a small library of compounds 
combined with each single compound in accumulation measurements. A concentration 
of 5 j..lM was chosen as the lowest concentration for the envisaged investjgations. 
Despite the CO+verapamil combination exhibiting a more pronounced effect at the 5 j..lM 
level, none of the compounds induced any marked increase in CO accumulation within 
resistant parasites (Fig. 6.3.3.1, connected lines). However, when a 10-times higher 
concentration was used, compounds PiS and P11 showed a 2-foldincrement in CO 
uptake while compound P26 enhanced CO accumulation 5- and 6-fold in RSA 11 (yellow 
bar) and K1 (pink bar), respectively. 
It is well described that CO resistant strains accumulate less CO than their 
drug-sensitive counterparts (Fitch, 1970). Potential CO resistance reverser P26 was 
regarded as the classical resistance modulator as it potentiated CO accumulation within 
resistant parasites and also showed significant reversal activity. Nevertheless, several 
structurally related compounds (P16, P19, P23, and P32) showed marked resistance 
reversal effects, compound P32 in particular, without stimulating CO uptake within the 
resistant parasites. It is reasonable to hypothesize that there may be another category of 
CO resistance modulators, which reverse CO resistance without potentiating CO uptake 
(Chibale et al., 2003). At present, the actual CO resistance mechanism is still not known 
and the exact mechanism for the reduced CO uptake by resistant strains is unclear. 
However, the mutated PfCRT transmembrane protein uncovered as the determinant of 
reversible CO resistance by Fidock and his colleagues (Fidock et al., 2000) will hopefully 
lead to a better understanding of CO resistance. Further work could be done to establish 
whether the synthesized compounds interact with the PfCRT protein. 
6.3 Discussion 
6.3.1 In vitro anti plasmodial activity, cytotoxicity screening and resistance 
reversal of the synthesized compounds 
From the library of synthesized compounds, compound P14 was shown to possess the 
greatest antiplasmodial activity in vitro. It exhibited strong intrinsic antimalarial activity in 
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the activity was comparable to CO (Table 6.2.1). Compound P26 was found to be more 
effective against CO resistant P. falciparum than the sensitive 010 (ICsl 1 == 0.60 11M, 
IC50RSA11 == 0.42 11M). Nevertheless, compounds P14 and P26 are less potent compared 
to P7, the hit compound previously identified (lC50D10 == 0.174 11M, IC50
K1 == 0.148 11M, 




. leN I 
MeO ~ A 
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Verapamil P26 P14 
Figure 6.4.1.1. Chemical structures of verapamil, compound P14 and P26. 
In order to establish which structural features are important for antiplasmodial and/or CO 
resistance reversal activity, P26 the simplest compound, incorporating a potential 
pharmacophoric biaryl motif and a piperazinyl substructure, was designed and 
synthesized. The piperazinyl moiety was incorporated based upon its presence in 
previously disclosed CO resistance reversal agents (Osa et al., 2003). Compound P26 
was found to be approximately 100 times more potent in K1 and RSA 11 than in 010 as 
an antiplasmodial agent (RIK1==RtSA11==0.01). This behaviour of compound P26 is 
reminiscent of aryl methanols exemplified by mefloquine which are substantially more 
active in K1 than in 010. The structural dissimilarity between P26 and mefloquine 
warrants further investigation into the mechanism of action of P26 especially in view of 
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Furthermore, the general finding for most compounds that the resistance reversing 
ability is more pronounced against African CQ resistant strain RSA 11 than against the 
K1 clone was also observed in compound P26 (RMIRsA11 = 0.50; RMIK1 = 0.84). In 
summary, the beneficial selective cytotoxicity was retained in P26 after the hit 
modifications, in which the alkyl amino side chain in P7 was substituted with a 
piperazinyl substructure. Moreover, the alteration of piperazinyl substitution improved 
the intrinsic antimalarial activity for potential chemosensitizers as well as retaining the 
reversal properties of the lead. 
P7 P26 mefloquine 
Figure 6.4.1.2. Chemical structures of hit compound P7, compound P26 and mefloquine. 
Ferrocene is an organometallic complex, which has a sandwich structure with the Fe 
atom sandwiched between two five-membered rings. It has a high hydrophobicity and 
low toxicity in vivo, which makes it very attractive for drug design (Biot, 2004). In view of 
this, CQ and the hydrophobic and cytotoxic ferrocene were incorporated into 
organometallic chloroquine analogues (Biot et al., 1997). One of the organometallic 
analogues, ferroquine, was investigated extensively and showed high antimalarial 
activity in vitro as well as in vivo in mice infected with P. berghei N. and P. yoeJii NS (Fig. 
6.4.1.3) (Biot et al., 1997). Ferroquine was believed to be able to diffuse across the 
parasite membranes freely since it has a high lipophilicity as well as providing an 
additional anchoring point suitable for hydrophobic interactions with haematin. In line 
with this, Pradines et al., 2001 described such an organometallic chloroquine analogue 
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chloroquine Ferroquine 
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Figure 6.4.1.3. Structures of chloroquine and organometallic chloroquine. 
In light of this, a potential ferrocene containing resistance modulator, Pi4, was 
synthesized for direct comparison with compound Pi3. This was with a view to exploring 
any potential beneficial effects of the ferrocenyl moiety. Like ferroquine, compound P14 
showed antiplasmodial activity not only towards ca susceptible falciparum, but also to 
ca resistant malaria parasites (ICsoD10::: 0.73 JlM; ICso
K1 ::: 1.49 JlM; ICstSA11::: 0.75 JlM), 
however, it was less active in K1 (RIK1::: 2.04). In addition, this compound also exhibits a 
high resistance reversal effect on RSA 11 (RMI ::: 0.53) similar to that of verapamil (RMI :::: 
0.60). It is noteworthy that in addition to the concentration-dependent dual 
(antiplasmodial and chemosensitization) activity of Pi4, this compound was found to be 
non-cytotoxic towards the mammalian CHO cell line at a concentration of 100 Jlg/ml. The 
partial structural similarity between verapamil and Pi4 with respect to the 3, 
4-dimethoxyphenyl substructure is also noteworthy. In comparison with its analogue Pi3, 
compound Pi4 showed superior antiplasmodial activities against both cas and caR 
strains tested (for Pi4: ICsoDi0. K1 and RSAii < 1.5 JlM vs. Pi3: ICso
DiO. K1 and RSA11 > 5 JlM). In 
line with this, when the ferrocenyl moiety was replaced with a hydrophobic aromatic ring 
system, compound Pi3 displayed an interesting superior activity against RSA11 
(Rt13::::O.78 VS Rt14:::1.03) than that of Pi4. In addition to its antiplasmodial property, 
compound Pi4 was shown to possess better resistance reversal activities than its 
analogue Pi3. This suggests that the ferrocenyl moiety may play an important role, 
possibly as a hydrophobic and/or lipophilic group, in the dual acting properties against 
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When compared to P26, compound P14 had a greater intrinsic antiplasmodial activity 
(ICSOD10 ::: 0.73 IlM, IC50
K1 ::: 1.49 IlM, ICstSA11 ::: 0.75) although P26 was potent in both 
caR strains (IC50D10 ::: 51.40 IlM, ICSOK1 ::: 0.60 IlM, ICstSA11 ::: 0.42). In terms of 
resistance reversal effects, P26 showed a slightly better activity profile in RSA11 while 
both compounds possessed a higher degree of chemosensitization than verapamil in 
this African strain as well as retaining selective cytotoxicity. Based upon this preliminary 
data, the biphenyl motif and a terminal tertiary amine nitrogen are proposed to play an 
important role in restoring ca sensitivity within this series of compounds. The ferrocenyl 
substituent seems to playa role in aspects of antiplasmodial activity. The lipophilicity of 
the compound may be a possible factor (Section 6.4.3). However, the role of 
dimethoxyphenyl substructure was further investigated along with the nature of the 
piperazinyl unit, section 6.4.2. 
6.3.2 Substructural features: methoxy and piperazinyl moieties 
As previously mentioned in this thesis (Section 2.2.2.1), previous SAR studies have 
pointed out the importance of Lewis basic sites on the aromatic hydrophobic unit for 
effective chemosensitization. This is exemplified by the 3,4-dimethoxyphenyl moiety in 
verapamil. In this regard, we wished to initially study the influence of the number of 
methoxy groups on chemosensitization. 
Given the importance of a protonatable nitrogen in chemosensitization of resistant 
malaria parasites, we also wished to study the effect of the nature and number of such 
nitrogens. Accordingly, N-methylpiperazine, phenylpiperazine and benzylpiperazine 
were selected for preliminary studies (Fig. 6.4.2.1). The products modified from 
N-methylpiperazine and benzylpiperazine both contain two protonatable basic nitrogens. 
The phenylpiperazine products contain one protonatable nitrogen since the (aniline) 
nitrogen attached directly to the phenyl ring is less basic due to conjugation of the lone 
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Figure 6.4.2.1. Chemical structures of commercially available piperazines studied. 
We also wished to explore the effect of the ~-amino alcohol moiety in compounds P23, 
P24, and P25 since this moiety is antimalarial pharmacophore as found in mefloquine. In 
addition, it is also present in some MDR reversal agents in cancer (Avendano and 
Menendez, 2002). Accordingly, compounds have been grouped on the basis of the 
aforementioned considerations, Fig. 6.4.2.2. 
Among these three closely related chemical analogues in group A, P11 exhibited the 
strongest antiplasmodial activity overall (IC50D10::: 17.54 11M, IC50
K1 ::: 10.03 11M, IC50RSA11 
::: 11.55 JiM). In terms of relative activi y against CO resistant malaria, both compounds 
P11 and P12 (RI < 1) were more active compared to the benzypiperazinyl derivative P13 
(RI> 1). The concentration dependent dual activity of P11 and P12 (RMIRsA11 ::: 0.75) are 
similar. 80th compounds improved their resistance modification index (RMI) to less than 
1 in K1. On the other hand, P13 showed a slightly greater intrinsic antimalarial activity 
with reduced resistance reversal effect (RMI > 1 for both CO resistant strains). These 
data suggest that the benzylpiperazinyl substructure in product P13 may be more 
important in antiplasmodial activity than in CO resistance reversal. 
With a view to establishing the effect of the number of methoxy groups in the aromatic 
ring on both the antiplasmodial and resistance reversal properties, group 8 and C 






























A. Dimethoxybiphenyl scaffold with N-methyl-, phenyl- and benzyl- piperazinyl. 
B. Trimethoxybiphenyl scaffold with N-methyl-, phenyl- and benzyl- piperazinyl. 
C. Monomethoxybiphenyl scaffold with N-methyl-. phenyl- and benzyl- piperazinyl. 
D. Trimethoxybiphenyl ~-alcohol scaffold with N-methyl-, phenyl- and benzyl-piperazinyl. 
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When compared within group B, compound Pi7 was expected to exhibit the strongest 
antiplasmodial activity as it contains the benzylpiperazinyl substructure present in Pi3. 
In addition, its resistance reversal effect was moderate without much improvement 
compared to the analogues in group A. N-methylpiperazine substituted analogue, PiS, 
demonstrated approximately 3-times greater antimalarial activity against the CO 
resistant isolates than against sensitive D10 (R1
K1 :::: 0.32; RIRSA11 :::: 0.34) whereas Pi6 
displayed similar antipiasmodial activity towards CO-sensitive and -resistant strains 
(IC50D10 :::: 7.69 JlM; IC5RSA11 :::: 8.31 JlM). Comparing compounds Pii and PiS, the 
additional methoxy group in position 2 of PiS showed no significant differences in either 
antiplasmodial or chemoreversal activity against P. falcipaurm though it demonstrated a 
better activity against CO resistant parasites (Rt15 ,.. 0.3 vs Rt11 .... 0.6). Additionally, the 
comparison between Pi2 and Pi6 revealed that the extra methoxy group found in the 
structure of Pi6 enhanced the antiplasmodial activity to ca 2.S fold in D10 and 
(lC50
P12::::22.13 JlM vs. IC50P16::::7.69 JlM) and RSA11 (IC50P12::::18.S1 JlM vs. 
IC50
P16::::8.31 JlM). 
In parallel, compound Pi7, which contains the trimethoxybiphenyl moiety, showed 
greater antiplasmodial as well as chemoreversal activity when compared to analogue 
Pi3 (P17: IC50D10, K1, RSA11 < SJlM vs. Pi3: IC50D10, K1, RSA11 > SJlM; Pi7: RMIK1/RSA11 < 1 vs. 
Pi3: RMIK1IRSA11 > 1). Compound Pi6, in particular, demonstrated significant CO 
resistance reversing effect (RMIRsA11 :::: 0.S9) which is comparable to that of verapamil 
(RMI :::: 0.60), though, it was not as successful in K1. Careful inspection of the structures 
may lead to a tentative hypothesis of a basic chemosensitizing pharmacophore 
comprising of a biphenyl fragment with a possible link to an arylpiperazinyl substructure, 
especially for restoring CO sensitivity in RSA 11. This hypothesis may be 
strain-dependent and needs to be tested further in a broader range of resistant strains. 
The antiplasmodial activities of the chemical analogues in group C were not distinctively 
different from each other and showed lower activities towards CO resistant parasites (RI 
> 1). However, it is noteworthy that Pi9 exhibited a remarkable resistance reversing 
ability in the African strain (RMIRsA11 :::: 0.S8) while Pi8 (RMIRsA11 :::: 0.82) and P20 
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consistent with earlier findings with compound P12 (RMIRsA11 ::: 0.77) and P16 (RMIRSA11 
. ::: 0.59) since P12, P16 and P19 all contain the phenylpiperazinyl structural moiety. 
Comparing compounds from groups A, Band C, the trimethoxybiphenyl-based 
compounds were the strongest antiplasmodial agents while group C compounds, which 
possess only one methoxy group showed the least antiplasmodial activity. These data 
suggest that the greater number of methoxy groups these compounds possess, the 
more potent antiplasmodial agents they are. Compound P17 (trimethoxybiphenyl-
benzylpiperazinyl) exhibited the strongest antiplasmodial activity amongst the series of 
compounds against falciparum 010, K1 and RSA 11. In terms of further development of 
more effective antiplasmodial agents within this series of compounds, the 
trimethoxybiphenyl and benzylpiperazinyl substructural motifs could form a basis. 
On the other hand, the phenylpiperazine modified compounds, P12, P16 and P19 
displayed substantial resistance reversal effects when compared with 
N-methylpiperazine and benzylpiperazine derivatives. While the comparative degrees of 
chemosensitization against mono-, di, and tri-methoxybiphenyl building templates were 
not determined, these results suggest that the phenylpiperazinyl moiety may be an 
important substructure in these CQ resistance modulators since modified analogues 
containing this moiety possess insignificant intrinsic antiplasmodial activity, which is a 
requirement for an ideal chemosensitiser. Furthermore, these chemically modified 
compounds in general all showed reduced antiplasmodial activity of which only the 
phenylpiperazine substituted derivatives revealed comparative degrees of 
chemosensitization when compared with P26 and P14. Nevertheless, all the novel 
compounds in groups A - C demonstrated a large therapeutic margin of safety on the 
mammalian cells of CHO. 
6.3.2.1 Substitutions with longer side chain 
In order to improve the potential of initially synthesized antiplasmodial agents and/or 
resistance reversers against CO resistant parasites, further chemical modifications were 
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group 0, the well recognized amino alcohol antiplasmodial pharmacophore was 
incorporated in order to enhance antiplasmodial activity. 
Within group 0, P25, as expected displayed the best antimalarial activity against both 
CQ-sensitive and -resistant strains of falciparum as its structure included the 
trimethoxybiphenyl and benzylpiperazinyl substructural motifs described previously. In 
addition, the indicator (RI) for potential novel antimalarials against CQ resistant malaria 
is well below 1 for all compounds in group D, this suggests that the p-alcohol amino 
group may be an important functional group for antimalarial agents particularly against 
CQ-resistant malaria. However, the amino alcohol analogue P24 (modified with 
phenylpiperazine) did not display the predicted high resistance reversal activity. Instead 
the N-methylpiperazine modified alcohol derivative (P23) was the most potent resistance 
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Figure 6.4.2.2. Chemical structures of closely related analogues. 
D. Trimethoxybiphenyl amino alcohol scaffold with N-methyl-, phenyl- and benzyl-piperazine. 
E. Extended N-methylpiperazine side chain with mono-, di- and Tri-methoxybiphenyl substructure. 
More diverse analogues of the identified biphenyl pharmacophore with mono-, di- and 
tri-methoxy functional groups in addition to different piperazines were incorporated to 
form group E compounds P31, P32 and P33. Out of the compounds in this group, a 
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of analogues all produced improvement as antimalarials against CQ-sensitive 
and -resistant P. falciparum (ICso < 8 IlM). However, in terms of selective cytotoxicity, 
analogue P31 (ICsocHO == 9.97±2.36 IlM) exhibited high cytotoxicity towards a 
mammalian cell line. Future development of compound P31 as a potential antimalarial 
agent will need to focus on reducing this cytotoxicity. 
It is noteworthy that amongst all the compounds synthesized in this study, derivative P32 
in particular showed a marked resistance reversal effect (RMIRSA11 == 0.31) while 
possessing antiplasmodial activity and, more importantly, a non-cytotoxic effect in a 
mammalian cell line. The weak intrinsic antimalarial effect found in P32 could be 
beneficial when it is used in combination with CQ since it restored CQ sensitivity in 
resistant cell lines. It could also function as an antimalarial (albeit weak), provided there 
is a large therapeutic safety margin. 
Since CQ's mode of action and the mechanism of CQ resistance still remain 
controversial at present, it is unclear why the dimethoxy derivative P32, is approximately 
3-times more active as a CQ resistance reverser than its analogues, P31 and P33. 
Coincidentally, one of the most successful resistance modulators in cancer therapy, 
verapamil, also consists of a dimethoxyphenyl substructural motif. Nonetheless, the 
important roles played by the bicyclic privileged biphenyl and phenylpiperazinyl 
substructural motifs in chemosensitization were established. In terms of further 
development of resistance reversers, attempts could be made to explore chemical 
analogues with reduced molecular weight which incorporate the biaryl and 
phenylpiperazinyl substructural motifs. 
6.3.3 Lipophilicity SAR 
In order to correlate the general properties of lipophilicity (hydrophobicity) to the 
structural analogues in antiplasmodial and/or chemoreversal activity, the measured and 
calculated partition coefficient, logP, is used. It is an indicator of the tendency of water to 
exclude the non-polar groups or molecules in an aqueous environment. Moreover, logP 
is known to correlate to compounds that contain one aliphatic tertiary amine whereas the 
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aliphatic chains 0Niese and Pajeva, 2001). For comparison purposes, the clogP values 
of corresponding compounds are tabulated in Table 6.4.3. 
Table 6.4.3. The clogP values for the library of compounds. 
v~ clogP Antimalarial I Reversal activity activity 
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Mao & MeO ~ M P33:++ P33:++ 
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5.83 5.56 4.65 
-
ClogP(21 )=4. 04 
+: weak: ++: moderate. +++: good 
It was found that there was a small increase in antimalarial activity (from weak to 
moderate) with an increase of lipophilicity (from left to right) for the compounds in group 
A-D. In terms chemoreversal effects, no clear trend of relationships with lipophilicity was 
observed. Compounds P13, P19, P20, P31 and P32 possess clogP values of greater 
than 5, which does not fulfil the 'Lipinski's rule of 5' (Section 2.1.1) and showed poor to 
moderate activities in antiplasmodial activities. In contrast, these compounds possessing 
high clogP values showed moderate to good chemosensitization of CO-resistant 
parasites. This suggests that these compounds may interact hydrophobically with the DV 
integral membrane proteins and replace the lost positive charge of PfCRT; this causes 
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verapamil as suggested by Sidu, Warhurst and their colleagues (Sidhu et al., 2002; 
Warhurst, 2003). These data concluded that lipophilicity is an important parameter for 
antiplasmodial activity as well as resistance reversal. 
In analysing structure-activity relationships from the series of compounds, several 
generalizations can be made as follows: 
(i) Addition of a benzylpiperazinyl unit to the biarylamino building block enhanced 
antiplasmodial activity, which was particularly enhanced when a ferrocenyl 
substructure in the piperazine nucleus was included, 
(ii) An increase in the number of methoxy substituents on the biaryl scaffold was 
accompanied by an increase in antiplasmodial activity, 
(iii) Incorporation of a phenylpiperazinyl substructural feature resulted in elevated 
resistance reversal effects, 
(iv) The shorter distance between the biaryl scaffold and amino functional group 
produced enhanced antiplasmodial activity and CQ resistance reversing ability, 
(v) The more hydrophobic the compound, the better antiplasmodial and 
chemoreversal activities they possess. 
To sum up the hit optimization process, organometallic compound P14 was the most 
active antipiasmodial agent against both CQ-sensitive and -resistant clones of 
falciparum infected parasites, while P26 was selectively more potent in resistant strains. 
On the other hand, in terms of chemosensitization, all the new compounds showed 
effective resistance reversal in the African CQR strain RSA 11, with P32 being the most 
potent. Moreover, 95% of the novel compounds synthesized showed little cytotoxicity, 
which is crucial in the later stage of drug discovery and development. A careful. 
inspection of the chemical structures of these modified compounds from lead P7 led to a 
tentative proposal that a combination of two privileged bicyclic structures, biphenyl and 
arylpiperazinyl moieties, is the chemoreversal pharmacophore in this series of 
compounds. One could therefore postulate from this that compounds P14, P26 and P32 
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6.4 Conclusion 
In this study, novel compounds synthesized on the basis of known structure-activity 
relationships studies were evaluated in vitro for antiplasmodial activity, CO resistance 
reversal, cytotoxicity and in CO accumulation assays. All of them showed no cross 
resistance with CO (the susceptibility to the compounds tested was not accompanied by 
an increase in CO resistance level) and were within a wide therapeutic safety margin 
except P31, which possessed high cytotoxicity against the CHO cell line. In terms of 
antiplasmodial activity, compounds P26 and P14 were shown to exhibit the greatest 
potential as the most promising antimalarials and warrant further investigation for lead 
generalization and optimization. It is noteworthy that although these compounds possess 
relatively high anti plasmodial activity to be ideal chemosensitizers, it may be an 
advantage as a dual acting (antiplasmodial and chemoreversal) drug from a therapeutic 
point of view (Chibale et al., 2003). In addition, P26 displayed classical resistance 
reversal activity while P32, which showed the greatest potential as a CO resistance 
modulator, showed no significant stimulation of CO retention in resistant P. falciparum. 
From the empirical data of the small library of compounds, tentative structure-activity 
relationships revealed that benzyl piperazine analogues displayed high antiplasmodial 
activity while phenylpiperazine substituted derivatives demonstrated enhanced CO 
resistant reversal effects. In terms of CO resistance modulators, an additional class of 
resistance modulators which showed effective resistance reversal activity without 
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Chapter 7 Drug interactions with ABC transporter in yeast 
7.1 Introduction 
One of the strategies used by microbes, parasites and tumor cells to evade 
chemotherapy is to overexpress broadly specific transporter proteins to extrude drugs 
out of the cells (Kolaczkowski et al., 1998). As a result, membrane transport phenomena 
have been implicated in the evolution of drug resistance in both prokaryotic (bacterial) 
and eukaryotic systems (yeasts, human tumor cells and intracellular parasites such as P. 
falciparum). In an effort to expand our understanding of the mechanism of action and 
resistance associated with CO, Saccharomyces cerevisiae was used as a model 
eukaryotic system in this study. 
The partial reversal of CO resistance by verapamil suggests that CO resistance 
phenotype may be based on verapamil-sensitive components mediated by the ABC 
transporter protein PfIVIDR1 and/or other verapamil-insensitive components (Klokouzas 
et al., 2003). This led to a hypothesis that ABC trans orters may be acting alongside 
other proteins to bring about the drug resistance. In addition, it was proposed that 
verapamil interact hydrophobically with CO transporter protein(s) in malaria to restore 
CO to sensitivity (Sidhu et al., 2002; Warhurst et al., 2002). The objective of this study 
was to investigate the specific transport in the membrane proteins of yeast S. cerevisiae 
in vitro to obtain more insight into the function and substrate specificity of the series of 
compounds synthesized. 
Drug interactions with transporter proteins can have a direct and/or adverse effect on the 
therapeutic safety and efficacy of many important drugs (Mizuno et al., 2003). This may 
be due to competitive substrate interactions at the transporter binding site. It is thus of 
interest to investigate whether the series of potential CO chemosensitizers are 
substrates for the ABC transporter proteins in efforts to investigate the drug resistance 
and/or reversal phenomenon. To obtain detailed information about the individual 
differences, two isogenic strains of S. cerevisiae of YOR1 and YCF1 were used in the 
study. The ABC transporters of YOR1 and YCF1 were found to localize to the yeast outer 
membrane and digestive vacuolar membrane, respectively. VOR 1 is involved in the 











Chapter 7 Drug interactions with ABC transporter in yeast 
plays an important role in vacuolar detoxification of heavy metals. In addition, the 
PfiVlDR1 transporter, which also localizes to the digestive vacuolar membrane of malaria 
parasites, has been proposed to be associated with the drug resistance process (Reed 
et al., 2000). With the functional and localization similarities of the ABC transporters in 
yeast (yCF1) and in malaria (PfiVlDR1), the potentially important information derived 
from the drug interaction with the yeast ABC transporter, YCF1, may provide information 
into the function of related eukaryotic transporter proteins in malaria. 
7.2 Results and discussion 
7.2.1 Solid medium assay 
The yeast oligomycine resistance protein, Yor1 p, is known for its ability to confer 
oligomycine resistance. The mutant strains AD1, AD1-3 and Super Yor with the 
corresponding wild type, US50-18C, were chosen to establish this technique 
(Decottignies et al., 1998). AD1 contains the deletion of yon gene and AD1-3 contains 
not only the deletion of yon gene but also other transporter genes. Super Yor is the 
overexpressed yor1 strain. 
Traditionally, the drug inhibition test has been performed on solid medium assay 
(Chapter 3.4.1) and the growth of yeast cells is inspected manually and physically (Fig. 
7.2.1-A). Various dilutions of test compounds were applied to the agar plates and an 
analysis of colonies grown was then performed (Table 7.2.1; Fig. 7.2.1 B). This assay 
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'fob -0\ 
US50-18C 
Figure. 7.2.1-A. Various dilutions of different clones of yeasts developed on solid 
YPO-agar medium assay_ 
Table 7.2.1. Analysis of different yeast clones grown against different concentrations of 
oligomycines_ 
S. cerevisiae [oligomycine] ~g/ml 
0.00 0.05 0.50 5.00 50.00 
US50-18C 5,0 5,7 6,0 0,0 0,0 
AD1 2,3 2,7 0,0 0,0 0,0 
AD1-3 1,0 1,7 0,0 0,0 0,0 
SuperYor 4,0 9,0 4,7 3,0 3,3 
The number of yeast clones is in arbitrary units. 
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Figure 7.2.1-8. Illustration of oligomycines response against different yeast clones. 
The results showed that the wild type (WT) strain, US50-18C (purple bar), was able to 
survive oligomycine pressure at a concentration of 0.5 Ilg/ml while the overexpressed 
yor1 mutant Super Yor strain (blue bar) was able to survive at the highest concentration 
of 50 Ilg/ml tested (Fig. 7.2.1-8). The isogenic mutant AD1 (yellow bar), which lacks only 
the Yor1 p transporter protein, and the mutant AD1-3 (green bar) bearing deletions in 
yor1, snq2 and pdr5 showed their limited tolerance to oligomycine even at a low 
concentration of 0.05 Ilg/ml. These data show that the Yor1 p is responsible for the 
oligomycine resistance. 
7.2.2 Liquid culture assay 
In an attempt to investigate substrate specificity of transport proteins in this study, the 
traditional sensitivity test was adapted for screening using 96-well microtitre plates 
(Chapter 3.4.2). Several S. cerevisiae cell lines were used of which the YOR 1 P was 
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This liquid culture assay (LCA) was successfully established and developed on the basis 
of the traditional solid medium assay. It was achieved through a series of data 
computations (Fig. 7.2.2-A, B, C and D) (Details in Section 3.4.2). Results from the LeA 
were consistent with earlier "findings (Decottignies et aI., 1998). A summary of 
dose-response curves of oligomycine against different S. cerevisiae used is also 
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Chapter 7 Drug interactions with ABC transporter in yeast 
The growth inhibition curves for the WT (US50-18C) and AD1 strains in various 
concentrations of oligomycine are shown in Fig. 7 .2.2-A and -C while the growth rates for 
both strains are shown in Fig. 7.2.2-B and -D, in which both stra.ins showed similar 
susceptibility to oligomycine. Results in this study confirm that growth of AD1 was not 
inhibited by oligomycine (Fig. 7.2.2) (Decottignies et 131., 1998; Kolaczkowski et 131., 1998). 
This finding was consistent with that observed in the traditional solid medium assay (Fig. 
7.2.1). 
In addition, the LCA results were confirmed in a cytotoxicity assay using single and 
multiple gene mutations in the ABC transporters. Of the S. cerevisiae strains tested, 
those with liyor1 deletion (AD1, AD1-3, AD1,2,4-7) (section 3.4) were shown to regain 
oligomycine sensitivity in Fig. 7.2.2-E and summarized in Table 7.2.2. 
E. 
120 
% cell survival vs. Oligomydne concentration (ug/ml) against 
US50-18C, AD1, AD1-3, and A01,2,4-7 strains 
.-.-/ /- '''''' .. , , "'" 




0.1 10 100 









USSD·18C is the wild type strain. AD1: Ayor1. AD1-3: Ayor1. Asnq2 and ll.prJr5. 
AD1,2,4-7: ll.yor1, Asnq2, t1pdr10, Llpdr11, Llycf1, t1pdr3 
Figure 7.2.2-E. A summary of dose-response curves of oligomycin~ against S. 
cerevisiae. 
The resistance factor, Rf, is an indicator to identify the relative activity of the drugs to the 
drug sensitive and/or drug resistant strains. Rf = ICsoresistant/ICsosenSitive. Therefore, if Rf >1, 
the more resistant the yeast strain is to the drug. The resistance factors of the strains 
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Rf :: ICso (strains)/ICso (AD1) 
1.38 ± 0.35 
0.31 ± 0.02 
0.19 ±0.01 
0.21 ± 0.02 





AD1-3 and AD1 ,2,4-7 = corresponding wild type yeast strain with YOR1 and other major transporter protein gene 
deletions. 
As can be seen, the US50-18C (Wf), which is the only strain possessing the yor1 gene, 
was the most resistant to oligomycine among the strains tested (ICso = 1.38 JlM.). When 
the AD1,2,4-7 strain, bearing more transporter gene deletions, was compared to AD1, 
the .dyor1 gene strain, both showed similar degrees of susceptibility to oligomycine as 
well as AD1-3 (Rf AD1 === Rf AD1-3 === Rf AD1,2,4-7 === 1). The results confirm that YOR 1 p is the 
major ABC transporter protein for oligomycine. The LCA results are consistent with those 
obtained "from the solid medium assay: YOR1p ABC transporter protein conferred 
oligomycine resistance. A 6-fold increase in oJigomycine tolerance in US50-18C, which 
contains the Yor1 p transporter protein, was shown. The newly developed LCA was thus 
capable of demonstrating the functional property of YOR1 p for the purpose of this study. 
LCA is much more efficient than the classical solid medium assay and it is comparable to 
the cytotoxicity assay as it possesses the advantage of taking into consideration the 
average duration of cell proliferation with respect to the single point evaluation in a 
cytotoxicity test. 
The series of novel compounds were investigated in the membrane protein, YOR1p, and 
vacuolar membrane protein, YCF1 p, for substrate specificities using LCA. Results 
obtained against YOR1 p were comparable to those of YCF1 p. Since the PfMDR1 gene 
product of PtPgh-1 was found to locate to the malaria vacuolar membrane, results 
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7.2.3 Transport activity ofYCF1p 
Prior to investigating novel compounds using the LCA, a positive control of Cd2+ was 
tested. A control using the WT was performed and illustrated in Fig. 7.2.3-A, -8 and C 
while the YCF1 strain are shown in Fig. 7.2.3-0, -E and -F, respectively. The growth 
curves of the WT and YCF1 displayed similar growth patterns (Fig. 7.2.3-A vs -0) as well 
as the growth rate (log00620 vs time) (Fig. 7.2.3-8 vs -E). When the growth rate was 
compared with Cd2+ (Fig. 7.2.3-C vs -F), IC50 values for WT and YCF1 are determined 
as 100.4±3.7 jlM and 26.7±2.2 jlM, respectively, which are consistent with literature 
findings that YCF1 is responsible for the Cd2+ response (Vido et aI., 2001). 
The synthesized compounds showed consistent non-inhibition effect on both YCF1 and 
its corresponding WT strain throughout the library of compounds generated. Results for 
the most promising lead compound P26 as potential effective chemosensitizer are 
shown below and compared with verapamil (Fig. 7.2.3-G to J). 
The well-known resistance modulator, VPL, showed a minor inhibition effect on growth in 
the transporters of the WT yeast cells (Fig. 7.2.3-G). However, the responsible 
transporter was shown not to be YCF1p since it showed no growth inhibition in YCF1 
against most of the concentrations u ed (Fig. 7.2.3-H). YCF1p was clearly not involved 
in the flux of the synthesized compounds as the representative data of compound P26 
revealed similar growth patterns in both WT and YCF1 (Fig. 7.2.3-1, -J). The highest 
concentration of 100 jlg/rnl of compound P26 used showed a small degree of inhibition 
against YCF1, which may be due to its toxicity at this level (shown in dark blue curve in 
Fig. 7.2.3-J). Thus both P26 and VPL appear not to be the substrates for the yeast 
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Figure 7.2.3. (Continued) 
G. VPL response in WT: cell growth vs. time (hr). 
H. VPL response in YCF1: cell growth vs. time (hr). 
I. Compound P26 response in WT: cell growth vs. time (hr). 




















The fact that YCF1 p localizes to the membrane of the digestive vacuole suggests 
similarity to that of P-glycoprotein homologue 1 in malaria and the PfCRT transporter 
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transporter proteins, it has shown that VPL and the related compounds which contain the 
hydrophobic biphenyl moiety and the basic piperazinyl substructural feature are not the 
substrates for YCF1. Thus no drug-protein interaction with this ABC transporter was 
suggested. It has been proposed that VPL interacts hydrophobicaUy with the receptors to 
restore CQ sensitivity in CQ resistant malaria parasites although there is no direct 
evidence that VPL binds to the ABC transporter protein, Pgph-1, and/or to the PfCRT, 
which does not belong to the ABC family (Sidhu et a/., 2002; Warhurst et a/., 2002). 
However, this study showed no hydrophobic interaction between verapamil (and the 
synthesized analogues) and YCF1. Further work on these compounds can be performed 
against the identified CQ resistance determinant, PfCRT and/or PFPgh1, to show if these 
compounds enhance CQ to sensitivity when used in combination with CQ in CQ 
resistant parasites. 
7.3 Conclusion 
Drug targeting is one effective approach to optimize the pharmacological profiles of drug 
candidates using transporter functions. To our knowledge, this is the first time studies on 
the effect of antimalarial resistance reversers on drug transporters in yeasts have been 
attempted. Even though this drug transporter study did not shed light on the CQ 
resistance mechanism, the effort reveals a possible means to study the structure and 
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8.1 Research summary 
Malaria is one of the world's most important infectious diseases and causes severe 
morbidity and mortality in tropical and sub-tropical regions of the world. Even today, the 
amazing adaptive qualities of the mosquito vector, Anopheles, combine with travel, trade 
and natural events to cause serious health and socioeconomic problems particularly in 
the poorest countries among the underprivileged populations. The worsening problems 
of drug and insecticide resistance as well as the limited number of antimalarials and 
effective antimalarial drug regimens have contributed to the increasing prevalence of 
malaria and the difficulties in providing adequate disease management. At present, since 
malaria control and treatment rely profoundly on chemotherapeutic agents, it is 
imperative to rapidly put in place strategic plans for the discovery and development of 
novel antimalarials and/or other alternatives to challenge the ever-increasing drug 
resistance phenomenon. An alternative strategy to overcome the malaria burden is drug 
combination. The pioneering work with multi-drug resistance in tumor cells has shown 
the possibility to reverse anticancer agent resistance by using a combination of 
chemosensitizers. The pressing need for new alternative, new resistance 
chemosensitizers in combinations with CO was investigated in light of the work in 
cancer. 
By combining the power of biology and medicinal chemistry, a small series of CO 
resistance reversal agents were rationally designed based on known structure-activity 
relationship studies. The compounds were synthesized in high yields and 
N'-[4-(biphenyl-2-ylmethoxy)-benzy~-N,N-dimethyl-propane-1,3-diamine (P1) showed 
the greatest potential as a dual-acting antimalarial agent (ICso < 0.6 J.1M) and 
CO-resistance reverser (RMIK1=0.67; RMIRSA11=0.82) in vitro. The potential 
pharmacophore of the identified hit compound, P1, was tentatively proposed as the 
biphenyl moiety in the initial exploratory process of the drug discovery and development. 
In light of the in vitro activity of P1, a library of analogous compounds focusing on 
replacing the flexible alkyl side chain with a piperazinyl moiety was successfully 
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cytotoxicity as well as their effect on tritiated CO accumulation. Among the 17 novel 
compounds, the organometallic ferrocenyl compound (P14) and 1-biphenyl-2-ylmethyl-
4-methyl-piperazine (P26) displayed the greatest potential as the most promising 
antimalarials (ICso < 1 IJ.M) and warrant further investigation for lead generation and 
optimization. In terms of resistance reversal effect, P26 showed the characteristic of a 
classical resistance reversal agent (RMIRsA11=0.50) while 1-[4-(3',4'-dimethoxy-biphenyl-
4-ylmethoxy)-benzy~-4- methoxy-piperazine (P32) displayed the greatest potential as a 
CO resistance modulator (RMIRSA11=0.31). An additional class of resistance modulators 
which showed effective resistance reversal activity without potentiating CO uptake within 
CO-resistant P. falciparum was identified. In addition, a number of generalizations were 
made based on the structure-activity relationships from the library of compounds. It is 
noteworthy that although P26 displayed relative high antiplasmodial activity to be an 
ideal chemosensitizer, it may be an advantage for such compounds to act as both 
antiplasmodial and chemoreversal agents (Chi bale et al., 2003). 
Furthermore, since drug targeting is an effective approach to optimizing the 
pharmacological profiles of drug candidates using transporter functions, substrate 
specificity on yeast transporter proteins was studied. In this study, studies on the effect of 
antimalarial resistance reversers on drug transporters in yeast have been attempted for 
the first time. Although the screen did not shed light on the CO resistance mechanism, 
the effort has provided a possible means to study the structure and function of yeast or 
malaria transporter proteins. 
The objective of this thesis was to IJse known structure-activity relationships of 
chemosensitizers to rationally design, synthesize and optimize a library of novel 
compounds to meet the basic in vitro requirements in the initial exploratory stage of drug 
discovery and development, and ultimately fulfill the criteria for a pre-clinical candidate. 
This study focused on drug discovery and optimization of the anti plasmodial and 
chemoreversal activity of a library of compounds. The information gained from the 
development of hits into potential lead molecules could provide a basis for further 
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8.2 Future investigations 
Although a library of biphenyl-based compounds was synthesized, a multitude of 
chemical modifications could potentially be made. Different substitution patterns of the 
biphenyl moiety would provide vast chemical diversity. This optimization process may 
identify more promising leads and ultimately more suitable drug candidate(s) for drug 
development. 
In addition, evaluation of these novel compounds for their clinical characteristics in vivo 
would also play an essential role in drug development. However, the ideal animal model 
for displaying the precise pharmacodynamic and pharmacokinetic properties for human 
malaria is not yet available. Regardless, all mammalian Plasmodium species share 
comparable life cycles and are sensitive to the same drugs and their diversity is similar to 
that observed in human Plasmodium. As a result the murine models, such as P. berghei, 
have become more and more widely used (Sherman et al., 1998). Careful time course 
studies correlating the host response with the environmental changes during 
development would provide valuable information about the in vivo intrinsic toxicity, 
antimalarial and/or chemoreversal activity, pharmacokinetic and pharmacodynamic 
profiles. The active metabolites of the compounds could also be investigated by 
radioactive labeling during drug metabolism studies in vivo. 
With the substrate specificity study established, further work on these compounds could 
be performed against the identi'fied transporter protein, PfCRT. The information may 
shed light on the mechanism of CO's action as well as CO resistance mechanism such 
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Figure A.4.1.20. 13C NMR spectrum of compound P16 in CDCI3 , 100 MHz. 
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Figure 8.4.1.5. 13C NMR spectrum of compound P24 in CDCb, 100 MHz. 
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1-(4-BenzyJ-piperazin-1-yl)-3-(2' ,3',4' -trimethoxy-biphenyJ-4-yJoxy)-propan-2-ol 
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1-Methyl-4-[ 4-(2',3',4' -trimethoxy-bipheny/-4-ylmethoxy)-benzyl-piperazine 
List of spectra: 
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Fig. 6.2.1.1.11. Intrinsic antimalarial effect Fig. 6.2.1.1.12. Intrinsic antimalarial effect 
of P23 on 010 of P24 on 010 
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Fig. 6.2.1.1.13. Intrinsic antimalarial effect Fig. 6.2.1.1.14. Intrinsic antimalarial effect 
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Fig. 6.2.1.1.15. Intrinsic antimalarial effect 
of P31 on 010 
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Fjg. 6.2.1.1.17. Intrinsic antimalarial effect 
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Fig.6.2.1.1.16. I ntrinsic antimalarial effect 
of P32 on 010 
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Fig. 6.2.1.2.3. Intrinsic antimalarial effec  Fig. 6.2.1.2.4. Intrinsic antimalarial effect 
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Fig. 6.2.1.2.5. Intrinsic antimalarial effect Fig. 6.2.1.2.6. Intrinsic antimalarial effect 
of P15 on K1 of P16 on K1 
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Fig. 6.2.1.2.7. Intrinsic antimalarial effect Fig. 6.2.1.2.8. Intrinsic antimalarial effect 
























-1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 
log[P20] IJ.M 
Fig. 6.2.1.2.9. Intrinsic antimalarial effect Fig. 6.2.1.2.10. Intrinsic antimalarial effect 
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Fig. 6.2.1.2.11. Intrinsic antimalarial effect Fig. 6.2.1.2.12. Intrinsic antimalarial effect 
of P23 on K1 of P24 on K1 
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Fig. 6.2.1.2.13. Intrinsic antimalarial effect Fig. 6.2.1.2.14. Intrinsic antimalarial effect 
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Fig. 6.2.1.2.15. Intrinsic antimalarial effect Fig. 6.2.1.2.16. Intrinsic antimalarial effect 









-1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 
log[p33] 11M 
Fig. 6.2.1.2.17. Intrinsic antimalarial effect 
of P33 on K1 
of P32 on K1 
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Fig. 6.2.1.3.1. I ntrinsic antimalarial effect 
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Fig. 6.2.1.3.3. Intrinsic antimalarial effect 
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Fig. 6.2.1.3.5. Intrinsic antimalarial effect 
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Fig.6.2.1.3.2. Intrinsic antimalarial effect 
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Fig.6.2.1.3.4. Intrinsic antimalarial effect 
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Fjg.6.2.1.3.6. Intrinsic antimalarial effect 
of P16 on RSA11 
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Fig. 6.2.1.3.7. I ntrinsic antimalarial effect 
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Fig. 6.2.1.3.8. Intrinsic antimalarial effect 
of P18 on RSA11 
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Fig. 6.2.1.3.9. Intrinsic antimalarial effect Fig. 6.2.1.3.10. Intrinsic antimalarial effect 
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Fig. 6.2.1.3.11. Intrinsic antimalarial effect Fig. 6.2.1.3.12. Intrinsic antimalarial effect 
of P23 on RSA11 of P24 on RSA11 
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Fig. 6.2.1.3.13. Intrinsic antimalarial effect Fig. 6.2.1.3.14, Intrinsic antimalarial effect 
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Fig. 6.2.1.3.15. Intrinsic antimalarial effect 
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Fig. 6.2.1.3.17. Intrinsic antimalarial effect 
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Fig. 6.2.1.3.16. Intrinsic antimalarial effect 
of P32 on RSA11 
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Fig. 6.2.1.4.1. Cytotoxicity effect of 












0 . P13 
-3 -2 -1 0 2 3 
log[P13] flM 
Fig. 6.2.1.4.3. Cytotoxicity effect of 
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Fig. 6.2.1.4.5. Cytotoxicity effect of 
P15 on CHO 
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Fig. 6.2.1.4.2. Cytotoxicity effect of 
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Fig. 6.2.1.4.4. Cytotoxicity effect of 
P14 on CHO 
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Fig. 6.2.1.4.6. Cytotoxicity effect of 
P16 on CHO 
Figure 6.2.1.4. Dose-response curves of various compounds against Chinese hamster 
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Fig. 6.2.2.1.13. Resistance reversal effect 
of P25 on 010 
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Fig. 6.3.2.1.15. Resistance reversal effect 
of P31 on 010 
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Fig. 6.3.2.1.17. Resistance reversal effect 
of P33 on 010 
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Fig.6.2.2.1.14. Resistance reversal effect 
of P26 on 010 
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log[CQ] IJ.M 
Fig. 6.3.2.1.16. Resistance reversal effect 
of P32 on 010 
Figure 6.2.2.1. (Continued) Resistance reversal effect of a single drug plus CO on COs 
strain of D10. Each point represents the mean of 3 independent experiments each performed in 
duplicate. 
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